



FEDERAL MINISTRY OF
HEALTH



NATIONAL GUIDELINE

**ON THE PREVENTION, CONTROL
AND MANAGEMENT OF DIABETES
MELLITUS**

Table of Contents

Table of Contents	2
List of Tables	9
List of Figures	10
Preface	11
Acknowledgements	12
Foreword	13
List of Contributors	14
Abbreviations & Acronyms	16
1. Introduction	18
2. The Rationale for Guidance	18
3. Methodology	19
3.1. Guideline development core team.....	19
3.2. Developing the scope, purpose and questions.....	19
3.3. Search for existing guidelines	21
3.4. Appraisal of eligible guidelines	22
3.5. Selecting guidelines to be used for adaptation.....	22
3.6. Developing guideline recommendations.....	22
3.7. Determining the level of evidence and grading of recommendations.....	23
3.8. External expert review and consensus building	23
4. Scope and Purpose	25
4.1. Health Questions	25
4.2. Target Audience.....	27
4.2.1. Role of the Different Cadres of Health Workers.....	27
4.2.2. Role of the Different Health Care Settings	29
4.3. Target Population.....	30
5. Classification and Diagnosis of Diabetes Mellitus	33
5.1. Classification of Diabetes Mellitus	33

5.1.1. Type 1 Diabetes Mellitus	33
5.1.2. Type 2 Diabetes Mellitus	34
5.1.3. Gestational Diabetes Mellitus	34
5.1.4. Other Types of Diabetes Mellitus	34
5.2. Diagnosis of Diabetes Mellitus	34
5.2.1. Diagnosis of Diabetes Mellitus in Adults	34
5.2.2. Diagnosis of Diabetes Mellitus in Children and Adolescents	36
5.2.3. Diagnosis of Gestational Diabetes Mellitus	38
5.3. Considerations About Recommendations on the Diagnosis of DM	39
5.3.1. Implementation Considerations for the Diagnosis of DM	39
5.3.2. Harms/Benefits of Recommendations on the Diagnosis of DM	39
6. Preventing Diabetes Mellitus	42
6.1. General Preventive Measures for Non-Communicable Diseases (NCDs)	42
6.1.1. General Measures for Preventing NCDs in Adults and Adolescents	42
6.1.2. General Measures for Preventing NCDs in Children	43
6.1.3. Community, Social, Economic, Environmental and Policy Interventions for Preventing NCDs	44
6.2. Prevention of T2DM Among High-Risk Individuals	45
6.2.1. Combined Diet and Physical Activity for Preventing or Delaying the Onset of T2DM or GDM Among Individuals with High Risk	46
6.2.2. Metformin for Preventing or Delaying the Onset of T2DM Among Individuals with Pre- diabetes	47
6.3. Considerations about Recommendations for Prevention	48
6.3.1. Implementation Considerations	48
6.3.2. Harms/Benefits of Recommendations on Prevention	48
7. Screening for Diabetes Mellitus in Adults	52
7.1. Rationale for Screening	52
7.2. FINDRISC Tool	52
7.3. Consideration about Recommendations on Screening	53
7.3.1. Implementation Considerations	53

7.3.2. Harms/Benefits of Recommendations on Risk Assessment and Screening	53
8. Diabetes Education for Adults and Caregivers of Children and Adolescents.....	57
8.1. Rationale for Diabetes Education and Support	57
8.2. Timing of Diabetes Education and Support	57
8.3. Content of Structured Diabetes Education.....	58
8.4. Considerations about Recommendations on Diabetes Education	58
8.4.1. Implementation Considerations	58
8.4.2. Harms/Benefits of Recommendations on Diabetes Education	58
9. Lifestyle Management for Adults.....	61
9.1. Nutritional Recommendations	61
9.1.1. Special Dietary Considerations for Adult T1DM.....	62
9.1.2. Special Dietary Considerations for T2DM.....	63
9.2. Physical Activity	63
9.2.1. Special Physical Activity Considerations for T1DM	64
9.2.2. Special Physical Activity Considerations for T2DM	64
9.3. Smoking and Alcohol	65
9.4. Considerations about Recommendations on Lifestyle Management	65
9.4.1. Implementation Considerations	65
9.4.2. Harms/Benefits of Recommendations on Lifestyle Management	65
10. Blood Glucose Control Targets in Adults.....	69
10.1. Recommended Blood Glucose Targets.....	69
10.2. Self-Monitoring of Blood Glucose	69
10.2.1. Special Considerations for Self-Blood Glucose Monitoring for Individuals on Insulin, During Pregnancy And Breastfeeding	70
10.3. Considerations about Recommendations on the Diagnosis of DM.....	70
10.3.1. Implementation Considerations	70
10.3.2. Harms/Benefits of Recommendations for Blood Glucose Control Targets	70
11. Drug Treatment for Diabetes	72
11.1. Drugs for Type 1 Diabetes Mellitus.....	73

11.1.1. Insulin Regimens.....	73
11.2. Drugs for Type 2 Diabetes Mellitus	74
11.2.1. Initial/First-line Treatment.....	74
11.2.2. Dual Therapy.....	77
11.2.3. Triple Therapy.....	77
11.2.4. Algorithm for Treating Adults with T2DM	78
11.3. Considerations about Recommendations on Drug Treatment for Diabetes	80
11.3.1. Implementation Considerations	80
11.3.2. Harms/Benefits of Recommendations for Drug Treatment for Diabetes.....	80
12. Managing Cardiovascular Risk Factors.....	83
12.1. Lifestyle Management.....	83
12.2. Aspirin for Managing Cardiovascular Risk Factors.....	83
12.3. Considerations about Recommendations for Managing Cardiovascular Risk Factors	84
12.3.1. Implementation Considerations	84
12.3.2. Harms/Benefits of Recommendations for Managing Cardiovascular Risk Factor	84
13. Early Identification of Complications.....	86
13.1. Common Diabetes-Related Complications	86
13.2. Identifying Diabetes-Related Complications at Primary Care.....	86
13.2.1. Identifying Diabetic Retinopathy at Primary Care.....	87
13.2.2. Identifying Diabetic Nephropathy at Primary Care	88
13.2.3. Identifying Diabetic Peripheral Neuropathy (DPN) at Primary Care	89
13.2.4. Diabetic Foot Care	90
13.2.5. Autonomic Neuropathy.....	90
13.3. Considerations about Recommendations on Early Identification of Complications.....	91
13.3.1. Implementation Considerations	91
13.3.2. Harms/Benefits of Recommendations for Early Identification of Complications	91
14. Managing Emergencies in Primary Care Settings.....	94
14.1. Hypoglycaemia	94

14.2. Diabetic Keto-Acidosis.....	96
14.2.1. Preventing DKA at Home and Primary Care.....	96
14.2.2. Treating DKA in Adults.....	97
14.3. Hyperglycaemic Hyperosmolar State	99
14.3.1. Clinical Evaluation.....	99
14.3.2. Treatment Goals.....	100
14.3.3. Treatment Procedure	100
14.4. Considerations about Recommendations on Managing Emergencies in Primary Care Settings.....	103
14.4.1. Implementation Consideration	103
14.4.2. Harms/Benefits of Recommendations for Management of Emergencies in Primary Care... Settings	103
15. Managing Comorbidities.....	105
15.1. High Blood Pressure.....	105
15.1.1. Target Blood Pressure in Individuals with Type 2 Diabetes Mellitus	105
15.1.2. Recommended Frequency of Blood Pressure Measurement.....	105
15.1.3. Recommended Management.....	106
15.2. Dyslipidaemias.....	110
15.2.1. Recommendations for Lipid Monitoring	110
15.2.2. Recommendations for Lipid-Lowering Therapy	111
15.3. HIV.....	113
15.4. Considerations about Recommendations for Managing Comorbidities.....	116
15.4.1. Implementation Considerations	116
15.4.2. Harms/Benefits of Recommendations for Managing Comorbidities.....	116
16. Managing Diabetes in Children and Adolescents	119
16.1. Blood Glucose Targets and Monitoring in Children.....	119
16.2. Treatment of Diabetes in Children.....	119
16.2.1. Lifestyle Management.....	119
16.2.2. Insulin Treatment	121

16.2.3. Use of Glucose-Lowering Drugs	121
16.2.4. Sick Day Rules.....	122
16.3. Management of Diabetic Emergencies in Children	122
16.3.1. Treating Diabetic Keto-Acidosis (DKA) in Children and Young People.....	122
16.3.2. Treatment of Hypoglycaemia.....	129
16.4. Transitioning to Adulthood.....	130
16.5. Considerations about Recommendations for Managing Diabetes in Children and Adolescents	130
16.5.1. Implementation Considerations	130
16.5.2. Harms/Benefits of Recommendations for Managing Diabetes in Children.....	130
17. Managing Diabetes in Pregnancy.....	133
17.1. Preconception Counselling	133
17.2. Blood Glucose Targets in Pregnancy	133
17.3. Management of Diabetes in Pregnancy	134
17.3.1. Treatment of Gestational Diabetes Mellitus	134
17.3.2. Treatment of Pre-existing Diabetes.....	134
17.4. Managing or Preventing Comorbidities During Pregnancy.....	135
17.5. Management of Diabetes after Delivery	136
17.6. Considerations about Recommendations for Managing Diabetes in Pregnancy	136
17.6.1. Implementation Considerations for Managing Diabetes in Pregnancy.....	136
17.6.2. Harms/Benefits of Recommendations for Managing Diabetes in Pregnancy.....	136
18. Advocacy.....	139
19. Monitoring and evaluation.....	139
20. Planning for update	139
21. Implications for practice	140
22. Implications for an update of 2016 Essential Medicines List	140
23. Implications for future research.....	140
24. Quality standards	141

Appendices.....	142
1.0. PPOH Checklist.....	142
2.0. Guideline Search and Retrieval.....	152
3.0. Guideline Assessment Checklist.....	154
4.0. Guideline Appraisal Inter-rater Spreadsheet and Scoring Sheet.....	157
5.0. Summary of Evidence for the Recommendations.....	159
6.0. Types of Glucose-Lowering Drugs.....	183

List of Tables

Table 1: Search Process and Results (May/June 2018)	21
Table 2: Guideline questions.....	25
Table 3: Common Presentations of DM in Children and Adolescents.....	36
Table 4: Diagnostic Algorithm for GDM	39
Table 5: Lifestyle Change Targets for Preventing NCDs.....	42
Table 6: Moderate and Vigorous Intensity Exercises.....	43
Table 7: Moderate-intensity statins	112
Table 8: Oral Diabetes Medications with Special Considerations in HIV.....	114
Table 9: Recommendations for Managing DKA in Children and Young People	125

List of Figures

Figure 1: FINDRISC tool.....	55
Figure 2: Treatment algorithm chart for Diabetes Mellitus.....	79
Figure 3: Algorithm for the treatment and management of hypoglycaemia in adults with Diabetes Mellitus in hospital.....	95
Figure 4: Workflow of management of adult with Diabetic Ketoacidosis	98
Figure 5: Treatment algorithm for Hypertension in Diabetes Mellitus	109

Preface

Diabetes is a common clinical condition in Nigeria. It is a major non-communicable disease that affects the highly productive segment of the nation's populace. Currently, it is being managed at primary, secondary and tertiary health centres, in both private and public health facilities across the country. Diabetes is caused by a relative or absolute lack of insulin, a hormone that regulates glucose utilization in the body.

According to the World Health Organization, 422 million people worldwide had diabetes in 2014 and an estimated 1.6 million death resulted from diabetes in 2016. The prevalence is significantly on the rise in low- and middle-income countries, including Nigeria. An estimated 5 million adult Nigerians live with diabetes and less than 50% of them are diagnosed with their condition. Furthermore, diabetes is a chronic illness that requires continuing medical care and patient self-management education for optimal management outcomes and reducing the risk of complications.

The Federal Ministry of Health (FMOH) recognizes that this chronic illness, which is assuming epidemic proportions in Nigeria requires management and control, based on a national guideline. This has informed the Federal Ministry of Health's decision to develop a guideline that will ensure standardized medical care and patient self-management education to prevent acute complications and reduce the risk of long-term debility from the disease.

It is our earnest desire therefore, that this document will form the foundation for improving the standard of care for people living with diabetes in all our healthcare facilities across the country.



Dr U.M. Ene-Obong
Director, Department of Public Health
Federal Ministry of Health
Abuja, Nigeria.

Acknowledgements

We are very delighted that the national guideline for the prevention and management of diabetes in Nigeria has become a reality, despite the challenges that slowed down the process. Our sincere gratitude goes to all stakeholders, who committed time and other resources towards developing this document.

The leadership role of the Head, Department of Public Health; the coordination of the process by the hardworking staff of the Non-Communicable Diseases Division, and the contributions of other officers from the Federal Ministry of Health, especially, Departments of Family Health and Hospital Services are acknowledged with thanks. So also, are those of the National Primary Health Care Development Agency, FCT Primary Health Care Board, Health & Human Services Secretariat of the FCT, the Academia, and Diabetes Association of Nigeria (DAN).

A special note of thanks goes to Health Strategy and Delivery Foundation (HSDF), who made significant financial and human resource contributions towards developing and finalizing the guideline. We also appreciate Cochrane Nigeria for the great work on the grading of evidence for this document.

Finally, profound gratitude goes to the World Diabetes Foundation (WDF), who catalyzed the guideline's development and supported the finalization and printing as part of the activities approved for the Diabetes Awareness and Care project under the grant, WDF17-1474.

We believe that the selfless dedication displayed this document's development would also be demonstrated in its use for effective management and control of Diabetes Mellitus in Nigeria.



Dr Nnenna Ezeigwe
National Coordinator, Non-Communicable Diseases Division
Federal Ministry of Health
Abuja, Nigeria.

Foreword

Diabetes is increasingly becoming an epidemic, especially among adolescents and young adults. The incidence and prevalence of the disease especially Type II, is increasing worldwide. The risk of developing diabetes (Type II) globally is rising; it is further accentuated by civilization and globalization, resulting in overweight/obesity, and the proliferation of industries producing unhealthy diets, including unhealthy fats and high sugar content. The current global burden of Diabetes Mellitus (DM) is estimated to be 425 million. A projection for the year 2045 is put at 629 million people, and 80% of this increase is expected to occur in developing countries, including Nigeria, if nothing urgent is done.

Fortunately, Type II DM can be prevented and controlled by avoiding risky behaviours and unhealthy lifestyle habits. The modifiable shared risk factors for diabetes include tobacco use, harmful use of alcohol, and unhealthy nutrition (such as excessive consumption of red meat, saturated fat, refined sugars in foods and drinks, inadequate consumption of fibre rich diet, vegetables and fruits) and physical inactivity.

Concerned about the enormous challenges caused by diabetes in Nigeria, the Federal Ministry of Health, in collaboration with stakeholders, developed the National guideline for the prevention, control and management of diabetes in Nigeria. This was to inform evidence-based interventions with regards to the prevention and management of the disease in Nigeria, such that standards are prescribed, quality of life and disease outcomes are improved.

Furthermore, the publication of this guideline shows the Nigerian government's continuous commitment to reduce the burden of diabetes in Nigeria, as affected individuals must receive appropriate clinical interventions in all healthcare facilities nationwide. This national guideline will ensure standardized medical care and patient self-management education to prevent acute complications, delay the onset of complications and reduce the risk of long-term complications among diabetic patients.

I, therefore, encourage all healthcare practitioners and facilities to take advantage of this opportunity to improve their standard of care for diabetic patients, thereby enhancing the management and control of diabetes in Nigeria. Also, this publication contributes to the government's efforts in bringing hope and succour to those affected by this disease.



Dr E. Osagie Ehanire MD, FWACS
Honorable Minister,
Federal Ministry of Health,
Abuja, Nigeria.

List of Contributors

Core Technical Team of the Guideline Development

Organization	Names
Federal Ministry of Health	Dr Nnenna Ezeigwe
	Dr Alayo Sopekan
	Mrs Chiamaka Omoyele
	Mr Emmanuel Abraham
	Mr Lawrence Ologidi
	Mrs Kehinde Akinkoye
World Health Organization (Nigeria)	Dr Mary Dewan
Health Strategy and Delivery Foundation	Dr Kelechi Ohiri
	Dr Lilian Anomnachi
	Dr Christine C. Ezenwafor
	Dr Bridget Nwagbara
	Dr Ndukwe Ukoha
	Dr Alero Ajayi
	Dr Beade Numbere
	Dr Damilola Oko
	Dr Ifeyinwa Aniebo
	Ms Priye Ruth Igali
	Mr Ibrahim Khalil Ibrahim

Expert Review Team

Name	Organization
Dr U.M Ene-Obong	Public Health Department, Federal Ministry of Health
Dr Evelyn Ngige	Public Health Department, Federal Ministry of Health
Dr Nnenna Ezeigwe	Non-Communicable Diseases Division, Federal Ministry of Health
Dr Alayo Sopekan	Non-Communicable Diseases Division, Federal Ministry of Health
Dr M.T Malau	Non-Communicable Diseases Division, Federal Ministry of Health
Dr Mansur Ashafa	Non-Communicable Diseases Division, Federal Ministry of Health
Mrs Amadi Dorothy	Non-Communicable Diseases Division, Federal Ministry of Health
Mrs Omoyele Chiamaka	Non-Communicable Diseases Division, Federal Ministry of Health
Mrs Kehinde Akinkoye	Non-Communicable Diseases Division, Federal Ministry of Health
Mr Ologidi Lawrence	Non-Communicable Diseases Division, Federal Ministry of Health

Mrs Evelyn Nwachukwu	Non-Communicable Diseases Division, Federal Ministry of Health
Mr Tokunbo Farayibi	Non-Communicable Diseases Division, Federal Ministry of Health
Mrs Ngozi Nwosu	Non-Communicable Diseases Division, Federal Ministry of Health
Ms Ijeoma C Ike	Non-Communicable Diseases Division, Federal Ministry of Health
Dr Jibril Mohammed Yahaya	National Primary Health Care Development Agency
Dr Uduak Uwakmfon	Public Health Department, Health and Human Services Secretariat
Dr Olubumi Adeyemi	Public Health Department, Health and Human Services Secretariat
Dr Saddiq Adburrahman	Public Health Department, Health and Human Services Secretariat
Dr Yakubu Mohammed	FCT Primary Health Care Board
Dr Mary Dewan	Technical Officer, Non-Communicable Diseases, World Health Organization, Nigeria
Dr Bilkisu Mubi	University of Maiduguri Teaching Hospital, Maiduguri, Borno State
Prof. Andrew E. Uloko	Aminu Kano Teaching Hospital, Kano, Kano State
Dr Celestine O John	University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State
Dr Afoke Isiauwe	Rainbow Specialist Medical Centre, Lekki, Lagos State
Dr Alkali Mohammed	Diabetes Association of Nigeria / Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Bauchi State
Prof. Abiola Oduwole	Lagos University Teaching Hospital, Lagos State
Prof. Felicia Anumah	University of Abuja Teaching Hospital, Gwagwalada, FCT
Prof Rosemary Ogu	Medical Women's Association of Nigeria/ University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State
Mr Bernard Enyia	Diabetes Association of Nigeria
Dr Okoye Douglas	Department of Health Gwagwalada Area Council/Gwagwalada Township Clinic
Dr Patricia Damian	Primary Healthcare Centre, Dutse, Jigawa State
Dr Ekpereonne B. Esu	Cochrane Nigeria, University of Calabar Teaching Hospital, Calabar, Cross River State
Dr Moriam Chibuzor	Cochrane Nigeria, University of Calabar Teaching hospital, Calabar, Cross River State
Dr Emmanuel Effa	Cochrane Nigeria, University of Calabar Teaching hospital, Calabar, Cross River State
Dr Kelechi Ohiri	Health Strategy and Delivery Foundation
Dr Lilian Anomnachi	Health Strategy and Delivery Foundation
Dr Christine C. Ezenwafor	Health Strategy and Delivery Foundation
Dr Bridget A. Nwagbara	Health Strategy and Delivery Foundation
Dr Ndukwe Ukoha	Health Strategy and Delivery Foundation
Dr Beade Numbere	Health Strategy and Delivery Foundation
Dr Damilola Oko	Health Strategy and Delivery Foundation
Mr Ibrahim Ibrahim	Health Strategy and Delivery Foundation
Ms Priye Ruth Igali	Health Strategy and Delivery Foundation
Ms Damilola Makanjuola	Health Strategy and Delivery Foundation

Abbreviations & Acronyms

ACEi	Angiotensin Converting Enzyme inhibitor
ADA	American Diabetes Association
AER	Albumin Excretion Rate
AGREE	Appraisal of Guidelines for Research & Evaluation
A2RB	Angiotensin II Receptor Blocker
ART	Antiretroviral Therapy
BP	Blood Pressure
CCB	Calcium Channel Blocker
CHEW	Community Health Extension Worker
CKDEpi	Chronic Kidney Disease Epidemiology Collaboration
DAN	Diabetes Association of Nigeria
DASH	Dietary Approach to Stop Hypertension
DKA	Diabetic Keto-Acidosis
DM	Diabetes Mellitus
DPP-4	Dipeptidyl Peptidase – 4
eGFR	Estimate glomerular filtration rate
EML	Essential Medicines List
FMoH	Federal Ministry of Health
FBS	Fasting Blood Sugar
FPG	Fasting Plasma Glucose
GCS	Glasgow Coma Scale
GDM	Gestational Diabetes Mellitus
GoN	Government of Nigeria
GRADE	Grading of Recommendations, Assessment, Development and Evaluations
GLD	Glucose Lowering Drugs
GLP	Glucagon like Peptide
HbA1C	Glycated Haemoglobin
HDL	High Density Lipoprotein
HHS	Hyperglycaemic Hyperosmolar State
HIV	Human Immuno-Deficiency Virus

IDF	International Diabetes Federation
ISH	International Society of Hypertension
ISO	International Standards Organization
JCHEW	Junior Community Health Extension Worker
LCHW	Lay Community Health Worker
LDL	Low Density Lipoprotein
MDRD	Modification of Diet in Renal Disease
NCDs	Non-Communicable Diseases
NGC	National Guideline Clearinghouse
NICE	National Institute for Health and Care Excellence
OGTT	Oral Glucose Tolerance Test
PA	Physical Activity
PIPOH	Population, Intervention, Professional, Outcomes/outcome measurement and Health settings
PLWHA	People Living with HIV/AIDS
RCT	Randomized Controlled Trial
T1DM	Type 1 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus
WDF	World Diabetes Foundation
WHO	World Health Organization

1. Introduction

Diabetes is a common clinical condition in Nigeria, being managed at primary, secondary, and tertiary health centres in both the private and public sectors. It is the most common endocrine disorder encountered in clinical practice. Presently, management and prevention strategies have been carried out at different centres using various local guidelines. The Federal Ministry of Health (FMoH) recognizes that this chronic illness, which is assuming epidemic proportions in Nigeria, requires management and control, based on national guidelines. This guideline will ensure standardized medical care and patient self-management education to prevent acute complications and reduce the risk of long-term complications.

The prevalence of diabetes is increasing worldwide. The global burden of diabetes mellitus (DM) is estimated to be 425 million among adults (20 to 79 years) in 2017.¹ A projection for the year 2045 is put at 629 million with the largest increase expected to take place in regions where economies are moving from low- to middle- income status.¹ The World Health Organization has described the situation of non-communicable diseases as “epidemic.” Consequently, many countries (developed and developing), have identified DM as one of the major public health problems. The prevalence of DM in Nigeria is increasing with current WHO estimates of 4.3%.² Local studies carried out by researchers have figures ranging from 3 – 10%.^{3,4,5,6}

2. The Rationale for Guidance

This minimum standard of care is intended to equip patients, clinicians, researchers, and other health care professionals with the components of diabetes care, treatment goals, and tools for adequate patient management. It provides goals and targets that are suitable for most patients. However, individual preferences, co-morbidities, and other patient-specific factors may occasionally require modification of goals and targets. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as required.

3. Methodology

The recommendations in this document were adapted from high-quality diabetes prevention, care and treatment guidelines. The tools and processes used to produce this guideline were guided by the ADAPTE guideline development methodology.⁷

3.1. Guideline development core team

The Federal Ministry of Health led the guideline development process and formed a core team to coordinate the guideline development process. This core group was mandated to:

- Develop the scope and purpose of the guidelines.
- Develop health questions to be addressed.
- Identify and appraise the quality of existing Diabetes Mellitus guidelines, using the AGREE II checklist and scoring system.
- Select the guidelines that will be used for the adaptation process.
- Extract recommendations from selected guidelines.
- Develop the zero draft of the guidelines.

The core team was made up of representatives from the Non-Communicable Diseases (NCDs) Division of the Public Health Department of the Federal Ministry of Health, Health Strategy & Delivery Foundation, Healthcare Leadership Academy and the Nigerian office of the World Health Organization.

3.2. Developing the scope, purpose and questions

The core team used the PIPOH checklist to define the scope, purpose and health questions to be addressed by the guideline. PIPOH is an acronym for **P**atient population (including disease characteristics), **I**nterventions, **P**rofessionals, **O**utcomes and outcomes measures and **H**ealth care setting and context.⁷

Each member of the team completed the PIPOH checklist and then discussions were held to build consensus on the items that would be included through simple majority votes. Disagreements that had a bearing on implementation or costs of the guideline recommendations were carried over for further discussions in subsequent phases of the guideline development.

Determining the scope, purpose and health questions using the PPOH checklist

- **Patient population (including disease characteristics):** The core team decided that recommendations should cover type 1 diabetes and type 2 diabetes in children, adolescents and young adults, gestational diabetes in pregnant women and pre-diabetes in adults. Other types of diabetes mellitus (DM) were excluded due to paucity of data to elucidate their burden in the country. Recommendations for complications of DM, management of DM related emergencies and co-morbidities such as hypertension, dyslipidemia and HIV will also be included.
- **Interventions:** These will cover prevention measures at individual, community and policy levels, screening to identify individuals at risk of DM, diagnosis in resource-constrained settings, structured diabetes education, lifestyle modification and pharmacological treatments. Early identification of complications of DM, as well as management of DM-related emergencies at primary care levels were also included.
- **Professionals:** Guideline recommendations will target health professionals such as primary care non-specialist/GP doctors, nurses, community health extension workers, junior community health extension workers and community volunteers. Individuals, organizations and stakeholder groups who were identified to have potential vested interests in the development, implementation, monitoring and evaluation of this guideline are FMoH, State Ministry of Health (SMoH), public health practitioners and implementing partners. The primary end-users of the recommendations were identified to be the patients and their caregivers.
- **Outcomes and outcome measures:** The recommendations will aim to primarily prevent or delay the onset of DM among high-risk individuals and improve survival among people with DM. Health system level outcomes of importance were cost of care, improvement in quality of care, achieving task-shifting of some aspects of DM care and treatment from doctors and nurses to lower cadre health professionals (CHEWs/JCHEWs) and lay health workers. The guideline also aims to define standards for quality of care to address variations in treatment across the various health facilities in the country. In a broader context, public health outcomes that will be addressed by the guideline recommendations include morbidity, mortality, incidence and prevalence of DM.
- **Health care setting and context:** The recommendations will primarily target communities for preventive interventions and primary health care settings for screening, diagnosis and treatment. These will also be tailored to address the resource constraints related to equipment, infrastructure, health workers, etc. in most primary health care settings.

3.3. Search for existing guidelines

The core team searched National Guideline Clearinghouse (NGC) and websites of National Institute for Health and Care Excellence (NICE), International Diabetes Federation (IDF), World Diabetes Foundation (WDF), and American Diabetes Association (ADA). Guidelines produced by the Diabetes Association of Nigeria (DAN) were sought through communication with experts due to the absence of a website.

The search term used was ‘[diabetes mellitus](#)’ or ‘[hyperglycaemia](#).’

Table 1: Search Process and Results (May/June 2018)

Database searched	Filters used	Search yield	Relevant to DM	Included for appraisal
NGC	Date limit: 2015 to 2018	133	17 guidelines	10
NICE	Date limit: 2015-2018 Document type: Guidance Guidance category: Clinical guideline, NICE guideline, public health guideline, quality standards.	90	6 guidelines 3 quality standards	6
IDF	No filters applied during the electronic search, but the manual screening was done to apply date limit from 2015 to 2018 and to make a clear distinction between job aids and practice guidelines.	20	4 guidelines	4
WDF	No filters were applied during the electronic search. But the manual screening was done to apply date limit from 2015 to 2018 and to make a clear distinction between job aids and practice guidelines.	36	7 guidelines	0
ADA	No filters applied.	1	1 guideline	1

Eight duplicates were identified from the NGC, NICE, IDF and WDF websites.

Only guidelines that addressed the pre-determined PIPOH scope/questions and which were published between 2015 and 2018 were included.

3.4. Appraisal of eligible guidelines

Two members of the core team applied the AGREE II tool to appraise the quality of eligible guidelines.⁸ AGREE II consists of 23 items grouped in six domains: scope and purpose; stakeholder involvement; rigour of development; clarity of presentation; applicability; and editorial independence. Items are rated on a 7-point Likert scale ranging from ‘1 = strongly disagree’ to ‘7 = strongly agree.’

All the AGREE II domains were used to rate the overall quality of the guideline as minimum quality (domain score $\geq 50\%$) or high quality (domain score $\geq 70\%$). All six domains were selected because they address the rigour needed to identify and interpret the risk of bias and quality of evidence for the recommendation in the guidelines.

In cases where the method and processes of all guidelines developed by an organization were identical (e.g.NICE), the guidelines were not appraised separately but rather they were appraised as a single guideline.

The two assessors then compared their scores for each item. When their scoring on each domain differed by more than three points, differences were resolved through discussion. If an agreement could not be reached, a third assessor helped to resolve the disagreement. The AGREE inter-rater agreement spreadsheet and AGREE score calculation spreadsheet was used to guide the scoring and consensus-building between the two assessors.

The Kappa statistic for the inter-rater agreement was also calculated using Stata version 13.

3.5. Selecting guidelines to be used for adaptation

Only guidelines that scored 70% and above were selected for adaptation.

3.6. Developing guideline recommendations

Recommendations in the selected guidelines that addressed the health questions were extracted by members of the core team using an extraction template. Discussions were held to decide if

the recommendations would be included in the guidelines based on the following considerations:

- Implementation considerations to determine if the extracted recommendations would fit into the patient needs, professional standards as well as the organizational, health system, economic, political, social/cultural context in Nigeria.
- Resource considerations to determine if the available resources (equipment, infrastructure and human resources) at community, primary, secondary and tertiary health care levels would be adequate to enable the application of the extracted guideline recommendation.
- Costs to determine if the recommendations will be affordable by the public and health care decision-makers.
- Equity to determine if the coverage and access to the health intervention in the recommendation can be achieved. The Nigerian Essential Medicines List (EML) of 2016,⁹ was searched to determine the equitable availability of drugs in extracted recommendations.

Extracted recommendations that included drugs that were not in the EML 2016 were mentioned but not included as final recommendations in the guideline. This also applied to recommendations that were deemed to be too costly or not feasible for implementation within the available resources and contextual factors at play in the Nigerian health system.

In cases, where a health question was not included in a guideline, a rapid electronic search for a systematic review, primary study or policy statement that addressed the recommendation was conducted.

3.7. Determining the level of evidence and grading of recommendations

The core team engaged with experts with strong technical expertise in the use of GRADE (Grading of Recommendations, Assessment, Development and Evaluation)¹⁰ methodology to determine the strength of each recommendation and the quality of the evidence.

3.8. External expert review and consensus building

An inclusive participatory process was used in the guideline development process to ensure that the diverse scenarios of clinical and public health practise across the country, technical expertise of health care providers, and lived experiences of people living with diabetes were adequately considered in the recommendations.

The zero-draft was reviewed by experts who are either endocrinologists or specialists with strong technical knowledge of diabetes mellitus, health care providers working in primary health care settings, people living with diabetes who are members of DAN, diabetes educators or guideline development experts as well as policy experts from the Federal Ministry of Health's Non-Communicable Diseases (NCDs) division.

The initial review was done remotely through electronic forms and templates to allow experts to review the guideline recommendations for technical accuracy, consistency and feasibility in the local context. The quality of evidence and risk of bias associated with each recommendation was also reviewed by guideline development experts. The input from the experts was used to build the first draft of the guideline.

This was followed by a two-day meeting to review the first draft. The experts reviewed the background information and recommendations to ensure that all guideline recommendations will ensure comprehensive prevention and management of the types of diabetes mellitus within the outlined scope. This review also ensured that recommendations were in line with current evidence, practice approaches and scenarios in the country, and could be applied given the resource constraints in the Nigerian health system. A consensus on the recommendations was reached by simple majority votes. The input from this meeting was collated to build the second draft of the guidelines.

A four-day meeting was held to review and finalize the second draft in line with the agreed scope and purpose as well as the overall vision and targets of the Federal Ministry of Health.

4. Scope and Purpose

This document aims to provide evidence-informed recommendations on the prevention, care and treatment of diabetes mellitus that are feasible in resource-constrained settings and the different levels of care in the Nigerian health system. This guideline will also set the quality standards to inform training and clinical practice on diabetes care and treatment in Nigeria.

The scope of this guideline will cover the following areas:

- Prevention of type 2 diabetes through community and policy level interventions.
- Screening to identify individuals at high risk for developing type 2 diabetes.
- Prevention or delay of onset of type 2 diabetes in individuals at high risk of developing type 2 diabetes.
- Lifestyle modification for managing type 1 and type 2 diabetes mellitus in children, adolescents and adults.
- Drugs for treating type 1 and type 2 diabetes mellitus in children, adolescents and adults.
- Screening to identify pregnant women with gestational diabetes mellitus.
- Lifestyle modification and drug treatment for managing diabetes in pregnancy.
- Prevention and early identification of diabetes mellitus complications.
- Management of diabetes mellitus related emergencies at primary and secondary health care levels in resource-constrained settings.
- Addressing risk factors and managing co-morbidities such as hypertension and HIV.

4.1. Health Questions

Table 2: Guideline questions

Prevention	<ol style="list-style-type: none">1. What community and policy level measures can be taken to prevent T2DM among the general population?2. What recommended intervention(s) can prevent or delay the onset of T2DM among individuals with a high risk of developing T2DM?3. What are the recommended measures for preventing progression to T2DM among individuals with pre-diabetes or impaired glucose tolerance?
Screening	<ol style="list-style-type: none">1. What are the recommended tools for risk assessment for T2DM?

Diagnosis	<ol style="list-style-type: none"> 1. What are the recommendations for the diagnosis of DM at the primary care level in resource-constrained settings?
Diabetes education for people with DM	<ol style="list-style-type: none"> 1. What is the evidence for including diabetes education in routine diabetes care and treatment? 2. What should be the recommended scope for diabetes education? 3. How should diabetes education be delivered in resource-constrained settings?
Lifestyle modification	<ol style="list-style-type: none"> 1. What are the recommended targets for lifestyle changes in the treatment of DM?
Drug treatment	<ol style="list-style-type: none"> 1. What drugs are recommended for treating T1DM in children? 2. What drugs are recommended for treating T2DM in children? 3. What drugs are recommended for treating T1DM in adults? 4. What drugs are recommended for treating T2DM in adults? 5. What add-on drugs are recommended for managing T1DM, and under what circumstances should they be used? 6. Which hierarchical order should be considered in the choice of first-line, second-line regimens for T2DM? 7. Should insulin be considered as a first or second-line drug in the treatment of T2DM? If yes, under what circumstances should it be considered as either? 8. Is there a preferred combination for triple therapy for T2DM? If yes, what combination?
DM-related emergencies	<ol style="list-style-type: none"> 1. What are the recommended life-saving measures that can be taken at primary health care level to manage DM related emergencies? (disaggregate by each type of complication). 2. What are the recommendations for the management of DM emergencies at the secondary care level?
DM complications	<ol style="list-style-type: none"> 1. What are the recommended measures for preventing DM related complications? 2. What are the recommendations for early identification of DM related complications?
Co-morbidities	<ol style="list-style-type: none"> 1. What are the recommendations for the management of other cardiovascular risk factors? 2. What are the recommended drug combinations for the treatment of high blood pressure in DM? 3. What are the recommendations for managing DM in HIV positive individuals?
DM & pregnancy	<ol style="list-style-type: none"> 1. What are the recommended tools for screening for gestational diabetes mellitus (GDM)? 2. How can GDM be diagnosed? How can you determine if a woman had overt diabetes before pregnancy? 3. What are the recommended measures for preventing the onset of GDM in pregnant women with high risk?

	<ol style="list-style-type: none"> 4. What are the recommended measures for managing GDM? 5. What are the recommendations for the management of DM in women who were diabetic before pregnancy?
Health professionals and settings	<ol style="list-style-type: none"> 1. What are the recommended roles of different cadres of health workers in the prevention, care, treatment and management of DM? 2. What are the recommended roles of different health care settings in the prevention, care, treatment and management of DM?

4.2. Target Audience

The guideline recommendations will target the following groups of health professionals:

- Primary care/general practice doctors.
- Non-physician health workers such as nurses, community health extension workers (CHEWs), junior community health extension workers (JCHEWs).
- Lay community health workers (LCHW).

The emphasis of recommendations in this section is on how non-physician and lay community health workers can work with skilled health workers to optimize diabetes prevention, care and treatment in resource-constrained, under-served and hard-to-reach settings.

4.2.1. Role of the Different Cadres of Health Workers

Primary Care/General Practice Doctors

Primary care or general practice doctors are responsible for

- Confirmation of diagnosis.
- Clinical evaluation.
- Follow-up of individuals with diabetes.
- Identification of the circumstances necessary for drug treatment.
- Prescription of drugs and determination of the line of management.
- Working with other members of the care team to provide structured diabetes education and support for self-care.

Nurses, CHEWs/JCHEWs

- To provide culturally- appropriate and structured diabetes education.
- To convey diabetes self-management information and healthcare provider recommendations accurately to people living with diabetes.

- To identify and refer high-risk individuals to physicians.
- To identify and overcome cultural barriers to self-care or behaviour change.
- To participate in the evaluation of program, unit, or agency using clinical practice guidelines.
- To support people with diabetes, prevent complications associated with DM and to identify them early when they do occur.

Lay Community Health Workers (LCHW)

A lay health worker (LHW) is defined as a health worker who performs functions related to health care delivery and is trained in some way in the context of an intervention, but who has not received a formal professional or paraprofessional certificate or tertiary education degree. Other terms for lay health workers include ‘community health workers’ (CHWs) and ‘village health workers’ (VHWs). They are also regarded as lay health workers.¹¹

Training and empowering LCHWs to deliver current, accurate, and evidence-based information is very important to support people living with diabetes in self-management, behavioural change and problem-solving skills. This support to patients optimizes the available health care services to improve health outcomes in people affected by diabetes and their communities. Lay community health workers should be trained by a skilled health worker who understands evidence-based guidelines for diabetes education.

Lay community health workers should play the following roles:

- Implement diabetes community awareness and prevention programmes.
- Provide diabetes prevention messages and information to community members.
- Support people living with diabetes to gain access to a diabetes support system in their communities.
- Work with the health provider team to apply basic concepts of behaviour change to support people living with diabetes in effective self-management.
- Build community coalitions to meet the needs of people living with diabetes in the community.

Recommendations for integrating Lay Community Health Workers into Diabetes Prevention, Care and Management

1. Lay community health workers should work under the supervision of a licensed skilled health care provider (e.g. doctors, nurses, CHEWs).
2. Lay community health workers should be trained and mentored on core diabetes prevention, care and management knowledge, skills and competencies.
3. Lay community health workers should be integrated as part of a multi-level diabetes education and support team.
4. Lay community health workers serve as a link between people with or at risk of diabetes and other healthcare providers and the health care system.
5. Other health professionals should support the role of CHWs in the primary prevention of diabetes.
6. Lay community health workers should be involved in community activities for advocacy and mobilization.

4.2.2. Role of the Different Health Care Settings

This guideline also recommends a multi-level approach in diabetes prevention, care and treatment with a focus on community and primary health care settings.

A. **At the community level**, the following aspects of diabetes prevention, care and treatment are recommended:

1. Community-based health promotion.
2. Screening to identify individuals at risk of developing DM using risk assessment tools. This can be done during outreaches, mobile health services and community engagement.
3. Support to individuals identified to be at high risk of developing DM to prevent or delay the onset of DM.
4. Support for people living with diabetes to achieve self-management and lifestyle changes.
5. Support for people living with diabetes to prevent and identify complications/emergencies.

B. **At the primary health care level**, in addition to community-level activities, the following aspects of diabetes prevention, care and treatment are recommended:

1. Diagnosis of DM using point-of-care devices, diagnostic algorithms and risk assessment tools.
2. Basic clinical management of non-complicated DM such as:

- a. Patient evaluation
 - b. Structured diabetes education
 - c. Drug treatment
 - d. Support for lifestyle changes
 - e. Prevention and early recognition of DM complications
 - f. Early recognition of other co-morbidities
3. Basic life-saving measures in the management of DM-related emergencies.
 4. Referral of complicated DM cases and emergencies.

C. **At the secondary and tertiary health care level**, in addition to A and B above, there will be comprehensive management of DM complications and emergencies.

Recommendations in this guideline aim to achieve the following health system outcomes:

- Reduced cost of care.
- Improved quality of care.
- Task-shifting of some aspects of DM care and treatment from doctors and nurses to lower cadre health professionals (CHEWs/JCHEWs) and lay health workers.
- Well defined standards for quality of care.
- Reduced variations in treatment across the various health facilities across the country.
- Reduced DM-related morbidity and mortality.
- Reduced incidence and prevalence of DM.

4.3. Target Population

The recommendations in this guideline are targeted at meeting the needs of people with diabetes, their caregivers and communities. It aims to achieve the following health outcomes among individuals:

- Primarily prevent or delay the onset of DM among high-risk individuals.
- Improve survival among people with DM.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. Available@ <http://www.diabetesatlas>.
2. World Health Organization. Diabetes country profiles [Internet]. 2016 [cited 2019 September 11]. Available from: https://www.who.int/diabetes/country-profiles/nga_en.pdf?ua=1
3. Sabir A, Ohwovoriolè A, Isezuo S, Fasanmade O, Abubakar S, Iwuala S. Type 2 diabetes mellitus and its risk factors among the rural Fulanis of Northern Nigeria. *Ann Afr Med*. 2013 Oct-Dec;12(4):217-22.
4. Enang OE, Otu AA, Essien OE, Okpara H; Fasanmade OA, Ohwovoriolè AE, et al. Prevalence of dysglycemia in Calabar: a cross-sectional observational study among residents of Calabar, Nigeria. *BMJ Open Diabetes Res Care*. 2014 Jun;2(1):e000032.
5. Nyenwe EA, Odia OJ, Ihekwaba AE, Ojule A, Babatunde S. Type 2 diabetes in adult Nigerians: a study of its prevalence and risk factors in Port Harcourt Nigeria. *Diabetes Res Clin Pract*. 2003 Dec;62(3):177-85.
6. Uloko AE, Musa BM, Ramalan MA, Gezawa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. *Diabetes Ther*. 2018;9(3):1307–1316. doi: 10.1007/s13300-018-0441-1.
7. The ADAPTE Collaboration. Guideline adaptation: a resource toolkit [Internet]. 2010 2016 [cited 2019 September 11]. 95p. Available from: <https://www.g-i-n.net/document-store/working-groups-documents/adaptation/adapte-resource-toolkit-guideline-adaptation-2-0.pdf>
8. AGREE Next Steps Consortium. Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument [Internet]. 2017 [cited 2018 Jul 10]. Available from: <http://www.agreetrust.org>
9. Federal Ministry of Health. Nigerian Essential Medicines List 2016. [https://www.health.gov.ng/doc/Essential%20Medicine%20List%20\(2016\)%206th%20Revision.pdf](https://www.health.gov.ng/doc/Essential%20Medicine%20List%20(2016)%206th%20Revision.pdf)
10. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008 Apr;336(7650):924-6.

11. Glenton C, Colvin CJ, Carlsen B, Swartz A, Lewin S, Noyes J, et al. Barriers and facilitators to the implementation of lay health worker programmes to improve access to maternal and child health: qualitative evidence synthesis. *Cochrane Database Syst Rev*. 2013 Oct;(10):CD010414.

5. Classification and Diagnosis of Diabetes Mellitus

5.1 Classification of Diabetes Mellitus

Depending on the aetiology (cause) and pathophysiology (abnormal course) of the disease, diabetes mellitus can be classified into^{1,2}:

- Type 1 diabetes mellitus (T1DM)
- Type 2 diabetes mellitus (T2DM)
- Gestational diabetes mellitus (GDM)
- Other types of diabetes mellitus

Paradigm shift in classifying DM

The traditional belief that Type 1 DM occurs only in children and Type 2 DM occurs only in adults is no longer accurate. Extensive clinical research suggests that it occurs in both age groups.

Extensive clinical research has also shown that Type 1 DM may be idiopathic but rare with no known cause among Africans and is strongly inherited.

5.1.1 Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus (T1DM) is caused by autoimmune destruction of β -cells with consequent absolute insulin deficiency. Extensive studies show that the persistent presence of two or more auto-antibodies is a strong marker for developing hyperglycaemia. However, the rate of progression to T1DM depends on the age at which the autoantibodies were first detected, the number, specificity and titer of autoantibodies.

Type 1 DM has three distinct stages that can be used to inform clinical decision making.^{3,4}

Stage 1 is characterized by autoimmunity, normal blood sugar levels and diagnosed by the presence of multiple autoantibodies but no impaired glucose tolerance or impaired fasting glucose.

Stage 2 is characterized by autoimmunity, impaired glucose tolerance and no symptoms, and can be diagnosed by the presence of multiple autoantibodies with impaired glucose tolerance or impaired fasting glucose. Fasting plasma glucose of 5.6 – 6.9 mmol/L (100 – 125 mg/dL) or 2-hour plasma glucose of 7.8 – 11.0 mmol/L (140 – 199 mg/dL) is suggestive of this stage.

Stage 3 is characterized by the onset of increased blood sugar levels (hyperglycaemia) and the presence of clinical symptoms and can be diagnosed using standard criteria of DM diagnosis.

5.1.2 Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM) is due to insulin resistance with a progressive loss of or impaired β -cell insulin secretion. This could be due to metabolic stress and other genetic or environmental factors.³ The condition also manifests as a continuum from normal to impaired glucose tolerance to overt diabetes.³

5.1.3 Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is high blood sugar levels (hyperglycaemia) that manifest for the first time in pregnancy, usually during the second or third trimester. A distinction between overt or pre-existing diabetes can be made if screening for pre-existing diabetes is done during the first trimester of pregnancy.^{5,6}

5.1.4 Other Types of Diabetes Mellitus

These include:

- Monogenic diabetes syndromes (neonatal diabetes, maturity-onset diabetes of the young).⁷
- Diseases of the pancreas (pancreatitis).⁸
- Drug or chemical induced diabetes due to the use of steroids or anti-retroviral treatment or organ transplantation.⁹

5.2 Diagnosis of Diabetes Mellitus

5.2.1 Diagnosis of Diabetes Mellitus in Adults

Diagnosis of diabetes mellitus in adults can be made based on either^{10,11,12}:

- Fasting blood glucose
- 75-g oral glucose tolerance test (OGTT)
- Random blood glucose
- HbA1C

Special diagnostic consideration for adults at primary health care level in resource-constrained settings

Random blood glucose of more than 11.1 mmol/L (200 mg/dL) in individuals with symptoms like frequent thirst, increased frequency of urination and increased appetite.

BOX 1: RECOMMENDATIONS FOR DIAGNOSIS OF DIABETES MELLITUS IN ADULTS^{10,11,12}

Diagnosis of diabetes mellitus should be made on any of the following:

Fasting blood glucose: Blood glucose of (≥ 7 mmol/L (126 mg/dL) after eight hours of no food/calorie intake (*Expert Consensus Opinion*)

OR

75-g oral glucose tolerance test (OGTT): Blood glucose of ≥ 11.1 mmol/L (200 mg/dL) after two hours following a glucose load of 75g of anhydrous glucose dissolved in water (*Expert Consensus Opinion*)

OR

Random blood glucose: Blood glucose of ≥ 11.1 mmol/L (200 mg/dL) in individuals with symptoms suggestive of hyperglycaemia or DM (increased thirst, increased frequency of urination and increased appetite) (*Expert Consensus Opinion*)

OR

HbA1C: $\geq 6.5\%$ (48 mmol/mol) (*Expert Consensus Opinion*)

In the absence of symptoms of hyperglycaemia, diagnosis requires two abnormal test results on two separate days or from two different test samples.

Pre-diabetes will give the following blood sugar ranges:

Fasting blood glucose: 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL). (*Impaired fasting glucose*)

2-h blood glucose during 75-g OGTT: 7.8 mmol/L (140 mg/dL) to 11.0 mmol/L (199 mg/dL) (*Impaired glucose tolerance*)

(*Expert Consensus Opinion*)

Procedure for OGTT in adults

Procedure for OGTT in adults using 75-g glucose

The individual should be fasting for at least eight hours (overnight). Note the time of last meal taken the previous night before commencing test.

The individual is advised not to consume any food, drink or smoke for the duration of the test.

In the fasting state, draw 5ml of venous blood into a fluoride tube.

Then a glucose solution consisting of 75g glucose powder in 200 to 300ml of water is administered and should be drunk by the person within five minutes.

At 1 and 2- hours after the glucose load, draw 5ml of venous blood.

5.2.2 Diagnosis of Diabetes Mellitus in Children and Adolescents

Diabetes mellitus in children can manifest through symptoms that are common to other diseases. These presentations can be misleading. Therefore, the recommendation is that children who present with these symptoms should be tested for diabetes mellitus.¹³

Table 3: Common Presentations of DM in Children and Adolescents

Symptoms of diabetes in children		Other diseases with similar symptoms
Most common symptoms	Weight loss, bedwetting (urinating while sleeping in a child that has achieved nighttime continence), polyuria (frequent urination during the day and night), excessive thirst and tiredness.	Tiredness and weight loss are common with malnutrition and malaria.
Less common symptoms	Excessive hunger, blurred vision, mood changes, infections and abdominal pain.	Abdominal pain is common in gastrointestinal and surgical problems.
Severe symptoms	Frequent vomiting, dehydration, decreased consciousness, rapid and deep breathing.	Vomiting and dehydration are common in gastroenteritis. Rapid and deep breathing is common in pneumonia or bronchitis.

BOX 2: RECOMMENDATIONS FOR DIAGNOSIS OF DIABETES MELLITUS IN CHILDREN¹³

Diagnosis of diabetes mellitus should be made on any of the following in addition to the presence of overt symptoms:

Fasting blood glucose: Blood glucose of ≥ 7 mmol/L (126 mg/dL) after eight hours of no food/calorie intake. (Expert consensus opinion)

OR

Random blood glucose: ≥ 11.1 mmol/L (200 mg/dL) (Expert consensus opinion)

OR

75-g oral glucose tolerance test (OGTT): ≥ 11.1 mmol/L (200 mg/dL) (*diabetes*)

75-g oral glucose tolerance test (OGTT): 7.8 mmol/L (140 mg/dL) to 11.0 mmol/L (199 mg/dL) (*Impaired glucose tolerance*)

(Expert consensus opinion)

Procedure for OGTT in Children

Procedure for OGTT in children

- Ensure that the child has had an adequate diet (minimum of 150 g/day of carbohydrate) for at least five days before the test.
- Child should be fasting overnight not less than 8 hours and not more than 10 hours (allow 4 hours in infants). Note the time of last meal taken the previous night before commencing the test.
- Child can consume water during this period, but consumption of sweet drinks is not allowed.
- Physical exercise is not allowed during this period.
- Use capillary blood and glucometer to measure blood sugar before administering the glucose load **OR** draw 1ml of venous blood into a fluoride tube before administering the glucose load and send to the lab.
- Then a glucose solution consisting of 1.75g glucose powder per kg body weight (maximum 75g) diluted in 200mls of water is administered and should be drunk by the child within five minutes.
- At 1 and 2- hours after the glucose load, repeat blood sugar test using capillary. blood and glucometer **OR** draw 1ml of venous blood and send to the lab.

5.2.3 Diagnosis of Gestational Diabetes Mellitus

Screen all pregnant women at their first appointment (booking) to enable early detection of GDM and rule-out pre-existing diabetes or overt diabetes mellitus before pregnancy. Repeat GDM screening test for all undiagnosed pregnant women at 24 – 28 weeks using OGTT,^{5,6} Fasting Blood Glucose, 2-hour Postprandial Blood Glucose assay or a Random Blood Glucose. Test women with GDM for persistent diabetes at 4 – 12 weeks postpartum, using OGTT.

BOX 3: RECOMMENDATIONS FOR DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS^{5,6}

- Screen all pregnant women at their first appointment (booking) to enable early detection of GDM:
 - Fasting Plasma Glucose (FPG) ≥ 5.1 mmol/L (92 mg/dL)
- OR**
- 2hr-Postprandial Blood Glucose (PPG) ≥ 8.5 mmol/L (153 mg/dL)
- And to rule out pre-existing diabetes or overt diabetes before pregnancy, that is:
 - Fasting Plasma Glucose (FPG) ≥ 7.0 mmol/L (126 mg/dL)
- OR**
- Random Plasma Glucose (RPG) ≥ 11.1 mmol/L (200 mg/dL)

(Expert consensus opinion)

- Perform GDM screening test for all undiagnosed pregnant women at 24 –28 weeks using Oral Glucose Tolerance Test (OGTT), Fasting Blood Glucose, 2-hr Postprandial Blood Glucose assay or a Random Blood Glucose. *(Expert consensus opinion)*
- Test women with GDM for persistent diabetes at 4 – 12 weeks postpartum, using the OGTT and clinically appropriate non-pregnancy values. *(Expert consensus opinion)*

Table 4: Diagnostic Algorithm for GDM⁷

Diagnostic Algorithm for GDM		
1. GDM Screening at booking using fasting or random blood glucose test		
Overt/pre-existing DM before pregnancy	GDM	Normal
FPG value ≥ 7.0 mmol/L (126 mg/dL) RPG ≥ 11.1 mmol/L (200 mg/dL)	FPG $>5.1 - 6.9$ mmol/L (92 – 125 mg/dL).	FPG <5.1 mmol/L (92 mg/dL)
2. GDM screening at 24 – 28 weeks using OGTT		
Fasting Plasma Glucose (FPG)	1-hour after glucose load	2-hour after glucose load
5.1 – 6.9 mmol/L (92 – 125 mg/dL)	>10 mmol/L (180 mg/dL)	>8.5 mmol/L (153 mg/dL)

5.3 Considerations About Recommendations on the Diagnosis of DM

5.3.1 Implementation Considerations for the Diagnosis of DM

Oral glucose tolerance test (OGTT) should only be performed by trained and skilled health workers. HbA1C result is affected by conditions that are characterized by rapid red blood cell turnover like anaemia. The results are also affected by haemoglobinopathies. HbA1C should also be conducted using a method that is standardized to the DCCT (Diabetes Control and Complications Trial) aligned assay and certified by NGSP (National Glycohemoglobin Standardization Program) and is thus not recommended for community-based screening.

5.3.2 Harms/Benefits of Recommendations on the Diagnosis of DM

No harm is associated with early detection of DM, while a late diagnosis is associated with more complications.

References

1. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003;26:3160-7.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2014 Jan;37(Suppl1):S81-90.
3. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. *Diabetes*. 2017 Feb;66(2):241-55.
4. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging pre-symptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*. 2015 Oct; 38(10):1964-74.
5. McIntyre HD, Sacks DA, Barbour LA, Feig DS, Catalano PM, Damm P, et al. Issues with the diagnosis and classification of hyperglycemia in early pregnancy. *Diabetes Care*. 2016 Jan;39(1):53-4.
6. Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. *Int J Gynaecol Obstet*. 2015 Oct;131(Suppl 3):S173–211.
7. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care*. 2010 Mar;33(3):676-82.
8. Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. *Curr Diab Rep*. 2018 Jun 22;18(8):58.
9. Meier JJ, Giese A. Diabetes associated with pancreatic diseases. *Curr Opin Gastroenterol*. 2015 Sep;31(5):400-6.
10. Hecking M, Werzowa J, Haidinger M, Hörl WH, Pascual J, Budde K, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. *Nephrol Dial Transplant*. 2013 Mar;28(3):550-66.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2011 Jan; 34 Suppl 1:S62-69.

12. International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009 Jul; 32(7):1327-34.
13. Mayer-Davis EJ, Kahkoska AR, Jefferies C, Dabelea D, Balde N, Gong CX, et al. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology and classification of diabetes in children and adolescents. *Pediatric Diabetes*. 2018 Oct; 19 Suppl 27:7-19.

6. Preventing Diabetes Mellitus

6.1. General Preventive Measures for Non-Communicable Diseases (NCDs)

Health promotion and lifestyle management are recommended for modifying both behavioural and metabolic risk factors for non-communicable diseases.¹ Health promotion for preventing non-communicable diseases include community, social, policy and environmental interventions that will enable individuals to make healthy lifestyle choices.² The holistic approach embodied in the recommendations in this guideline is, therefore, in line with the WHO Global NCD Action Plan 2013-2020³ and the Nigerian multi-sectoral action plan for NCD prevention and control.⁴

6.1.1. General Measures for Preventing NCDs in Adults and Adolescents

Adults (pregnant women inclusive) and adolescents can take lifestyle measures to reduce their modifiable risk factors for NCDs.² Their surrounding policy, social, physical and economic environments should also support these healthy lifestyle choices.²

Lifestyle measures for preventing NCDs focus on diet, physical activity, smoking and alcohol intake.^{3,5} The lifestyle change targets are shown in table 5 below.

Table 5: Lifestyle Change Targets for Preventing NCDs^{5,6,7}

Healthy eating	Physical activity	Smoking and alcohol
<ul style="list-style-type: none">• Reduce saturated fatty acid intake to less than 7-10% of total energy intake.• Increase dietary fibre (minimum of 20g daily intake).• Intake of at least six servings of fruits and vegetables a day.	<ul style="list-style-type: none">• 150 minutes of moderate-intensity aerobic physical activity a week; OR• 75 minutes of vigorous-intensity aerobic physical activity a week.• Muscle strength training and balance exercise in older adults above 64 years.	<ul style="list-style-type: none">• Quit smoking or never smoke at all.• Avoid exposure to passive smoking.• Reduce alcohol intake.

<ul style="list-style-type: none"> • Reduce intake of free sugars to less than 5-10% of total energy intake. • Reduce sodium/salt intake to not more than 2g/day. 		
---	--	--

Physical activity intensity refers to the effort required to perform an activity. It depends largely on a person’s fitness or experience in doing physical activity. Moderate-intensity activities can be described as those that increase the heart rate with little or no rapid breathing while vigorous-intensity activities increase the heart rate substantially and cause significant rapid breathing. The table below provides examples of moderate- and vigorous-intensity exercises.

Table 6: Moderate and Vigorous Intensity Exercises⁵

Moderate-intensity physical activity	Vigorous-intensity physical activity
Brisk walking	Running
Dancing	Walking/climbing up a hill
Gardening	Fast cycling
Housework or domestic chores	Aerobics
Traditional hunting and gathering	Fast swimming
Active involvement with games and sports with children/walking domestic animals	Competitive sports and football
General building tasks (e.g. roofing, thatching, painting)	Heavy shovelling and digging
Carrying or moving loads less than 20kg	Carrying or moving loads more than 20kg

6.1.2. General Measures for Preventing NCDs in Children

Breastfeeding is associated with the prevention of childhood obesity and it reduces the risk of developing obesity and its associated NCDs later in life.^{5,8,9} For the first six months of life, exclusive breastfeeding is recommended for adequate nutrition and child survival.¹⁰ Breast milk provides all the essential nutrients, enzymes and antibodies that children need to grow well in the first six months of life and beyond.⁹ After six months, continued breastfeeding and complementary feeding with nutritious food groups (semi-solids and soft foods) help to meet

the energy and nutritional demands of infants and promotes healthy eating patterns in the long run.¹¹

Promoting physical activity through both structured and unstructured playtime is also critical and essential for preventing childhood obesity and its associated NCDs in later life.¹²

6.1.3. Community, Social, Economic, Environmental and Policy Interventions for Preventing NCDs

Whole-of-community health promotion activities

Community members and their leaders can initiate, implement and sustain interventions that help individuals within the communities to eat healthy diets and increase physical activity.⁵ Examples of communities include schools, workplaces, residential areas, health professional groups, etc. The box below provides examples of whole-of-community health promotion activities.

Whole-of-community health promotion interventions

Educational programs on healthy diet, physical activity, tobacco use cessation and reduced alcohol intake

- Information, education and communication.
- Mass media public awareness/social marketing campaigns.
- SMS based mobile applications (SMS based) for education and risk assessment and management.

Healthy feeding/eating programs

- Healthy infant and young children feeding programs.
- School based feeding programs.
- Removal of vending machines from schools and communities.
- Garden to kitchen cooking programs in schools.

Targeted community-based activities

- School based physical activity programs.
- Community physical activity programs like marathons, swimming, dancing etc.

Workplace interventions

- Discounted vouchers for sports/gym facilities.
- Active spaces or gyms in the workplace.
- Periodic workplace recreational

Environmental and Policy Health Promotion Interventions

These interventions are adapted from the *Nigerian Multi-Sectoral Action Plan (MSAP) for the prevention and control of NCDs*. Examples of these interventions are shown in the box below.

Environmental and policy health promotion interventions from the Nigerian MSAP⁴

- Create active spaces and opportunities for physical activity.
- Effective implementation, prioritization and enforcement of the National Tobacco Control Act, 2015.
- Enactment and implementation of a National alcohol control law (act).
- Develop a regulation on the reformulation of industrially produced foods to reduce the salt content and replace trans-fats and saturated fats with unsaturated fats.
- Develop and implement a policy on marketing sweetened foods and non-alcoholic beverages to children.

6.2. Prevention of T2DM Among High-Risk Individuals

Individuals at high risk for developing T2DM can be identified through risk assessment using a web-based or paper-based validated questionnaire/tool and/or blood glucose tests.

There are two categories of high-risk individuals:

- Category 1: Individuals that have a high-risk score using a validated risk assessment questionnaire **BUT** have fasting blood glucose levels of 5.5 mmol/L (99 mg/dL) or less.

BOX 4: RECOMMENDATIONS FOR PREVENTION/ DELAY OF ONSET OF T2DM/GDM IN HIGH-RISK INDIVIDUALS^{12,13,14,15}

Combined diet and physical activity are recommended for preventing onset of T2DM and GDM among individuals with high risk.

(Moderate certainty evidence, strong recommendation)

Combined diet and physical activity can be enhanced and sustained through behavioural counselling/therapy.

Web-based and mobile apps can be used to deliver combined diet and physical activity programs.

(Low certainty evidence, weak recommendation)

- Category 2: Individuals that have a high-risk score using a validated risk assessment questionnaire **AND** have fasting blood glucose levels between 5.6 mmol/L (100 mg/dL) and 6.9 mmol/L (125 mg/dL). This second category is considered pre-diabetes.

Intensive lifestyle management is essential for delaying progression to T2DM among individuals with high risk.²⁰

INDIVIDUAL, COMMUNITY AND POLICY LEVEL RECOMMENDATIONS FOR PREVENTION OF T2DM

Individual level^{13,14,15}

- Individual behaviour for preventing diabetes should focus on healthy eating/diet, increased physical activity, reduced smoking habits and alcohol intake.
(Moderate–high certainty evidence, strong recommendation).
- Individual level behaviour change interventions are enhanced and sustained through behavioural counselling/therapy.
- Devices such as pedometers or mobile phone applications should be used to support and monitor behaviour change (Moderate certainty evidence, strong recommendation).

Community Level^{16,17}

- Whole-of-community preventive measures are important for engaging communities to support community members to achieve behaviour changes that will prevent DM.
- Community rail- trails, pedometers, and school-health education programmes are the most cost-effective population wide interventions (Moderate certainty evidence, weak recommendation).

Policy Level^{18,19}

- Environmental and policy approaches for promoting healthy eating, physical activity and alcohol/drinking habits include:
 - Town/city planning to promote active recreation and physical activity fiscal policies to reduce the consumption of calorie-dense foods, alcohol and tobacco to prevent diabetes. (Low certainty evidence, strong recommendation)

6.2.1. Combined Diet and Physical Activity for Preventing or Delaying the Onset of T2DM or GDM Among Individuals with High Risk

All individuals with a high risk for developing T2DM should be counselled on combining diet and physical activity.²⁰ Combining diet and physical activity is effective in reducing blood glucose to normal thresholds and also reduces other cardiovascular disease risk factors (weight, blood pressure, and lipid levels).²¹

Combined diet and physical activity can be enhanced and sustained through behavioural counselling/therapy.^{21,22} Support from family members also helps to initiate and sustain behaviour change regarding diet and physical activity.^{21,22} Also, technology such as web-based and mobile applications can be used to provide counselling and support, as well as monitor behaviour change.^{23,24}

6.2.2. Metformin for Preventing or Delaying the Onset of T2DM Among Individuals with Pre-diabetes

Metformin has demonstrated long-term effectiveness and safety prevention in clinical trials for preventing or delaying the onset of T2DM in individuals with pre-

BEST PRACTICE STATEMENT ON PREVENTION OF DIABETES

Monitor individuals with pre-diabetes using metformin for 6 – 12 months and stop if there is no improvement in blood sugar level²⁰.

diabetes.²⁵ Metformin is recommended for individuals with pre-diabetes especially those who have BMI ≥ 35 kg/m², those aged 60 years, and women with prior gestational diabetes mellitus.^{26,27,28,29} Metformin is also recommended when intensive lifestyle modifications are not feasible, or when it is not achieving the desired blood glucose control in individuals with pre-diabetes.¹³

An initial low dose of 500mg daily should be the starting dose. This can be increased gradually as tolerated. Modified release metformin can be used if the standard metformin is not well tolerated.²⁰

Individuals with pre-diabetes placed on metformin should be monitored by checking fasting blood glucose every 3 months for about 6 – 12 months. If no improvement in blood sugar is observed, metformin should be stopped.²⁰

BOX 5: RECOMMENDATIONS FOR PREVENTING ONSET OF T2DM AMONG INDIVIDUALS WITH PRE-DIABETES^{26,27,28,29}

Intensive lifestyle modification should be used to prevent onset of DM.

(High certainty evidence, strong recommendation)

Metformin should only be used when intensive lifestyle modification is not feasible among pre-diabetes individuals with BMI ≥ 35 kg/m², those aged 60 years, and women with prior GDM.

(Moderate certainty evidence, strong recommendation)

6.3. Considerations about Recommendations for Prevention

6.3.1. Implementation Considerations

Combined diet and physical activity programs can be delivered as a group or individual sessions to support individuals in setting goals for weight loss, diet, exercise and address barriers that impede behaviour change. Group programmes are more cost-effective¹⁵ and should be considered in resource-constrained settings.

These programmes may include structured dietary and physical activity interventions. Due to low internet penetration and coverage in Nigeria, SMS based mobile applications can be used to deliver content for these programmes. The local languages should also be considered when developing content and mode of delivery for these programmes.

In rural settings with limited access to the internet and smartphones, use basic phones to send text messages. Customized diabetes education messages should be translated into local languages and circulated as posters, flyers, etc. Non-electronic tools can also be used for behavioural change communication (BCC).

Diaries for recording physical activity duration, intensity and dietary intake can be considered when web-based or mobile applications are not readily available.

6.3.2. Harms/Benefits of Recommendations on Prevention

There is no harm associated with lifestyle changes for preventing diabetes mellitus and other NCDs. Metformin use may be associated with vitamin B12 deficiency and peripheral neuropathy.

References

1. McQueen DV. NCDs, health promotion and public health. *Glob Health Promot*. 2013 Dec;20(4 Suppl):90-2.
2. The Ottawa Charter for Health Promotion [Internet]. 1986 [cited 2018 Jun 23]. Available from:
<http://www.who.int/healthpromotion/conferences/previous/ottawa/en/>
3. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020 [Internet]. Geneva, Switzerland: World Health Organization; 2013 [cited 2018 Jun 23]. 103 p. Available from:
http://www.who.int/nmh/events/ncd_action_plan/en/
4. Federal Ministry of Health. National Multi-Sectoral Action Plan for the prevention and control of non-communicable diseases (2019-2025) [Internet]. 2019 [cited 2019 Sep 11]. 137p. Available from:
https://www.iccp-portal.org/system/files/plans/NCDs_Multisectoral_Action_Plan.pdf
5. Waxman A, World Health Assembly. WHO global strategy on diet, physical activity and health. *Food Nutr Bull*. 2004 Sep;25(3):292-302.
6. World Health Organization. Guideline: Sugars intake for adult and children [Internet]. Geneva, Switzerland World Health Organization; 2015 [cited 2018 Jun 23]. Available from:
http://www.who.int/nutrition/publications/micronutrients/guidelines/vas_mtct_hiv/en/
7. World Health Organization. Guideline: Sodium intake for adults and children [Internet]. Geneva, Switzerland World Health Organization; 2012 [cited 2018 Jun 23]. Available from:
https://www.who.int/nutrition/publications/guidelines/sodium_intake_printversion.pdf
8. Yan J, Liu L, Zhu Y, Huang G, Wang PP. The association between breastfeeding and childhood obesity: a meta-analysis. *BMC Public Health*. 2014 Dec;14:1267.
9. Horta BL, Loret de Mola C, Victora CG. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-analysis. *Acta Paediatr*. 2015 Dec;104(467):30-7.
10. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. *Cochrane Database Syst Rev*. 2012 Aug;(8):CD003517.

11. World Health Organization, UNICEF. Global strategy for infant and young child feeding [Internet]. Geneva, Switzerland: World Health Organization; 2003 [cited 2018 Jun 23]. 30p. Available from:
<http://apps.who.int/iris/bitstream/handle/10665/42590/9241562218.pdf?sequence=1>
12. Bleich SN, Vercammen KA, Zatz LY, Frelief JM, Ebbeling CB, Peeters A. Interventions to prevent global childhood overweight and obesity: a systematic review. *Lancet Diabetes Endocrinol.* 2018 Apr;6(4):332-46.
13. American Diabetes Association Standards of medical care in diabetes—2014. *Diabetes Care.* 2015;38(Suppl 1):S31-S33.
14. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, et al. Using pedometers to increase physical activity and improve health: a systematic review. *JAMA.* 2007 Nov;298(19):2296-304.
15. Patnode CD, Evans CV, Senger CA, Redmond N, Lin JS. Behavioural counselling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2017 Jul;318(2):175-93
16. Laine J, Kuvaja-Köllner V, Pietilä E, Koivuneva M, Valtonen H, Kankaanpää E. Cost-effectiveness of population-level physical activity interventions: a systematic review. *Am J Health Promot.* 2014 Nov-Dec;29(2):71-80.
17. McGill R, Anwar E, Orton L, Bromley H, Lloyd-Williams F, O'Flaherty M, et al. Are interventions to promote healthy eating equally effective for all? Systematic review of socioeconomic inequalities in impact. *BMC Public Health.* 2015 May;15:457.
18. Powel LM, Chiqui JF, Khan T, Wada R, Chaloupka FJ. Assessing the potential effectiveness of food and beverage taxes and subsidies for improving public health: a systematic review of prices, demand and body weight outcomes. *Obes Rev.* 2013; Feb;14(2):110-28.
19. Andreyeva T, Long MW, Brownell KD. The impact of food prices on consumption: a systematic review of research on the price elasticity of demand for food. *Am J Public Health.* 2010 Feb;100(2):216–22.
20. National Institute for Clinical Excellence. Type 2 diabetes: prevention in people at high risk. NICE guideline (PH38). 2012 Feb.
21. Balk EM, Earley A, Raman G, Avendano EA, Pittas AG, Remington PL. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons

- at increased risk: a systematic review for the Community Preventive Services Task Force. *Ann Intern Med.* 2015 Sep;163(6):437-51.
22. Li R, Qu S, Zhang P, Chattopadhyay S, Gregg EW, Albright A, et al. Economic evaluation of combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. *Ann Intern Med.* 2015 Sep;163(6):452-60.
 23. Chen F, Su W, Becker SH, Payne M, Sweet CM, Peters AL, et al. Clinical and economic impact of a digital, remotely delivered intensive behavioural counselling program on medicare beneficiaries at risk of diabetes and cardiovascular disease. *PLoS One.* 2016 Oct;11(10):e0163627.
 24. Sepah SC, Jiang L, Peters AL. Long-term outcomes of a web-based diabetes prevention program: 2-year results of a single-arm longitudinal study. *J Med Internet Res.* 2015 Apr; 17(4):e92.
 25. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. *Diabetes Care.* 2012 Apr;35(4):731-7.
 26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002 Feb;346(6):393-403.
 27. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet.* 2009 Nov;374(9702):1677-86.
 28. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program outcomes study. *Lancet Diabetes Endocrinol.* 2015 Nov;3(11):866-75.
 29. Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH, Barrett-Connor E, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. *J Clin Endocrinol Metab.* 2015 Apr;100(4):1646-53.

7. Screening for Diabetes Mellitus in Adults

7.1. Rationale for Screening

About half of the people with Type 2 Diabetes Mellitus (T2DM) are not aware that they have the condition and may develop complications before they are diagnosed or even treated.¹ Screening for T2DM helps people understand their risk of developing the disease and then take measures to prevent or delay progression to diabetes.² A two-stage screening for T2DM facilitates early diagnosis, prevention and initiation of treatment.² It also provides an opportunity to identify and manage other cardiovascular risk factors.²

The first stage involves the use of a validated risk assessment questionnaire to elucidate known risk factors for developing T2DM and calculates a risk score that categorizes a person to have a high, moderate or low risk for developing T2DM. An example of a risk assessment questionnaire is the FINDRISC (Finnish Diabetes Risk Score), an eight-item questionnaire that provides a measure of the probability of developing T2DM over the following ten years. This assessment tool has been validated in Nigeria.³ The second stage of the screening will depend on the diabetes risk score elucidated in the first stage. Individuals with moderate to very high-risk scores should proceed to do a diagnostic blood glucose test.

If the diabetes risk score is moderate to high, but the result of the diagnostic blood glucose test is normal, the diagnostic blood glucose test should be repeated every year. The person should also be advised on lifestyle management for preventing the onset of T2DM. Other identified cardiovascular risk factors should also be actively managed.

Screening should be provider-initiated within health facilities. Community screening programs should only be carried out when there is a strong referral system.

7.2. FINDRISC Tool

The Finnish Diabetes Risk Score (FINDRISC) questionnaire is a user-friendly and affordable two-page tool that is suitable to predict future risk of diabetes development and detect non-symptomatic T2DM in most populations. Its performance and effectiveness have been evaluated in Nigeria.

7.3. Consideration about Recommendations on Screening

7.3.1. Implementation Considerations

The FINDRISC questionnaire can be used either as a paper-based form or an electronic form.

- Risk-based screening for pre-diabetes and/or type 2 diabetes should be considered in children and adolescents after the onset of puberty or ≥ 10 years of age, whichever occurs earlier, who are overweight (BMI >85th percentile) or obese (BMI >95th percentile) and who have one or more additional risk factors for diabetes.

7.3.2. Harms/Benefits of Recommendations on Risk Assessment and Screening

There is no risk or harm associated with the use of the FINDRISC questionnaire as a risk assessment tool.

References

1. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. *Diabetes Res Clin Pract.* 2017 Oct;132:169-70.
2. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. *Lancet.* 2011 Jul;378(9786):156-67.
3. Olamoyegun AM, Oluyombo R, Iwuala OS. The Performance of the Finnish Diabetes Risk Score (FINDRISC) questionnaire for screening individuals with undiagnosed type 2 diabetes and dysglycaemia in Nigeria. *J Adv Med Med Res.* 2017 Jan;1-8.
4. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. *BMJ.* 2011 Nov;343:d7163.

TYPE 2 DIABETES RISK ASSESSMENT FORM

Circle the right alternative and add up your points.

1. Age

- 0 p. Under 45 years
- 2 p. 45–54 years
- 3 p. 55–64 years
- 4 p. Over 64 years


2. Body-mass index

(See reverse of form)

- 0 p. Lower than 25 kg/m²
- 1 p. 25–30 kg/m²
- 3 p. Higher than 30 kg/m²

3. Waist circumference measured below the ribs (usually at the level of the navel)

- | | MEN | WOMEN |
|------|------------------|-----------------|
| 0 p. | Less than 94 cm | Less than 80 cm |
| 3 p. | 94–102 cm | 80–88 cm |
| 4 p. | More than 102 cm | More than 88 cm |



4. Do you usually have daily at least 30 minutes of physical activity at work and/or during leisure time (including normal daily activity)?

- 0 p. Yes
- 2 p. No

5. How often do you eat vegetables, fruit or berries?

- 0 p. Every day
- 1 p. Not every day

6. Have you ever taken medication for high blood pressure on regular basis?

- 0 p. No
- 2 p. Yes

7. Have you ever been found to have high blood glucose (eg in a health examination, during an illness, during pregnancy)?

- 0 p. No
- 5 p. Yes

8. Have any of the members of your immediate family or other relatives been diagnosed with diabetes (type 1 or type 2)?

- 0 p. No
- 3 p. Yes: grandparent, aunt, uncle or first cousin (but no own parent, brother, sister or child)
- 5 p. Yes: parent, brother, sister or own child

Total Risk Score

The risk of developing type 2 diabetes within 10 years is

- Lower than 7** Low: estimated 1 in 100 will develop disease
- 7–11** Slightly elevated: estimated 1 in 25 will develop disease
- 12–14** Moderate: estimated 1 in 6 will develop disease
- 15–20** High: estimated 1 in 3 will develop disease
- Higher than 20** Very high: estimated 1 in 2 will develop disease

Please turn over

WHAT CAN YOU DO TO LOWER YOUR RISK OF DEVELOPING TYPE 2 DIABETES?

You can't do anything about your age or your genetic predisposition. On the other hand, the rest of the factors predisposing to diabetes, such as overweightness, abdominal obesity, sedentary lifestyle, eating habits and smoking, are up to you. Your lifestyle choices can completely prevent type 2 diabetes or at least delay its onset until a much greater age.

If there is diabetes in your family, you should be careful not to put on weight over the years. Growth of the waistline, in particular, increases the risk of diabetes, whereas regular moderate physical activity will lower the risk. You should also pay attention to your diet: take care to eat plenty of fibre-rich cereal products and vegetables every day. Omit excess hard fats from your diet and favour soft vegetable fats.

Early stages of type 2 diabetes seldom cause any symptoms. If you scored 12–14 points in the Risk Test, you would be well advised to seriously consider your physical activity and eating habits and pay attention to your weight, to prevent yourself from developing diabetes. Please contact a public-health nurse or your own doctor for further guidance and tests.

If you scored 15 points or more in the Risk Test, you should have your blood glucose measured (both fasting value and value after a dose of glucose or a meal) to determine if you have diabetes without symptoms.

BODY-MASS INDEX

The body-mass index is used to assess whether a person is normal weight or not. The index is calculated by dividing body weight (kg) by the square of body height (m). For example, if your height is 165 cm and your weight 70 kg, your body-mass index will be $70/(1.65 \times 1.65)$, or 25.7.

If your body-mass index is 25–30, you will benefit from losing weight; at least you should take care that your weight doesn't increase beyond this. If your body-mass index is higher than 30, the adverse health effects of obesity will start to show, and it will be essential to lose weight.

BODY-MASS INDEX CHART




Figure 1: FINDRISC tool

8. Diabetes Education for Adults and Caregivers of Children and Adolescents

8.1 Rationale for Diabetes Education and Support

Structured diabetes education is effective in supporting individuals diagnosed with diabetes to achieve self-care, adopt lifestyle changes, adhere to medications, monitor blood glucose, meet glucose control targets, prevent complications and emergencies and improve treatment outcomes.^{1,2}

BEST PRACTICE STATEMENT ON DIABETES EDUCATION

- Diabetes education must be delivered by a health worker trained on diabetes education according to national standards.⁵

Diabetes education should also be aimed at supporting family members and caregivers in developing attitudes, beliefs, knowledge and skills for home care and to support self-management.

BOX 7: RECOMMENDATIONS FOR DIABETES EDUCATION.^{3,4,6,7}

- A structured diabetes education program is recommended as part of comprehensive diabetes care and treatment.
- Diabetes education should be offered immediately after diagnosis. (Very low to low certainty evidence, strong recommendation)
- Diabetes education must cover prevention, changes, medication adherence and self-care including footcare education. (Evidence not Graded)
- Diabetes education should be delivered in a mode, intensity, frequency and duration that is suitable to the patient needs and health care settings.⁴ (Evidence not Graded)

8.2 Timing of Diabetes Education and Support

Structured diabetes education should be offered at the following four critical timepoints⁸:

1. **At diagnosis:** All adults or children with diabetes should be offered an effective structured education programme immediately after the diagnosis has been made. If a person is unable to participate in a structured education programme, an alternative form of diabetes education that is equally effective should be provided.
2. **Annually:** To assess nutritional, emotional and educational needs of the person with diabetes every year.

3. When there is a change in factors that affect self-management and may also cause complications. Such factors include a change in health condition, living conditions or emotional needs.
4. When there is a change or transition in care and treatment.

8.3 Content of Structured Diabetes Education

Structured diabetes education should cover the following areas: nutrition advice and skills to estimate the nutritional content (especially carbohydrates) of locally available foods, physical activity, weight control, how to take medications including how to inject the right dose of insulin for individuals on insulin, blood glucose monitoring and strategies to achieve the targeted blood glucose level and diabetes foot care.⁸

Children, adolescents and young people with diabetes and their parents/caregivers (for patients aged less than 19 years) should receive culturally sensitive and developmentally appropriate individualized diabetes self-management education and support according to national standards at diagnosis and routinely thereafter. Individuals with diabetes including children, adolescents and young people should be offered information and education to promote mental wellbeing.

8.4 Considerations about Recommendations on Diabetes Education

8.4.1. Implementation Considerations

Intensity, duration and mode of delivery of diabetes education

The effectiveness of diabetes education depends on the duration, intensity, mode of delivery and person delivering the education.⁹ Duration, intensity and mode of delivery of structured diabetes education must be appropriate, feasible for the implementation context and settings, and suitable to the patient's needs.

Inter-personal (group/one-on-one), electronic/digital platforms (videos and mobile apps) and printed forms (brochures and booklets) can be used to deliver diabetes education.^{10,11,12,13}

8.4.2. Harms/Benefits of Recommendations on Diabetes Education

Diabetes education is associated with better treatment outcomes. It is associated with improved knowledge and self-care behaviour.¹³

References

1. Cooke D, Bond R, Lawton J, Rankin D, Heller S, Clark M, et al. Structured type 1 diabetes education delivered within routine care: impact on glycaemic control and diabetes-specific quality of life. *Diabetes Care*. 2013 Feb;36(2):270-2.
2. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycaemic control. *Diabetes Care*. 2002 Jul;25(7):1159-71.
3. Butcher MK, Vanderwood KK, Hall TO, Gohdes D, Helgeson SD, Harwell TS. Capacity of diabetes education programs to provide both diabetes self-management education and to implement diabetes prevention services. *J Public Health Manag Pract*. 2011 May-Jun;17(3):242-7.
4. Beck J, Greenwood DA, Blanton L, Bollinger ST, Butcher MK, Condon JE, et al. 2017 national standards for diabetes self-management education and support. *Diabetes Care*. 2017 Oct;40(10):1409-19.
5. Worswick J, Wayne SC, Bennett R, Fiander M, Mayhew A, Weir MC, et al. Improving quality of care for persons with diabetes: an overview of systematic reviews - what does the evidence tell us? *Syst Rev*. 2013 May;2:26.
6. National Clinical Guideline Centre (UK). Type 1 Diabetes in adults: diagnosis and management [Internet]. London: National Institute for Health and Care Excellence (UK); 2015 [cited 2019 May 10]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK315808/>
7. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. *Diabetes care*. 2018 Jan;41(Suppl 1):S13-27.
8. Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Hess Fischl A, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. *Diabetes Care*. 2015 Jul;38(7):1372-82.
9. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycaemic control. *Patient Educ Couns*. 2016 Jun;99(6):926-43.
10. Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes

mellitus. A systematic review with meta-analysis. *BMC Health Serv Res.* 2012 Jul;12:213.

11. Deakin T, McShane CE, Cade JE, Williams RDRR. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2005 Apr;(2):CD003417.
12. Cochran J, Conn VS. Meta-analysis of quality of life outcomes following diabetes self-management training. *Diabetes Educ.* 2008 Sep;34(5):815-23.
13. He X, Li J, Wang B, Yao Q, Li L, Song R, et al. Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. *Endocrine.* 2017 Mar;55(3):712-31.
14. Deakin T, Cade J, Williams R, Greenwood DC. Structured patient education: the Diabetes X-PERT Programme makes a difference. *Diabet Med.* 2006 Sep;23(9):994-54.
15. Department of Health and Diabetes UK. Structured patient education in diabetes. Report from the Patient Education Working Group [Internet]. 2005 [cited 2019 May 20]. 74 p. Available from:
<https://www.diabetes.org.uk/resources-s3/2017-11/structuredpatiented.pdf>

9. Lifestyle Management for Adults

Lifestyle management is necessary to achieve blood glucose control target and reduce associated cardiovascular risk factors. Strict blood glucose control is vital for preventing or delaying the onset of complications,³ but this may not be easily achievable without lifestyle changes.

Lifestyle changes focus on diet, physical activity, alcohol and tobacco intake, and are usually targeted at weight loss or control, and strict blood glucose control.^{4,5,6,7}

BOX 8: RECOMMENDATIONS FOR LIFESTYLE CHANGES IN DM MANAGEMENT^{1,2}

- Lifestyle changes are an essential add-on to drug treatment in diabetes management.
- Lifestyle changes should begin as soon as a diagnosis is made to achieve targeted blood glucose control.
- Lifestyle changes focus on diet, physical activity, alcohol & tobacco intake.

(Moderate certainty evidence, strong recommendation)

9.1. Nutritional Recommendations

Reducing or controlling caloric intake, as well as improving the nutritional content of foods consumed to healthier options is imperative to achieve strict blood glucose control and reduce cardiovascular risk.

General nutritional recommendations associated with reduced cardiovascular risk are:

BOX 9: RECOMMENDED CALORIC TARGETS FOR LIFESTYLE CHANGE^{1,2}

- Reduce daily caloric intake by 500 to 600 calories in obese and overweight individuals with DM.
- Follow a low-calorie diet (800 to 1200 calories per day) under the supervision of a health worker or diabetes educator.

(Moderate certainty evidence, strong recommendation)

- Avoiding processed foods high in free sugars.
- Increased consumption of high fibre foods.
- Increased consumption of fruits and vegetables.
- Higher intake of nuts, berries and unsweetened yoghurt.
- Avoiding saturated fats and replacing cooking fats with monounsaturated or polyunsaturated fats.

Evidence supports the use of Dietary Approaches to Stop Hypertension (DASH)⁸ and Mediterranean dietary plans for reducing cardiovascular risk factors. Locally available foods that are similar or fit into food types in either the DASH or Mediterranean diet are, therefore, recommended.

The quantity and frequency of diets are also important in achieving targeted metabolic goals for keeping blood glucose and blood lipid levels within normal thresholds. Health care providers and diabetes educators should evaluate their patients for the presence of eating disorders, disrupted eating patterns and circumstances that could disrupt eating patterns. The treatment regimen and meal plan of people with diabetes who present with symptoms of eating disorders or disrupted eating patterns should be reviewed. There are dietary considerations that are specific to either T1DM or T2DM.

Weight loss targets for lifestyle changes in overweight or obese individuals with DM

- Reduce weight by 5 to 10% over a period of 12 months.
- BMI should be monitored at each encounter with a health worker or diabetes educator.

9.1.1. Special Dietary Considerations for Adult T1DM

In a person with T1DM, the following nutritional advice should be considered and discussed by health workers or diabetes educators:

- Carbohydrate counting where the carbohydrate content of the food, as well as fat and protein gram estimation, is known is important.
- Low glycaemic index diet for blood glucose control is not recommended.
- A food plan that enables the person to make optimal choices using the variety of locally available foods which fits into evidence-based dietary plans like DASH or Mediterranean diet.

BEST PRACTICE STATEMENT ON DIET FOR PEOPLE WITH T1DM

Health care providers and diabetes educators should work with their patients to develop individualized meal plans that suit the patient's taste, budget, culture, family situation and which can be made from cheap, locally available foods.

Fad diets (such as ketogenic, banting or atkins diet etc.) that are not evidence-based should be avoided. Caution should also be applied in consuming foods that are labeled to be suitable for diabetes. The content of such foods should be reviewed in line with dietary recommendations from a diabetes educator or health care provider.

- The appropriate insulin dose changes required when taking different quantities of these foods.
- Choice of snacks with an emphasis on the content, timing and quantity of snacks that will be consumed between meals.
- The different alcohol content of drinks and their effects on blood sugar and calorie intake.
- The benefits of healthy eating (consuming the appropriate amount of fats, fruits and vegetables) in managing blood glucose and in reducing cardiovascular risk factors.
- Unique features of the person like obesity, eating disorders, other co-morbidities like hypertension, renal disease and cultural/religious requirements.⁹⁻²⁰

9.1.2. Special Dietary Considerations for T2DM

People with T2DM should be advised on:

- Diets that are rich in fibre and low-glycemic index foods that can be sourced locally.
- Consumption of three to five daily portions of vegetables and/or fruits, fish, grains, and monounsaturated fats.
- Avoiding sugar, sweets and sweetened beverages.
- Use of individualized diet plans that promote caloric restriction but differ in the type of protein, carbohydrate, and fat content.
- Review of the medication plans to identify potential treatment-related effects (signs of increased or reduced sugar levels) associated with consuming different diets or caloric quantity.

9.2. Physical Activity

Physical activity in people with DM should be structured and regular to achieve the best glycaemic and cardiovascular results.

General physical activity recommendations for people with DM include:

- Moderate-intensity physical activity of 150min/week (see section 6.1 for descriptions of moderate and vigorous intensity) not more than 48 hours apart.

BOX 10: RECOMMENDATIONS FOR PHYSICAL ACTIVITY FOR PEOPLE WITH DM^{1,2}

Moderate-intensity physical activity of 150min/week, not more than 48 hours apart.

(Moderate certainty evidence, strong recommendation)

- Avoid prolonged sedentary time.
- Breaking up prolonged sedentary time periodically helps in lowering glucose levels after mealtimes.

There are special considerations for physical activity in T1DM and T2DM.

9.2.1. Special Physical Activity Considerations for T1DM

Glycaemic response to exercise in individuals with T1DM varies by person. These differences should be considered when recommending the type, intensity and duration of exercise for a person with T1DM.

Physical activity may cause hypoglycaemia if the dose of insulin or carbohydrate consumption is not altered. It may be necessary to consume additional carbohydrates if pre-exercise glucose levels are less than 5.6 mmol/L (100 mg/dL)²¹, depending on whether insulin doses can be lowered during the workout (such as with an insulin pump or reduced pre-exercise insulin dosage), the timing of the exercise (morning/evening), and the intensity and duration of the activity. In some patients, exercise increases insulin sensitivity and may cause hypoglycaemia to persist for several hours after exercise.

- Emphasize that physical activity helps in reducing cardiovascular risk in the medium and long term.
- Advice on the adequate intensity, duration and frequency of physical activity, and the effects on blood glucose level and nutritional needs.
- Emphasize the effect of exercise in reducing blood glucose level when insulin is adequate and the risk of worsening hyperglycaemia and ketonaemia when insulin levels are low.
- Advice on appropriate adjustments of insulin dosage and nutritional intake during and after exercise.
- Advice on the effect of alcohol on exercise and vice versa.

9.2.2. Special Physical Activity Considerations for T2DM

- People with T2DM who are not physically active should increase their physical activity.
- Such individuals should start with brisk walking for at least 150 minutes per week, at intervals of no longer than 48 hours.
- Vigorous-intensity exercise of at least 90 minutes a week may be needed for overweight and obese people with T2DM to achieve weight loss and to avoid regaining weight.²¹

9.3. Smoking and Alcohol

- Avoid smoking for individuals who have never smoked.
- Quit smoking for individuals who smoke.
- Avoid excess alcohol intake.
- Alcohol affects blood sugar levels and should be continued moderately in people who are unable to quit or who drink customarily and should not exceed 1 to 2 units per day.
- Alcohol should be avoided when taking low-calorie diets.

Steps for counseling on cessation of tobacco use²¹

The five steps are:

1. Reinforce message that tobacco increases cardiovascular risk.
2. Advise to quit in a clear, strong and personalized manner.
3. Provide information on health hazards of tobacco and give leaflet to the patient if available.
4. Assist in preparing a quitting plan.
5. At follow up visit, congratulate success and reinforce messages. If patient has relapsed, consider more intensive follow-up and support.

9.4. Considerations about Recommendations on Lifestyle Management

9.4.1. Implementation Considerations

- Mobile and internet applications can support lifestyle changes and goals.
- Locally available foods can be used to ensure adherence to dietary recommendations.
- Physical activity can also be achieved through home-based activities.

9.4.2. Harms/Benefits of Recommendations on Lifestyle Management

There is no risk associated with lifestyle management interventions.

References

1. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management (NICE guideline No. 17) [Internet]. London: National Institute for Health and Care Excellence (UK); 2015 [cited 2019 May 10] Available from: <http://www.nice.org.uk/guidance/ng17>.
2. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. *Diabetes Care*. 2018 Jan;41(Suppl 1):S13-27.
3. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*. 2005 Dec;353(25):2643-53.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002 Feb;346(6):393-403.
5. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. *Lancet*. 2006 Nov;368(9548):1673-9.
6. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009 Nov;374(9702):1677-86.
7. Smith GD, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH, et al. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. *Ann Intern Med*. 2005 Mar;142(5):313-22.
8. Izadi V, Tehrani H, Haghghatdoost F, Dehghan A, Surkan PJ, Azadbakht L. Adherence to the DASH and Mediterranean diets is associated with decreased risk for gestational diabetes mellitus. *Nutrition*. 2016 Oct;32(10):1092-6.
9. Jacobs S, Harmon BE, Boushey CJ, Morimoto Y, Wilkens LR, Le Marchand L, et al. A priori-defined diet quality indexes and risk of type 2 diabetes: the Multiethnic Cohort. *Diabetologia*. 2015 Jan;58(1):98-112.
10. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. *Lancet*. 2014 Jun;383(9933):1999-2007.

11. Chiuve SE, Fung TT, Rimm EB, Hu FB, McCullough ML, Wang M, et al. Alternative dietary indices both strongly predict risk of chronic disease. *J Nutr.* 2012 Jun;142(6):1009-18.
12. Salas-Salvadó J, Bulló M, Babio N, Martínez-González MÁ, Ibarrola-Jurado N, Basora J, et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care.* 2011 Jan;34(1):14-9.
13. Salas-Salvadó J, Guasch-Ferré M, Lee CH, Estruch R, Clish CB, Ros E. Protective effects of the Mediterranean diet on type 2 diabetes and metabolic syndrome. *J Nutr.* 2015 Apr;146(4):920S–927S.
14. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis. *Ann Intern Med.* 2016 Jul;165(7):491-500.
15. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. *Am J Clin Nutr.* 2014 Jul;100(1):278-88.
16. Mursu J, Virtanen JK, Tuomainen T-P, Nurmi T, Voutilainen S. Intake of fruit, berries, and vegetables and risk of type 2 diabetes in Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr* 2014;99:328–333.
17. Chen M, Sun Q, Giovannucci E, Mozaffarian D, Manson JE, Willett WC, et al. Dairy consumption and risk of type 2 diabetes: 3 cohorts of US adults and an updated meta-analysis. *BMC Med.* 2014 Nov;12:215.
18. Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. *Circulation.* 2016 Jan;133(2):187-225.
19. Parker AR, Byham-Gray L, Denmark R, Winkle PJ. The effect of medical nutrition therapy by a registered dietitian nutritionist in patients with prediabetes participating in a randomized controlled clinical research trial. *J Acad Nutr Diet.* 2014 Nov;114(11):1739-48.
20. Fedewa MV, Gist NH, Evans EM, Dishman RK. Exercise and insulin resistance in youth: a meta-analysis. *Pediatrics.* 2014 Jan;133(1):e163-74.
21. American Diabetes Association. 5. Lifestyle management: Standards of Medical Care in Diabetes – 2019. *Diabetes Care* 2019;42(Suppl. 1):S46–S60.

22. World Health Organization. A guide for tobacco users to quit [Internet]. Geneva, Switzerland: World Health Organization; 2014 May [cited 2019 May 14]. 16p. Available from:
https://www.who.int/tobacco/publications/smoking_cessation/9789241506939/en/

10. Blood Glucose Control Targets in Adults

10.1. Recommended Blood Glucose Targets

Individuals with diabetes should aim to achieve the following blood glucose targets:

HbA1c

HbA1c is effective in monitoring long term blood glucose control.¹ An HbA1c target of 48 mmol/mol – 53 mmol/mol (6.5% - 7%) is recommended to reduce the risk of vascular complications when a person has access to HbA1C and can afford it.^{2,3,4,5,6}

- HbA1c of 64 mmol/mol (8%) may be appropriate for patients with a history of severe hypoglycaemia, limited life expectancy, advanced microvascular or macrovascular complications, extensive comorbid conditions, or long-standing diabetes.¹

Fasting and postprandial blood glucose targets

Fasting and postprandial blood glucose in self-monitoring should be:

- 5 – 7 mmol/L (90 mg/dL – 126 mg/dL) when waking up in the morning.
- 4 – 7 mmol/L (72 mg/dL – 126 mg/dL) before meals and other times of the day in individuals with T1DM.
- 5 – 9 mmol/L (90 mg/dL – 162 mg/dL) after meals in individuals with T1DM.

BOX 11: RECOMMENDATIONS FOR BLOOD SUGAR TARGETS AND MONITORING IN RESOURCE-CONSTRAINED SETTINGS⁷

A fasting capillary blood glucose <6 mmol/L (roughly 110 mg/dL) and postprandial blood glucose <10 mmol/L (180 mg/dL) in most measurements may predict an HbA1c <7% (53 mmol/mol).

This does not replace HbA1c.

10.2. Self-Monitoring of Blood Glucose

Self-monitoring of blood glucose using a glucometer that meets current ISO standards is essential in achieving strict blood glucose targets. It helps the individual to tailor their diet and physical activity to the observed blood glucose level, predict periods of hypoglycaemia and take the needed measures to avoid emergencies.

Self-monitoring is only useful for long term blood glucose control if it is used to inform clinical decisions and self-management plans.⁷ Educating people with diabetes on how to interpret results is very important.⁸

The fingertip is the recommended site for self-monitoring. Use of other sites is not recommended for conventional routine self-monitoring.

In resource-constrained settings where HbA1c is not readily available, achieving targeted fasting blood glucose levels daily can be useful as an insight into HbA1c.⁷

10.2.1. Special Considerations for Self-Blood Glucose Monitoring for Individuals on Insulin, During Pregnancy And Breastfeeding

- Advise on routine self-monitoring of blood glucose for at least four times a day (before meals and before bed) in individuals on insulin.^{9,10} On some occasions, when blood glucose levels are suspected to be low, it can be monitored before exercise or after meals.
- Advise the patient to test more often and when affordable; if the desired target for blood glucose control is not achieved, if there is an increase in the frequency of hypoglycaemia, when unwell or during periods of increased physical activity, during pregnancy or breastfeeding.
- Individuals with T2DM using insulin or sulfonylurea (SU) should monitor blood glucose before driving or exercise.

10.3. Considerations about Recommendations on the Diagnosis of DM

10.3.1. Implementation Considerations

HbA1c is not readily available in primary health care settings in Nigeria and is very expensive. It should be used only when it is accessible, available and affordable.

10.3.2. Harms/Benefits of Recommendations for Blood Glucose Control Targets

Very tight blood glucose control targets may lead to repeated episodes of hypoglycaemia and weight gain. On the other hand, intensive control has been shown to prevent or slow down the progression of diabetes-related complications. There is a need to balance the risks and benefits in children, the elderly, those who have experienced repeated episodes of hypoglycaemia as well as those with severe cardiovascular complications.

References

1. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes—2018. *Diabetes Care*. 2018 Jan;41(Suppl 1):S55-64.
2. The Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993 Sep;329(14):977-86.
3. Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*. 2000 Aug;321(7258):412-9.
4. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med*. 2009 Jan;360(2):129–39.
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008 Jun;358(24):2560-72.
6. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. *Lancet*. 2010 Aug;376(9739):419-30.
7. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. *Diabetes Res Clin Pract*. 2017 Oct;132:169-70.
8. Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. *Diabetes Care*. 2011 Feb;34(2):262-7.
9. Miller KM, Beck RW, Bergenstal RM, Golland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and haemoglobin A1c levels in T1D Exchange clinic registry participants. *Diabetes Care*. 2013 Jul;36(7):2009-14.
10. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R, et al. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. *Pediatr Diabetes*. 2011 Feb;12(1):11-7.

11. Drug Treatment for Diabetes

Individualized care should be considered when initiating drug treatment for people living with diabetes.¹ This involves tailoring the medication to meet the patient's needs/ preferences and entails considering the following:

- Efficacy of the drugs
- Risk of hypoglycaemia
- Blood glucose levels at the time of diagnosis
- Bodyweight
- Side effect(s)
- Cost of medication
- Patient's income
- Patient's activities and preferences

Because of resource constraints and equity, only drugs in the 2016 Essential Medicines List² will be

recommended in this guideline (see box above). Clinical inertia, that is, failure to initiate or intensify treatment promptly in individuals when needed to avoid raised blood glucose levels and subsequent complications, should be avoided in the treatment of T2DM.

Intensifying drug treatment by using combinations, changing drug types when necessary, or adjusting dosages when blood glucose targets are not met within 3 – 6 months, is very important for improving treatment outcomes and avoiding complications.

Glucose Lowering Drugs for Diabetes in the 2016 Essential Medicines List

Insulin injections

Mixed insulin	Biphasic isophane insulin	30% soluble, 70% isophane, 100 units/ml
Short-acting /bolus	Insulin, soluble (short acting)	100 units/ml in 10-ml vial
Long-acting/basal	Insulin, glargine	100 units/ml in 10-ml vial

Oral anti-diabetic medications (tablets)

Second generation sulphonylurea	Glibenclamide	5mg
	Gliclazide	80mg
	Glimepyride	1mg, 2mg, 3mg, 4mg
Biguanides	Metformin (hydrochloride)	500mg
DPP-4 inhibitors	Vidagliptin	50mg

11.1. Drugs for Type 1 Diabetes Mellitus

Insulin is recommended for T1DM. However, metformin should be considered as an add-on to insulin therapy, in adult patients with T1DM who are overweight or obese or in circumstances where the person wants to reduce daily insulin requirement and improve blood glucose control.^{3,4}

11.1.1. Insulin Regimens

- Multiple daily injection basal-bolus insulin regimens/prandial and basal insulin should be offered as the insulin injection regimen of choice for adults.
- Guidance should be provided to the individual on how to use multiple daily injection basal-bolus insulin regimens.
- Newly diagnosed patients with type 1 diabetes should not be offered non-basal-bolus insulin regimens (that is, twice-daily mixed, basal only or bolus only).
- Twice-daily insulin detemir should be offered as basal insulin therapy for adults with type 1 DM.
- Continue to use an existing insulin regimen that has achieved agreed blood glucose control targets.
- Use once-daily insulin glargine or insulin detemir if twice-daily basal insulin injection is not acceptable to the person, or once-daily insulin glargine if insulin detemir is not tolerated.
- Rapid-acting insulin analogues injected before meals should be offered instead of rapid-acting soluble human insulin to reduce the risk of hypoglycaemia for mealtime insulin replacement for adults with type 1 diabetes.
- Routine use of rapid-acting insulin analogues after meals is not advised for adults.

BOX 12: RECOMMENDATIONS FOR DRUG TREATMENT OF ADULTS WITH T1DM IN RESOURCE-CONSTRAINED SETTINGS

Insulin regimens recommended at primary care level in resource-constrained settings

Insulin detemir and rapid-insulin analogues are not in the current (2016) Nigerian Essential Medicines List

Based on this,

- a basal-bolus regimen made up of rapid-acting soluble human insulin and insulin-glargine should be used with strict self-blood glucose monitoring to avoid hypoglycaemia.
- use a twice-daily human or analogue mixed insulin regimen when a multiple daily injection basal-bolus insulin regimen is not possible or a twice-daily mixed insulin regimen is preferred.

(Moderate certainty evidence, strong recommendation)

- If a multiple daily injection basal–bolus insulin regimen is not possible and a twice-daily mixed insulin regimen is preferred, a twice-daily human mixed insulin regimen for adults should be offered.
- If hypoglycaemia that considerably affects the quality of life occurs frequently in an adult using a twice-daily human mixed insulin regimen, twice-daily analogue mixed insulin regimen should be considered.

BOX 13: RECOMMENDATIONS FOR DRUG TREATMENT OF CHILDREN WITH T1DM

The treatment for type 1 diabetes in children is insulin.

- Twice-daily insulin using both short-acting and intermediate-acting insulin. (If these insulins are not always available, pre-mixed insulin can be used as an alternative regimen).
- Basal-bolus regimen (the preferred option) - with short acting insulin given with main meals (usually three times per day) and intermediate-acting insulin given once or twice daily (evening, or morning and evening).

(High certainty evidence, strong recommendation)

11.2. Drugs for Type 2 Diabetes Mellitus

11.2.1. Initial/First-line Treatment

Drugs are the first-line of treatment to be given to a person that has been newly diagnosed with T2DM. The choice of initial or first-line treatment should depend on the effectiveness of the drug, presence of other diseases, weight, blood sugar level of the newly diagnosed person, kidney function and drug safety.⁵

Initial treatment may involve the use of one drug (monotherapy), a combination of drugs (combination therapy), or even insulin.

BOX 14: RECOMMENDATIONS FOR FIRST-LINE DRUG TREATMENT OF T2DM IN ADULTS

- Metformin is the preferred choice for initial monotherapy. Dosage should be titrated from 500 to 2000 mg per day with or after meals.
- Initial combination therapy is recommended when there is marked cardiovascular risk factor or high blood sugar levels between 11-15 mmol/l. A combination of metformin and another glucose lowering drug is recommended.

(High certainty evidence, strong recommendation)

Monotherapy

The choice of drug for initial first-line treatment with one drug in primary care settings should depend on making quick clinical decisions based on efficacy, safety, preference, patient compliance and cost-effectiveness.¹ Clinical decisions on efficacy should be made quickly with minimal clinical and laboratory evaluations. This is because the equipment and expertise for extensive clinical evaluation that will inform drug efficacy and safety for the person with T2DM may not be available at primary care level.

Monotherapy is not recommended when blood glucose at diagnosis is up to 16.7mmol/L or the person clearly shows symptoms like frequent urination and frequent thirst.

Metformin is the recommended initial or first-line drug for monotherapy when there is no clear contraindication.^{6,7} This treatment must be accompanied by lifestyle changes.

The use of metformin is associated with better blood glucose control, reduced cardiovascular risk and safety among individuals with some reduction in kidney function (estimated glomerular filtration rate as low as 30ml/min/1.73m²). Metformin is also effective in overweight and obese individuals.^{3,4}

Metformin should not be used when there is marked vomiting and dehydration. It is also important to note that the use of metformin is associated with vitamin B12 deficiency, so long-term use of metformin should be accompanied with vitamin B12 supplementation and monitoring.⁸ When metformin plus lifestyle change is unable to achieve blood glucose control targets, then dual therapy should be considered.

BOX 15: RECOMMENDATIONS FOR FIRST-LINE DRUG TREATMENT OF T2DM IN CHILDREN AND ADOLESCENTS^{3,4}

- Metformin is the first-line drug for treating T2DM in adolescents and young people.
- Basal insulin can be used as first-line if blood glucose level is as high as 13.9 mmol/L and there is marked symptoms such as frequent urination (bedwetting), weight loss, frequent thirst and dehydration.
- Basal insulin can also be used when metformin fails to achieve the targeted blood glucose levels.

(High certainty evidence, strong recommendation)

Initial combination therapy

Initial combination therapy has been shown to achieve better reduction in fasting blood glucose compared to monotherapy.⁹ Initial combination therapy should be considered when there is narrowing of the arteries because of plaque build-up (atherosclerosis) or hypertension and therefore the need to reduce cardiovascular risk is a priority.

Due to the efficacy and safety of metformin, initial combination therapy comprising metformin and any other drug in the essential medicines list can be used.

For patients with narrowing of the arteries, hypertension or cardiovascular disease, use of another drug for which there is clear evidence of efficacy in reducing cardiovascular risk factors, such as SGLT-2 inhibitors (e.g. empagliflozin) and GLP-1(e.g. Liraglutide), should be considered.^{5,6}

When metformin is poorly tolerated, other drugs in the essential medicines list can be used to replace metformin in the combination.

Initial insulin

Insulin only or in combination with other glucose-lowering drugs in the essential medicines list can be considered in the following conditions:

- Very high blood glucose level above 16 mmol/L
- Acute weight loss
- Dehydration
- Acute illness or
- Presence of ketones

Basal (long-acting) insulin is preferable to achieve a target fasting blood sugar level between 3.9 – 7.2 mmol/L.

BOX 16: RECOMMENDATIONS FOR INITIAL INSULIN FOR TREATMENT OF T2DM¹⁰

Insulin only or in combination with other glucose-lowering drugs in the essential medicines list can be considered as first-line treatment in the following conditions:

- Very high blood glucose level above 16 mmol/L
- Acute weight loss
- Dehydration
- Acute illness or
- Presence of ketones

(Very low certainty evidence, strong recommendation)

11.2.2. Dual Therapy

When metformin plus lifestyle change is unable to achieve blood glucose control targets within 3 to 6 months, then dual therapy should be considered.⁵

The choice of drugs for dual therapy is similar to initial combination therapy. The preferred combination for metformin is a sulfonylurea that is on the essential medicines list.

The choice of second-line drugs for dual therapy should be informed by the following:^{5,13}

- **Age:** Lower blood glucose targets should be set for younger people.
- **Bodyweight:** Drugs that help in weight loss should be considered in overweight or obese individuals.
- **Complications:** People with chronic kidney disease, cardiovascular disease or who are likely to have very low blood sugar levels should use drugs that aid in reducing these complications.
- **Duration:** People who have had the condition for a longer period and are yet to achieve blood glucose targets are likely to experience complications. These patients require combinations that will achieve targeted blood sugar levels quickly.

BOX 17: RECOMMENDATIONS FOR DUAL/TRIPLE THERAPY FOR TREATMENT OF T2DM^{11,12}

- The preferred combination for dual therapy is metformin + sulfonylurea. Consider person's **Age**, **Body weight**, the presence of **Complications** and **Duration** of disease.
(Low certainty evidence, strong recommendation)
- When triple therapy becomes imperative, the recommended and most feasible combination is Metformin + sulfonylurea + vildagliptin (DPP-4 inhibitor). Basal insulin can also be added if dual or triple therapy does not yield the blood glucose targets.
(Moderate certainty evidence, strong recommendation)

11.2.3. Triple Therapy

When dual therapy is unable to achieve blood glucose control targets within three to six months, then triple therapy should be considered.⁵

The third drug of choice will depend on the patient's health status, weight loss goals, cardiovascular risk factors as well as the efficacy and safety of the drug.

The third drug can be another oral glucose-lowering drug in the essential medicines list or basal insulin.

It is advisable to try a combination of three oral glucose-lowering drugs and then assess the patient after three months before adding insulin.

Based on the Essential Medicines List,² the triple therapy combination of oral glucose-lowering drugs readily available in Nigeria is:

Metformin + sulfonylurea + vildagliptin (DPP-4 inhibitor).

Note that DPP-4 inhibitors raise concerns about major adverse cardiovascular outcomes. However cardiovascular safety studies show that apart from saxagliptin, other DPP-4 inhibitors do not seem to have any effect on major adverse cardiovascular outcomes and risk for heart failure.^{14,15} Saxagliptin is associated with an increased risk for hospitalization for heart failure particularly in patients with chronic kidney disease or pre-existing heart failure.¹⁶

11.2.4. Algorithm for Treating Adults with T2DM

At diagnosis, there are four critical blood glucose levels to consider when deciding on the choice of drugs. These critical blood glucose levels are at HbA1c (corresponding blood glucose levels in mmol/l or mg/dl):

1. Less than 9% (11.7 mmol/L or 210 mg/dL).
2. Greater than or equal to 9% (11.7 mmol/L or 210 mg/dL).
3. Greater than or equal to 10% (13.3 mmol/L or 239.4 mg/dL).
4. Greater than or equal to 12% (16.7 mmol/L or 300 mg/dL) plus symptoms.

Note this algorithm is adapted from the ADA 2018 Standards for Diabetes care.⁵ A conversion table¹⁷ was used to approximate the average blood glucose level for a period of two to three months which corresponded to the HbA1c level.

Treatment Algorithm Chart




Figure 2: Treatment algorithm for Diabetes Mellitus

11.3. Considerations about Recommendations on Drug Treatment for Diabetes

11.3.1. Implementation Considerations

A stepped care approach is necessary for optimizing blood glucose levels using drugs that are available, accessible, and affordable.

Primary care physicians should initiate therapy and refer to specialists when triple therapy may be required.

For children and adolescents, having a flexible insulin regimen is preferred.

The offerings in the Essential Drug List and coverage by the National Health Insurance Scheme (NHIS) should be considered in choosing the medications for patients. However, this should not be allowed to limit the choice of therapy.

11.3.2. Harms/Benefits of Recommendations for Drug Treatment for Diabetes

The various diabetes medications may cause hypoglycaemia (low blood sugar) with devastating consequences. Some medications have adverse cardiovascular or neurologic effects. These should be explained to patients, appropriate risk stratification should be done, and treatments instituted to mitigate them. Good blood glucose control with drugs has the benefit of preventing or slowing down the onset of complications.

References

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan; 38(1):140-9.
2. Federal Ministry of Health. Nigerian Essential Medicines List 2016 [Internet]. 2016 [cited 2019 May 14]. Available from: <https://apps.who.int/medicinedocs/documents/s23528en/s23528en.pdf>
3. Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017 Aug;5(8):597-609.
4. Al Khalifah RA, Alnhdi A, Alghar H, Alanazi M, Florez, ID. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus in children: a systematic review and meta-analysis. *Pediatr Diabetes*. 2017 Nov;18(7):664-73.
5. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. *Diabetes Care*. 2018 Jan;41(Suppl 1):S73-S85.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008 Oct;359(15):1577-89.
7. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Ann Intern Med*. 2016 Jun;164(11):740-51.
8. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. *J Clin Endocrinol Metab*. 2016 Apr;101(4):1754-61.
9. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. *Ann Intern Med*. 2011 May;154(9):602-13.
10. Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: synopsis of the

World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. *Ann Intern Med.* 2018 Sep;169(6):394-7.

11. Madsen KS, Kähler P, Kähler LKA, Madsbad S, Gnesin F, Metzendorf MI, et al. Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2019 Apr;(4): CD012368.
12. Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2013 Mar;15(3):252-7.
13. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. *JAMA Intern Med.* 2014 Aug;174(8):1227-34.
14. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015 Sep;373(22):2117-28.
15. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017 Aug;377(7):644-57.
16. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med.* 2013 Oct;369(14):1317-26.
17. Diabetes.co.uk. Convert HbA1c to Average Blood Sugar Level [Internet]. 2019 Jan [cited 2019 May 21]. Available from: <https://www.diabetes.co.uk/hba1c-to-blood-sugar-level-converter.html>

12. Managing Cardiovascular Risk Factors

12.1. Lifestyle Management^{1,2}

Cardiovascular risk factors in individuals with diabetes mellitus can be managed through lifestyle management to achieve the following goals:

- Weight loss in obese and overweight individuals
- Lower blood pressure
- Lower blood lipid levels
- Improved metabolic and vascular health
- Prevention of adverse cardiovascular events like stroke

Lifestyle management for lowering cardiovascular risk factors in individuals with diabetes is specifically focused on:^{2,3}

- Caloric restriction
- Reducing sodium intake to 2,300 mg/day
- Increasing consumption of fruits and vegetables (8–10 servings per day) and low-fat dairy products (2–3 servings per day).
- Reducing alcohol intake to no more than 2 servings per day in men and no more than 1 serving per day in women.
- Increasing physical activity levels (see section 6.1).

The DASH (Dietary Approaches to Stop Hypertension) diet is particularly helpful as dietary support for managing cardiovascular risk factors in individuals with diabetes.¹

Drug treatment for managing cardiovascular risk factors such as hypertension and dyslipidaemia is discussed in section 11.

12.2. Aspirin for Managing Cardiovascular Risk Factors

Low-dose aspirin is useful for both primary and secondary prevention of atherosclerotic cardiovascular diseases in certain circumstances.

It is no longer recommended to use aspirin for primary prevention among adults with DM who have increased cardiovascular risk but no previous history of vascular disease and have an increased risk of bleeding.⁴

Aspirin is shown to be effective in reducing adverse cardiovascular events among individuals with diabetes who have had a previous cardiovascular event like myocardial infarction or stroke (secondary prevention).⁵

Aspirin is recommended for primary prevention in adults with diabetes who are aged 50 years or older and have at least one additional major risk factor (family history of premature atherosclerotic cardiovascular disease, hypertension, dyslipidemia, smoking, or chronic kidney disease/ albuminuria) who are not at increased risk of bleeding (e.g., older age, anaemia, renal disease).

BOX 18: RECOMMENDATIONS FOR THE USE OF ASPIRIN FOR SECONDARY PREVENTION OF CARDIOVASCULAR RISK FACTORS IN PEOPLE WITH DIABETES⁶

Use aspirin (75 – 162 mg/day) as a secondary prevention strategy in those with diabetes and a history of atherosclerotic cardiovascular disease.

(High certainty evidence, strong recommendation)

12.3. Considerations about Recommendations for Managing Cardiovascular Risk Factors

12.3.1. Implementation Considerations

Low dose aspirin is widely available, as captured in the essential medicines list and covered by the National Health Insurance Scheme. Patients with diabetes (especially T2DM) should have a risk assessment done, taking into consideration bleeding risk, age, baseline CVD risk as well as patient's preferences about taking aspirin and then availed the opportunity of its appropriate use.

12.3.2. Harms/Benefits of Recommendations for Managing Cardiovascular Risk Factor

The use of aspirin is of substantial benefit in reducing the risk for cardiovascular events such as non-fatal myocardial infarction and stroke in adults with diabetes who have prior cardiovascular disease. Aspirin use increases the risk of gastrointestinal bleeding and haemorrhagic stroke. The overall benefits should be weighed against the harms for individual patients.

References

1. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med*. 2001 Jan;344(1):3-10.
2. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014 Feb;311(5):507-20.
3. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. *Diabetes Care*. 2018 Jan;41 (Suppl 1):S86-104.
4. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care*. 2010 Jun;33(6):1395-402.
5. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009 May;373(9678):1849-60.
6. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet*. 2014 Jun;383(9933):1973-80.

13. Early Identification of Complications

13.1. Common Diabetes-Related Complications

Complications of diabetes are mainly due to damage of small blood vessels in the eye, kidney and foot as well as damage to large blood vessels in the heart and lower limbs. These complications occur when blood glucose control is very poor and there are prolonged high blood sugar levels (hyperglycaemia).

The most common complications that result from damage of small blood vessels include ¹:

- Progressive damage to the retina (retinopathy).
- Progressive loss of kidney function (nephropathy).
- Damage to peripheral nerves (peripheral neuropathy).
- Foot ulcers or blisters due to damage to the blood vessels of the foot.

BOX 19: RECOMMENDATIONS ON MEASURES FOR PREVENTING DM-RELATED COMPLICATIONS AT PRIMARY CARE LEVEL

Generally, primary health care workers can work with individuals with diabetes to prevent all complications by:

- Ensuring the person with diabetes achieves and sustains the targets for blood sugar control to reduce or slow disease progression.
- Ensuring that blood pressure and blood lipid levels are within normal limits to reduce or slow the disease progression.

(Evidence not graded)

Damage to large blood vessels was discussed in the previous section 8 on managing cardiovascular risk factors.

13.2. Identifying Diabetes-Related Complications at Primary Care²

Diabetes-related complications require specialist care and advanced medical evaluations for monitoring and management. They cannot be managed at primary care level given the lack of specialist care and equipment for definitive diagnosis and management.

See Box 19 for recommendations on measures that primary healthcare workers can take to prevent complications in individuals with diabetes.

13.2.1. Identifying Diabetic Retinopathy at Primary Care

A health worker at primary care should do the following to prevent and identify early signs of diabetic retinopathy ^{2,3}:

- Ask the person with diabetes about their sight and any problems they are experiencing with vision. Ask for common symptoms of retinopathy such as:

- Seeing spots or floaters
- Blurred vision
- Having a dark or empty spot in the centre of vision
- Difficulty seeing well at night

BOX 20: RECOMMENDATIONS FOR SCREENING FOR DIABETIC RETINOPATHY AT PRIMARY CARE³

- Ask questions about difficulties with vision.
- Conduct visual acuity using a simple visual acuity chart.
- Refer for comprehensive eye examination.

(Evidence not graded)

- Conduct visual acuity measurements using simple and easy to use visual acuity charts to determine how much central vision is affected.
- Counsel and refer the person for a comprehensive eye examination to screen for retinopathy.

BEST PRACTICE STATEMENT ON FREQUENCY OF SCREENING FOR DIABETIC RETINOPATHY

- Individuals with T1DM should have an initial dilated and comprehensive eye examination within five years of the onset of diabetes.
- Individuals with T2DM should have an initial dilated and comprehensive eye examination at the time of diagnosis.
- If blood sugar is well controlled and previous comprehensive eye examinations do not show any sign of retinopathy, then follow-up eye examinations should be done every 1 to 2 years.
- If previous comprehensive eye examinations showed signs of retinopathy, then follow-up eye examinations should be repeated at least annually. If retinopathy is progressing or sight-threatening, the examinations will be required more frequently.

13.2.2. Identifying Diabetic Nephropathy at Primary Care

A health worker at primary care should do the following to prevent and identify early signs of diabetic nephropathy:³

- Estimate albumin excretion rate (AER)
 - Use microalbumin/creatinine urine reagent strips (dipsticks) for urinalysis in a random spot urine sample. Timed or 24-hour collections are very cumbersome and do not yield any advantage in terms of accuracy.
 - Albumin excretion rate is estimated by the albumin-creatinine ratio (urine albumin per gram of urine creatinine in the same sample of urine).
 - A reading of 30 micrograms per gram of creatinine in a sample in two or three measurements taken 4 to 6 weeks apart shows persistent albuminuria.
- Estimate glomerular filtration rate (eGFR) by measuring serum creatinine.
 - Serum creatinine can be converted to eGFR using validated calculators such as MDRD (Modification of Diet in Renal Disease) or CKDEpi (Chronic Kidney Disease Epidemiology Collaboration) in people with T2DM.
 - Glomerular Filtration Rate (eGFR) of $<60 \text{ mL/min/1.73m}^2$ shows evidence of diabetic nephropathy.
 - Diabetic nephropathy is divided into the following stages:
 - Stage 3A when eGFR is $59\text{-}45 \text{ mL/min/1.73m}^2$
 - Stage 3B when eGFR is $44\text{-}30 \text{ mL/min/1.73m}^2$
 - Stage 4 when eGFR is $29\text{-}15 \text{ mL/min/1.73m}^2$
 - Stage 5 when eGFR is $<15 \text{ mL/min/1.73m}^2$
- Refer individuals with diabetes who show persistent albuminuria or abnormal glomerular filtration rate for specialist care.

BOX 21: RECOMMENDATIONS FOR SCREENING FOR DIABETIC NEPHROPATHY³

- Assess urinary albumin or albumin-to-creatinine ratio at least once a year.
- Estimate glomerular filtration rate in patients who have had T1DM for up to five years, in all patients with T2DM and in all patients with comorbid hypertension.

(Evidence not graded)

13.2.3. Identifying Diabetic Peripheral Neuropathy (DPN) at Primary Care^{4,5,6}

A health worker at primary care should do the following to prevent and identify early signs of diabetic neuropathy:

- Ask simple questions about the presence of abnormal sensation and the type of abnormal sensation in the feet. These abnormal sensations vary based on the class of sensory fibres affected.
 - Unpleasant or painful burning and tingling sensations show that small fibres are involved.
 - Numbness and loss of protective sensations (not being aware of pain) show that large fibres are involved. Loss of protective sensation is a serious risk factor for diabetic foot ulcers.
- Conduct the following simple tests to assess if small and large-fiber function and protective sensation are present:
 - Pinprick and temperature sensation test to evaluate small fibre function.
 - Vibration perception and 10-g monofilament to assess large fibre function.
 - 10-g monofilament to evaluate for loss of protective sensation.

BOX 22: RECOMMENDATIONS FOR IDENTIFYING DIABETIC PERIPHERAL NEUROPATHY (DPN) AND FOOT PROBLEMS^{3,7}

- Screen for DPN within five years of diagnosis of T1DM and immediately after diagnosis of T2DM.
- After the initial screening, screen annually, regardless of the results.
- Conduct full sensory and foot examination annually.
- Inspect foot at every visit to the health facility.

(Low certainty evidence, strong recommendation)

13.2.4. Diabetic Foot Care^{8,9}

Health workers in primary health care facilities should work with individuals with diabetes to prevent diabetic foot ulcers.

This can be achieved by:

- Complete foot examination. This entails:
 - Foot inspection with shoes and socks removed in a well-lit room.
 - Checking for the presence of calluses, nail abnormalities, and foot abnormalities.
 - Taking foot temperature.
 - Checking for pulses in the lower legs and feet.
- Educating the person on foot care as part of self-management. The person with diabetes should be taught to do the following:
 - Check foot every day for red spots, cuts, blisters and swellings.
 - Wear comfortable shoes.
 - Wash feet every day and dry them carefully, particularly between the toes.
 - Trim toenails carefully and file the edges with an emery board to avoid cuts while trimming the nails.
 - Avoid putting feet in hot or cold water.
 - Put feet up when sitting and do not cross legs for long periods.
 - Avoid smoking.
- Referral of individuals that show loss of sensation or foot abnormalities for specialist care.

13.2.5. Autonomic Neuropathy

Another serious complication of DM is autonomic neuropathy. This is due to damage to the nerves that control body functions and that are involuntary such as blood pressure, bladder function, temperature control, digestion and sexual function.^{10,11} The health workers should ask

for common symptoms of autonomic neuropathy that can be elucidated at primary care level such as:

- Not being aware of when blood sugar levels become very low (hypoglycaemia unawareness)
- Rapid heartbeats even when at rest (resting tachycardia)
- Low blood pressure on standing (orthostatic hypotension)
- Constipation
- Diarrhoea
- Not being able to control the urge to go to defecate (faecal incontinence)
- Erectile dysfunction
- Urgency to urinate, frequent urination and sometimes retention of urine (neurogenic bladder)
- Sudomotor dysfunction with either increased or decreased sweating

13.3. Considerations about Recommendations on Early Identification of Complications

13.3.1. Implementation Considerations

Primary care practitioners should recognize the thresholds for referring patients with any diabetes-related complication to the appropriate specialist. An initial link should be established with the relevant experts and care planned collaboratively. At primary health care centres where tests may not be available, a checklist of symptoms should be used for assessment and patients referred accordingly.

13.3.2. Harms/Benefits of Recommendations for Early Identification of Complications

The assessment for early diabetic complications is done with instruments that lead to minimal harm or no harm at all. The psychological distress associated with the diagnosis of any complication of diabetes should be borne in mind. The benefits of early diagnosis far outweigh the risks of non- or delayed diagnosis.

References

1. Fowler MJ. Microvascular and macrovascular complications of diabetes. *Clinical Diabetes*. 2008 Apr;26(2):77-82.
2. American Diabetes Association. 10. Microvascular complications and foot care: Standards of medical care in diabetes—2018. *Diabetes Care*. 2018 Jan;41(Suppl 1):S105-18.
3. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. *Diabetes Res Clin Pract*. 2017 Oct;132:169-70.
4. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care*. 2017 Jan;40(1):136-54.
5. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. *Curr Diab Rep*. 2014 Sep;14(9):528.
6. Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. *Diabetes Care*. 2014 Jan;37(1):31-8.
7. Bus SA, Van Netten JJ, Lavery LA, Monteiro-Soares M, Rasmussen A, Jubiz Y, et al. IWGDF Guidance on the prevention of foot ulcers in at-risk patients with diabetes. *Diabetes Metab Res Rev*. 2016 Jan;32(Suppl 1):16-24.
8. Boulton AJ, Armstrong DG, Albert SF, Frykberg RG, Hellman R, Kirkman MS, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. *Diabetes Care*. 2008 Aug;31(8):1679-85.
9. Hingorani A, LaMuraglia GM, Henke P, Meissner MH, Loretz L, Zinszer KM, et al. The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. *J Vasc Surg*. 2016 Feb;63(2 Suppl):3S–21S.
10. Pop-Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *Diabetes Care*. 2010 Jul;33(7):1578-84.

11. Pop-Busui R, Cleary PA, Braffett BH, Martin CL, Herman WH, Low PA, et al. Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications). *J Am Coll Cardiol*. 2013 Jan;61(4):447-54.

14. Managing Emergencies in Primary Care Settings

14.1. Hypoglycaemia

Hypoglycaemia, also known as low blood sugar levels of less than 4 mmol/L (72 mg/dL) can pose an emergency in individuals with diabetes.¹ It could be mild, moderate or severe. It is a life-threatening condition when it occurs in severe forms and warrants urgent management.

Although most people with DM know when their blood glucose is getting very low, some who have had DM for a very long time are not aware of this and as such are more likely to experience the serious forms of hypoglycaemia.²


Those on insulin and/or sulfonylureas (glibenclamide, glyburide, gliclazide, glimepiride, glipizide and tolbutamide) are more prone to having very low blood sugars less than 4 mmol/L (72 mg/dL).³

Primary health care workers should work with people with diabetes to help them recognize when their blood sugar level is getting lower than 4 mmol/L (72 mg/dL) by informing them to look out for the following basic symptoms:

- Sweating
- Dizziness or tiredness
- Blurred vision
- Confusion
- Increased heart rate
- Convulsion
- Loss of consciousness
- Coma

The following algorithm shows the management of very low blood sugar levels at primary health care centres and higher levels of care.

Algorithm for Treating and Managing Hypoglycaemia



Important notes: Do not omit subsequent doses of insulin. Also continue monitoring of blood sugar using capillary blood and glucometer for up to 48 hours. Review dosage of insulin or oral glucose lowering drugs. Provide Diabetes education with emphasis on hypoglycaemia and refer to management team.

Figure 3: Algorithm for Treating and Managing Hypoglycaemia at Home and in Hospital⁴

14.2. Diabetic Keto-Acidosis

Diabetic keto-acidosis (DKA) is a serious complication that occurs most commonly due to infections but also following non-adherence to insulin treatment plans⁵ or unrecognized symptoms of new-onset T1DM. People with T1DM are particularly at risk for DKA.

High blood glucose, if not treated for a long time can lead to the build-up of harmful ketones in the blood.

Managing DKA requires emergency treatment in hospital by a specialist care team.⁶ However, DKA can be prevented at home and at primary health care to avoid emergencies.

14.2.1. Preventing DKA at Home and Primary Care

Primary health care workers should be able to provide education on the warning symptoms and signs of DKA in all age groups.

These warning signs are:

- Experience of frequent thirst, frequent urination and frequent appetite up to 20 days at a stretch
- Blood glucose levels ≥ 13.32 mmol/L (240 mg/dL)
- Periods of illness
- Ketones in urine using dipsticks
- Signs of dehydration like dry lips and mouth

Diabetic keto-acidosis can be prevented by observing sick day rules by adjusting insulin during periods of illness, frequent glucose monitoring and checking urine ketone levels using a dipstick test at home.

Refer individuals with diabetes presenting with high ketones and very high blood glucose levels and symptoms of high blood sugar for secondary care.

BOX 23: RECOMMENDATIONS FOR MANAGING DKA AT PRIMARY CARE LEVEL

DKA cannot be treated at primary care, as it requires specialist management.

(Evidence not graded)

BEST PRACTICE STATEMENT ON PREVENTING DKA AT PRIMARY CARE LEVEL

DKA can be prevented from occurring at primary health care by:

- Looking out for symptoms of hyperglycaemia and dehydration
- Monitoring blood glucose and ketone levels at home
- Adjusting insulin dosage during sick days and when blood sugar is still very high
- Adjusting insulin dosage with food consumption quantity and pattern to achieve best results
- Referring patients as soon as warning signs are recognized

14.2.2. Treating DKA in Adults

- Evaluate individuals presenting with DKA to assess the blood glucose level, dehydration, ketones, potassium loss, blood pH.
- Replace fluids.
- Give insulin intravenously.
- Maintain serum potassium levels between 4 and 5 mEq per L (4 and 5 mmol per L).
- Bicarbonate replacement should be recommended in individuals with a pH lower than 6.9 using 100 mEq of sodium bicarbonate in 400 mL of sterile water with 20 mEq of potassium chloride at a rate of 200 mL per hour for 2 hours.

The algorithm below should be followed to guide the management of DKA in adults.

Management of Diabetic Keto-acidosis




Figure 4: Workflow of Management of Adult DKA⁷

14.3. Hyperglycaemic Hyperosmolar State

The hyperglycaemic hyperosmolar state (HHS) is associated with significant morbidity and higher mortality than DKA and must be diagnosed promptly and managed intensively by a specialist team.⁶

At primary health care, the following signs can be used to recognize HHS:

- Blood glucose level of levels ≥ 33.3 mmol/l (600 mg/dl)
- Excessive thirst
- Dry mouth
- Increased urination
- Warm, dry skin
- Fever
- Drowsiness, confusion
- Hallucinations
- Vision loss
- Convulsions
- Coma

Hyperglycaemic hyperosmolar state cannot be managed at primary health care but it can be prevented.

BEST PRACTICE STATEMENT FOR PREVENTING HYPERGLYCAEMIC HYPEROSMOLAR STATE (HHS) AT HOME OR AT PRIMARY CARE LEVEL

- Recognize the symptoms of high blood glucose like increased thirst, increased urinating, dry mouth and skin or fever.
- Monitor your blood glucose level and be alert when it is above 13 mmol/L. This is because HHS may occur when it increases up to 30 mmol/L.
- Drink plenty of water when sick.
- Adhere to medications as well as dietary and physical activity plans.

14.3.1. Clinical Evaluation

As soon as HHS is diagnosed, assess for the severity by measuring the following:

- Serum electrolyte, urea and creatinine
 - plasma osmolality >350 mOsmol/kg (Normal range 280 – 300)
 - hypernatraemia with sodium >160 mmol/L (Normal range 135 – 145)
 - venous/arterial pH <7.1 (Normal range 7.35 – 7.45)

- hypokalaemia (<3.5 mmol/L) or hyperkalaemia (>6 mmol/L) (Normal range 3.5 – 5.0)
- serum creatinine >200 µmol/L (Normal range 60 – 110)
- Systolic blood pressure < 90 mmHg
- Pulse >100 or <60 bpm
- Urine output <0.5 ml/kg/hr
- Temperature below normal
- Level of consciousness below 12 using the Glasgow Coma Scale (GCS)

Check for other adverse cardiovascular events such as myocardial infarction or stroke.

14.3.2. Treatment Goals

The goals of treatment of HHS are to treat the underlying cause and to gradually and safely:

- Normalise plasma osmolality
- Replace fluid and electrolyte losses
- Normalise blood glucose

Other goals include prevention of:

- Arterial or venous thrombosis
- Other potential complications e.g. cerebral oedema/central pontine myelinolysis
- Foot ulceration

14.3.3. Treatment Procedure

A. Hour 1: Immediate management upon diagnosis: 0 to 60 minutes

- Commence IV 0.9% sodium chloride – 1 litre to run over 1 hour.
- Consider more rapid replacement if SBP is below 90 mmHg.
- Caution in the elderly where too rapid rehydration may precipitate heart failure but at the same time insufficient rehydration may fail to reverse acute kidney injury.
- Only commence insulin infusion (0.05 units/kg/hr) IF there are ketones in the urine (2+ or more).

Conduct full evaluation

B. 60 minutes to 6 hours

- Using 0.9% sodium chloride, aim to give a further 0.5 – 1 L/hr depending on clinical assessment of dehydration/ risk of precipitating heart failure and fluid balance (target is to achieve a positive fluid balance of 2 – 3 L by 6 hours).
- Measure glucose, urea and electrolytes hourly and calculate osmolality (2Na^+ + glucose + urea).
- If plasma sodium is increasing but osmolality is declining at an appropriate rate, continue 0.9% sodium chloride.
- If plasma sodium is increasing AND osmolality is increasing (or declining at less than 3 mOsmol/kg/hr), check fluid balance.
- If the positive balance is inadequate, increase the rate of infusion of 0.9% sodium chloride.
- If osmolality is increasing and fluid balance is adequate, consider switching to 0.45% sodium chloride at the same rate.
- If osmolality is falling at a rate exceeding 8 mOsmol/kg/hr consider reducing the infusion rate of IV fluids and/or insulin (if already commenced).
- If blood glucose is falling at less than 5 mmol/L per hour check fluid balance.
- If the positive balance is inadequate, increase the rate of infusion of 0.9% sodium chloride.
- If positive fluid balance is adequate, commence low dose IV insulin (0.05 units/kg/hr) or if already running, increase rate to 0.1 units/kg/hr.
- To maintain potassium in the normal range:
 - Hypokalaemia (<3.5 mmol/L) and hyperkalaemia (>6 mmol/L) are life-threatening conditions and warrant senior review.
 - Potassium replacement in infusion solution if potassium levels are very low.
 - Treat for high potassium levels.
- Avoidance of hypoglycaemia
 - Aim to keep blood glucose between 10 – 15 mmol/L in first 24 hours.
 - If blood glucose falls below 14 mmol/L commence 5% or 10% glucose at 125 ml/hr AND CONTINUE 0.9% sodium chloride solution.
- Monitor vital signs and chart Early Warning Score (EWS).
- Maintain accurate fluid balance chart (minimum urine output 0.5 ml/kg/hr).
- Repeat clinical evaluation.

C. 6 to 12 hours

The aim in this time is to:

- Ensure that clinical and biochemical parameters are improving.
- Continue charting blood glucose hourly, sodium and calculated osmolality 2 hourly.
- Continue IV fluid replacement to achieve a positive balance of 3 – 6 litres by 12 hours.
- Maintain an accurate fluid balance chart.
- Assess for complications of treatment e.g. fluid overload, cerebral oedema, extra pontine myelinolysis (e.g. deteriorating conscious level).
- Continue treatment of any underlying precipitant.
- Call for help if the patient is not improving.
- Avoid hypoglycaemia.
- Aim to keep blood glucose between 10 – 15 mmol/L in first 24 hours.
- If blood glucose falls below 4 mmol/L commence 5% or 10% glucose at 125 ml/hr AND CONTINUE 0.9% sodium chloride solution.
- Ensure referral has been made to the diabetes team.

D. 12 to 24 hours

- Ensure continuous improvement of clinical and biochemical parameters.
- Continue charting blood glucose hourly. The frequency for measurement of sodium and calculated osmolality can be reduced (4 hourly) if improvement is maintained (if not continue 2 hourly).
- Do not expect biochemistry to have normalised by 24 hours (sodium and osmolality are likely to be raised).
- Take appropriate action as outlined in time 60 minutes to 6 hours depending on results.
- Continue IV fluid replacement to achieve remaining replacement of estimated fluid losses within the next 12 hours – this will be dependent on factors such as initial degree of dehydration/body weight etc. and MOST IMPORTANTLY the response to treatment so far.
- Therefore, continue maintaining accurate fluid balance chart, plotting osmolality and making appropriate adjustments to fluid replacement rates.
- Continue IV insulin with or without 5 or 10% glucose solution to maintain blood glucose at 10 – 15 mmol/L.
- Adjust insulin infusion rate hourly by 1 unit/hr increments or decrements to achieve desired blood glucose.

- Assess for complications of treatment e.g. fluid overload, cerebral oedema, extra pontine myelinolysis (e.g. deteriorating conscious level).
- Continue treatment of any underlying precipitant. If the patient is not improving seek senior advice.

E. 24 hours to Day 3

- Ensure that clinical and biochemical parameters are improving or have normalized.
- Continue IV fluids until eating and drinking normally.
- Vary dosage of insulin if not eating and drinking and convert to the appropriate subcutaneous regime when biochemically stable.
- Encourage early movement.
- Assess for signs of fluid overload or cerebral oedema.
- Review the patient.

F. Aftercare at primary care level

- Most patients should go home on subcutaneous insulin (the regime is determined by their circumstances).
- For patients with previously undiagnosed diabetes or well controlled on oral agents, switching from insulin to the appropriate oral hypoglycaemic agent should be considered after a period of stability (weeks or months).
- Ensure the patient has appropriate diabetes education before discharge and arrange follow-up by the diabetes team.

14.4. Considerations about Recommendations on Managing Emergencies in Primary Care Settings

14.4.1. Implementation Considerations

The management of diabetic emergencies should be left for specialists. However, primary care practitioners should identify these emergencies and offer appropriate initial emergency care before referring for specialist care.

14.4.2. Harms/Benefits of Recommendations for Management of Emergencies in Primary Care Settings

The risk of increased morbidity and mortality is high with missed or delayed diagnosis. Low blood glucose and electrolyte disorders may result from the use of inappropriate fluids. However, outcomes are better with prompt initial management and the aggressive institution of appropriate therapy supervised by a diabetes specialist.

References

1. Workgroup on hypoglycaemia, American Diabetes Association. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on hypoglycaemia. *Diabetes Care*. 2005 May;28(5):1245-9.
2. Martín-Timón I, Del Cañizo-Gómez FJ. Mechanisms of hypoglycaemia unawareness and implications in diabetic patients. *World J Diabetes*. 2015 Jul;6(7):912-26.
3. Moghissi E, Ismail-Beigi F, Devine RC. hypoglycaemia: minimizing its impact in type 2 diabetes. *Endocr Pract*. 2013 May-Jun;19(3):526-35.
4. Algorithm for the treatment and management of hypoglycaemia in adults with diabetes mellitus in hospital. Available from:
https://www.nhshighland.scot.nhs.uk/YourHealth/Diabetes/Documents/hypoalgorithm_vsn8.pdf
5. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. *Diabetes Care*. 2009 Jul;32(7):1335-43.
6. Nyenwe EA, Kitabchi AE. Evidence-based management of hyperglycemic emergencies in diabetes mellitus. *Diabetes Res Clin Pract*. 2011 Dec;94(3):340-51.
7. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. *Diabetes Metab Syndr Obes*. 2014 Jun;7:255-64.

15. Managing Comorbidities

15.1. High Blood Pressure

Both diabetes and high blood pressure are serious cardiovascular risk factors on their own. The presence of high blood pressure (HBP) in a person with diabetes, therefore, constitutes a very serious cardiovascular risk which must be managed adequately to reduce the risk.^{1,2,3} Management of these co-morbidities involves both lifestyle modification and drug treatment.

15.1.1. Target Blood Pressure in Individuals with Type 2 Diabetes Mellitus

While the evidence from epidemiological studies and randomized controlled trials (RCTs) show that it is possible to achieve intensive blood pressure control with a systolic blood pressure <140 mmHg and a diastolic blood pressure <80 mmHg,⁴ the experience of clinicians is that this may be difficult to achieve in some instances.^{5,6} Individual blood pressure targets, therefore, need to be set following an informed discussion between the patient and provider after weighing the risks and benefits of therapy.

BOX 24: RECOMMENDATIONS FOR BLOOD PRESSURE TARGETS IN INDIVIDUALS WITH T2DM⁷

Target blood pressure in people with diabetes should be:

- <140/80 mmHg where there is no sign of kidney, eye, or cerebrovascular damage.
- <130/80 mmHg where there is evidence of kidney (including microalbuminuria), eye, or cerebrovascular damage.

(Expert consensus opinion)

15.1.2. Recommended Frequency of Blood Pressure Measurement

BEST PRACTICE STATEMENT ON FREQUENCY OF BP MEASUREMENT

- For adults with DM but no history of hypertension or kidney disease, measure BP annually.
- For adults with DM with known hypertension, measure every:
 - 1 month if blood pressure is higher than 150/90 mmHg.
 - 2 months if blood pressure is higher than 140/80 mmHg.
 - 2 months if blood pressure is higher than 130/80 mmHg and there is kidney (including microalbuminuria), eye or cerebrovascular damage.

Provide lifestyle advice, if blood pressure is confirmed as being consistently above 140/80 mmHg (or above 130/80 mmHg if there is kidney, eye or cerebrovascular damage), and add medications if lifestyle advice does not reduce blood pressure to below 140/80 mmHg (below 130/80 mmHg if there is kidney, eye or cerebrovascular damage).

For adults with DM with known hypertension who have consistently maintained their blood pressure target, measure BP every 4 to 6 months, and at these visits, assess for side effects of treatment including risks from unnecessarily low blood pressure.

15.1.3. Recommended Management⁸

Provide lifestyle advice to individuals with DM at every visit even where there is no history of hypertension. For adults with DM already on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used and make changes **only** if there is poor control or if the current drug treatment is not appropriate because of microvascular complications or metabolic problems. Where the person is already on antihypertensive therapy, and there is kidney, eye, or cerebrovascular damage, intensify treatment until the blood pressure is consistently below 140/80 mmHg or 130/80 mmHg.⁹

First-line antihypertensive drug treatment

The number and combination of drugs that will be used as first-line depend on:

- Blood pressure at diagnosis (between 140/90 mmHg and 160/100 mmHg or above 160/100 mmHg).
- The presence of proteins (albumin) in urine. (See Box 21)

For those intolerant of ACE inhibitors (where this intolerance does not include hyperkalaemia or renal dysfunction), substitute with an angiotensin II-receptor antagonist (A2RB) – however, **do not** combine an ACE-inhibitor with an A2RB to treat hypertension.^{9,10,11}

BOX 25: RECOMMENDATIONS FOR DRUG COMBINATIONS FOR FIRST-LINE TREATMENT OF HIGH BLOOD PRESSURE IN DM

Depending on the blood pressure at diagnosis or presence of proteins in urine, the first-line antihypertensive drug treatment should be a combination that contains Angiotensin Converting Enzyme inhibitor (ACEi) plus either a thiazide-diuretic (long-acting versions have been shown to reduce cardiovascular events) or a generic calcium-channel blocker (CCB).

(High certainty evidence, strong recommendation)

Note: *There is no ACEi in the 2016 EML, therefore, the recommended first-line drug is either a thiazide diuretic or a calcium channel blocker if there is no protein in urine.*

BOX 26: RECOMMENDATIONS FOR FIRST-LINE TREATMENT IN WOMEN PLANNING PREGNANCY

A calcium channel blocker (CCB) should be the first-line antihypertensive drug treatment for a woman, where it is agreed that there is possibility of her becoming pregnant – this decision should be made following an informed discussion with the woman – avoid ACEi or A2RB in women who are planning a pregnancy as these drugs cause fetal damage.

(Very low certainty evidence, strong recommendation)

Second-line antihypertensive drug treatment

Where blood pressure does not meet the set target with first-line therapy, add whichever drug that was not a part of the initial combination (CCB or diuretic).

Third-line antihypertensive drug treatment

Where the blood pressure does not meet the set target despite the addition of both a CCB and a diuretic, an additional antihypertensive should be introduced (see Box 28 for recommendations for third-line drug treatment).

If there is albumin in the urine or signs of kidney disease, ACEi or A2RB should be used as first-line and included in the combinations.

We maintain this recommendation despite the absence of ACEi or A2RB in the EML because they are the only class of anti-hypertensives that show protective effects in the kidneys in people with T2DM.

BOX 27: RECOMMENDATIONS FOR DRUG COMBINATIONS FOR SECOND-LINE TREATMENT OF HIGH BLOOD PRESSURE IN DM

Where blood pressure does not meet the set target with first-line therapy, add whichever drug that was not a part of the initial combination (CCB or diuretic).

(High certainty evidence, strong recommendation)

BOX 28: RECOMMENDATIONS FOR DRUG COMBINATIONS FOR THIRD-LINE TREATMENT OF HIGH BLOOD PRESSURE IN DM

Add an alpha-blocker, a beta-blocker or a *potassium-sparing diuretic or a mineralocorticoid receptor antagonist.

(*where the person is on either an ACEi or A2RB, potassium-sparing diuretics should be added with caution and serum potassium carefully monitored – additionally, spironolactone should **not** be administered to a pregnant woman as it causes fetal damage).

For patients on any one of the following: ACEi, A2RBs, thiazide diuretics, or potassium-sparing diuretics, renal function (serum creatinine and estimated glomerular filtration rate) and serum potassium should be checked at least annually.

(Moderate certainty evidence, strong recommendation)

Treatment Algorithm for Hypertension in DM




Figure 5: Treatment Algorithm for Hypertension in Diabetes Mellitus

15.2. Dyslipidaemias

Individuals with T2DM have a higher prevalence of dyslipidaemia, which is a well-recognised cardiovascular risk factor. Various lipid patterns may be seen in people with diabetes, however, the most commonly observed is an elevated triglyceride level often with a low level of HDL (high-density lipoprotein) cholesterol.¹² Of the lipid abnormalities, a high level of LDL (low-density lipoprotein) cholesterol is of concern and statins remain the preferred treatment option for LDL cholesterol reduction and cardio-protection.

Multiple clinical trials have shown that statins have beneficial effects on cardiovascular disease outcomes in people with or without pre-existing coronary heart disease, and subgroup analyses show that this is true for people with diabetes on statins.¹³ Also, there is evidence of benefit from very low-dose statins even when these are not taken daily – for example, in patients who are unable to tolerate higher, more frequent doses due to side effects. While there is limited trial data on the effectiveness of statin therapy in people with type 1 diabetes mellitus, the current recommendations are that similar approaches should be adopted for lipid-lowering in people with type 1 and type 2 diabetes mellitus.

There is much evidence from randomised controlled trials¹⁴⁻¹⁷ to support the use of statins in people with diabetes between the ages of 40 and 75 years in the primary prevention (where they do not have pre-existing atherosclerotic cardiovascular disease) or secondary prevention of atherosclerotic cardiovascular disease. This recommendation remains the same for those aged >75 years due to the higher cardiovascular risk conferred by age. Commencement of lipid-lowering therapy in people with diabetes <40 years should be made after consideration of the presence of additional cardiovascular risk factors and an informed discussion with the individual, carefully weighing the risks and benefits of therapy.

15.2.1. Recommendations for Lipid Monitoring

Where resources permit, it is advised that a lipid profile (serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) is performed:

- At the time of diabetes diagnosis or the initial medical review.
- Within 1 to 3 months post commencement of statins, or following a change in statin dose or type, to assess the individual's response.
- At least once every 5 years in <40 years old patients with diabetes who are not on lipid-lowering medication.

LDL cholesterol ≥ 100 mg/dL (2.6 mmol/L) is considered a risk factor for atherosclerotic cardiovascular disease, and in individuals who are known to have pre-existing cardiovascular disease, a target LDL < 70 mg/dL (1.8 mmol/L) is recommended.

There is currently no consensus on a threshold for triglycerides, though levels > 500 mg/dL (5.7 mmol/L) are considered to increase the risk of pancreatitis.

Statins are required to achieve targeted blood lipid levels in people with diabetes as follows:

- LDL cholesterol of < 70 mg/dL (1.8 mmol/L) in people that have/had cardiovascular disease.
- LDL cholesterol of < 70 mg/dL (1.8 mmol/L) in people with a high risk of having cardiovascular disease based on the WHO/ISH cardiovascular risk calculator.
- LDL cholesterol of < 100 mg/dL (2.6 mmol/L) in people that do not have cardiovascular disease or high risk of having cardiovascular disease based on the WHO/ISH cardiovascular risk calculator.
- Triglyceride level of > 500 to 1000 mg/dL (5.7 – 11.4 mmol/L) that persists in people with lifestyle management and good blood sugar control.

15.2.2. Recommendations for Lipid-Lowering Therapy

Lifestyle modification advice should be given to all individuals living with diabetes, with specific advice to:

- Lose weight, where the person is overweight or obese.
- Increase physical activity.
- Reduce the consumption of trans fat, saturated fat, and cholesterol.
- Increase the consumption of dietary n-3 fatty acids, plant sterols/stanols, and viscous fibre.

Where the individual already has atherosclerotic cardiovascular disease, high-intensity statin treatment is required in addition to lifestyle modification for secondary prevention of further cardiovascular events. (See Box 29 for recommended therapy)

- Where the patient is not known to have atherosclerotic cardiovascular disease but is ≥ 40 years, moderate-intensity statins should be initiated for primary prevention. There are several statins available within this category, and the choice of statin should depend on

what is affordable, available and accessible within the community, and tolerated by the patient.

A few options are presented in Table 7.

- It is advised that statins are continued lifelong following initiation, provided they are tolerated by the patient.
- Statins are potentially teratogenic and must be avoided in pregnancy.

Table 7: Moderate-intensity statins

Atorvastatin 10 – 20mg od
Rosuvastatin 5 – 10mg od
Simvastatin 20 – 40mg od
Pravastatin 40 – 80mg od
Lovastatin 40mg od

od – once-daily dosing

- Combination therapy of statins with fibrates or niacin to improve lipid profiles is not recommended as there is trial evidence to suggest that they carry a higher risk of side effects including an increased risk of rhabdomyolysis and myositis with the fibrate/statin combination, and increased risks of stroke with the statin/niacin combination. Moreover, they do not provide an overall cardiovascular benefit above that attributable to statins alone.
- Where fasting triglyceride levels are ≥ 500 mg/dL (5.7 mmol/L), the patient should be investigated for secondary causes of hypertriglyceridaemia and advised to avoid alcohol due to the increased risk of acute pancreatitis.
- Improved glycaemic control combined with intense lifestyle measures (as listed above) is recommended for improving the lipid profile of patients with elevated triglyceride and low HDL levels. Where the patient has poor glycaemic control and markedly elevated triglycerides (≥ 500 mg/dL), insulin may be considered.

There are no statins in the 2016 Essential Medicines List. Therefore, the choice of statin depends on the cost and efficacy of the drug.

BOX 29: RECOMMENDATIONS FOR MANAGING DYSLIPIDEMIAS IN PEOPLE WITH DM

Where the individual already has atherosclerotic cardiovascular disease, high-intensity statin treatment is required in addition to lifestyle modification for secondary prevention of further cardiovascular events.

High-intensity statin therapy with either Atorvastatin 40mg – 80mg daily or Rosuvastatin 20mg to 40mg daily has been shown to reduce LDL cholesterol by ³ 50%.

(High certainty evidence, weak recommendation)

In patients with atherosclerotic cardiovascular disease in whom the serum LDL cholesterol remains ≥ 70 mg/dL despite high intensity statin therapy (at maximal dosage) and lifestyle modifications, Ezetimibe may be added to the regime following an assessment of the patient's risk, and after careful consideration of the patient's preferences and the side effect profile of the medications.

(High certainty evidence, weak recommendation)

BOX 30: RECOMMENDATIONS FOR MANAGING DM IN HIV+ INDIVIDUALS

Recommendations for blood glucose targets and lifestyle management for managing DM in PLHIV is the same as in HIV- individuals.

However due to drug interaction between glucose lowering drugs and anti-retroviral drugs, there are special considerations for treating diabetes in PLHIV.

(Low certainty evidence, strong recommendation)

15.3. HIV

Depending on age, lifestyle, environmental and genetic factors, the risk for developing NCDs exist among people living with HIV/AIDS (PLWHA).

Some anti-retroviral drugs like protease inhibitors (PIs) increase insulin resistance and use of first-generation antiretroviral therapy (ART) agents, such as stavudine and indinavir have been strongly associated with developing DM. Efavirenz has also been found to increase glucose levels.¹⁸

Recommendations for blood glucose targets and lifestyle management for managing DM in PLHIV is the same as in non-HIV individuals.

However, due to drug interaction between glucose-lowering drugs and antiretroviral drugs, there are special considerations for treating diabetes in PLHIV.

Table 8: Oral Diabetes Medications with Special Considerations in HIV

Class	Mechanism	Special Considerations in HIV
Biguanides (Metformin)	<p>Decrease hepatic glucose production.</p> <p>Improve insulin sensitivity.</p>	Dolutegravir increases metformin concentrations.
Sulfonylureas (glibenclamide, glimepiride, glyburide, glicazide, glipizide)	<p>Stimulate insulin release from the pancreatic β cells.</p> <p>Reduce glucose output from the liver.</p> <p>Increase insulin sensitivity.</p>	
Thiazolidinediones (rosiglitazone, pioglitazone)	<p>Lower blood glucose by improving target cell response to insulin.</p> <p>Do not increase pancreatic insulin secretion.</p>	When used with CYP2C8 inhibitors (many PIs), rosiglitazone/ pioglitazone levels may increase. Monitor carefully.
GLP-1 Analogues (liraglutide, exenatide, exenatide LAR)	<p>Increase glucose-dependent insulin secretion.</p> <p>Decrease inappropriate glucagon secretion.</p> <p>Increase β-cell growth/replication.</p> <p>Slow gastric emptying.</p>	

Class	Mechanism	Special Considerations in HIV
DPP-IV inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin)	<p>Increase insulin synthesis and release from pancreatic β cells.</p> <p>Decrease glucagon secretion from pancreatic α cells.</p> <p>Decreased glucagon secretion results in decreased hepatic glucose production.</p>	<p>Gliptins have molecular targets on immune cells; however, no evidence that gliptin use changes CD4 or HIV RNA.</p> <p>Saxagliptin interacts with strong CYP3A4/5 inhibitors (eg, ritonavir); reduce saxagliptin dose when used with CYP3A4/5 inhibitors.</p>
Gliflozins (dapagliflozin, canagliflozin)	<p>Reduce the reabsorption of filtered glucose from the tubular lumen and lower the renal threshold for glucose.</p> <p>Increase urinary excretion of glucose.</p>	<p>If UGT enzyme inducers (eg, ritonavir) are co-administered with canagliflozin, consider increasing the dose to 300 mg</p>
Meglitinides	<p>Stimulate insulin release from pancreatic β-cells</p>	<p>When used with CYP3A4/CYP2C8 inhibitors (many PIs), repaglinide/nateglinide levels may increase. Monitor carefully.</p> <p>EFV and ETR may increase nateglinide</p>

15.4. Considerations about Recommendations for Managing Comorbidities

15.4.1. Implementation Considerations

Some of the medications with proven efficacy for treating diabetes comorbidities are not in the Essential Medicines List. Practitioners should be aware of this and advise their patients appropriately. Adverse drug reactions should be monitored closely, reported and medications changed as appropriate. Where monitoring facilities are not available, patients should be referred to the next level of care.

15.4.2. Harms/Benefits of Recommendations for Managing Comorbidities

ACEi and A2RBs for blood pressure control as well as statins for lipids treatment have substantial benefits in reducing the risk of cardiovascular diseases. Antiretroviral drugs have also been shown not only to improve outcomes in HIV infected patients but also to prolong life. However, the risk of low blood pressure, high potassium levels and impaired kidney function associated with the use of ACEi or A2RBs should be weighed against the benefits. Patients on statins should be warned of the risk of muscle inflammation and breakdown and those on ARTs of the risk of worsening blood sugar control. The risk of increased incidence of adverse events from drug-drug interactions should be discussed with the patients. All the medications should be avoided in pregnancy.

References

1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*. 2000 Aug;321(7):412-9.
2. Gosmanov AR, Lu JL, Sumida K, Potukuchi PK, Rhee CM, Kalantar-Zadeh K, et al. Synergistic association of combined glycemic and blood pressure level with risk of complications in US veterans with diabetes. *J Hypertens*. 2016 May;34(5):907-13.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care*. 1993 Feb;16(2):434-44.
4. U.K. Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998 Sep;317(7160):713-720.
5. Banegas JR, Lundelin K, de la Figuera M, de la Cruz JJ, Graciani A, Rodríguez-Artalejo F, et al. Physician perception of blood pressure control and treatment behaviour in high-risk hypertensive patients: a cross-sectional study. *PLoS One*. 2011; 6(9): e24569.
6. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010 Apr;362(17):1575-85.
7. Pasquale Passarella, Tatiana A. Kiseleva, Farida V. Valeeva, Aidar R. Gosmanov. Hypertension Management in Diabetes: 2018 Update *Diabetes Spectrum* Aug 2018, 31 (3) 218-224; DOI: 10.2337/ds17-0085.
8. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*; 2014 Feb;311(5):507-20.
9. Pasquale P, Kiseleva TA., Valeeva FV, Gosmanov AR. Hypertension management in diabetes: 2018 Update. *Diabetes Spectr*. 2018 Aug;31(3):218-24.
10. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet*. 2008 Aug;372(9638):547-53.

11. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008 Apr;358(15):1547-59.
12. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. *J Clin Endocrinol Metab*. 2001 Mar;86(3):965-71.
13. Haffner SM. Management of dyslipidemia in adults with diabetes. *Diabetes Care*. 1998 Jan;21(1):160-78.
14. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012 Aug;380(9841):581-90.
15. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005 Oct;366(9493):1267-78.
16. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care*. 1997 Apr;20(4):614-20.
17. Collins R, Armitage J, Parish S, Sleight P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003 Jun;361(9374):2005-16.
18. Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. *Clin Infect Dis*. 2015 Feb;60 (3):453-62.

16. Managing Diabetes in Children and Adolescents

16.1. Blood Glucose Targets and Monitoring in Children

Blood glucose levels should be monitored regularly in children (at least two times a day for those on a twice-daily insulin regimen, or a minimum of four times a day for those on multiple daily dose insulin regimen) to ensure optimal blood glucose control in children.

Self-monitoring of blood glucose (SMBG) is an important part of managing and achieving blood glucose control in children and adolescents. The optimal blood glucose targets are:

- Before meals: 4 – 7 mmol/L (72– 126 mg/dL)
- After meals: 5 – 10 mmol/L (90 – 180 mg/dL)
- At bedtime: 4.4 – 7.8 mmol/L (80 – 140 mg/dL)
- At 3am: 5 – 8 mmol/L (90 – 144 mg/dL)¹

16.2. Treatment of Diabetes in Children

Treatment of diabetes in children entails both lifestyle management and drug treatment. Individualized nutrition management is highly recommended for children and adolescents. Comprehensive nutrition education at the time of diagnosis is important, followed by annual reviews by the dietician or nutritionist.

16.2.1. Lifestyle Management

Diet & Carbohydrate counting

Carbohydrate (CHO) counting is a diet strategy that emphasizes the role of carbohydrates as the primary nutrient that increases blood glucose after meals. It involves flexible meal plans that help in achieving blood glucose control.^{2,3}

There are three levels of CHO counting: (Use level 1 only when levels 2 and 3 are not feasible. Flexibility and individualized insulin use are highly recommended).

- **Level 1 - Consistent CHO intake**

This involves a consistent carbohydrate intake of pre-specified quantities of food. This is appropriate for those using twice-daily insulin.

- **Level 2 - Pattern management principles**

An intermediate step in which patients maintain a consistent carbohydrate intake, use a consistent baseline insulin dose and frequently monitor blood glucose level. They learn to recognize patterns of blood glucose response to carbohydrate intake modified by insulin and exercise. With this understanding and team support, they adjust their insulin dose for food and exercise to achieve blood glucose goals.

- **Level 3 - Insulin to carbohydrate ratios (ICR)**

Appropriate when using basal-bolus (multiple daily injections). The ICR (amount of carbohydrates in grams covered by 1 Unit of insulin) is calculated and individualized according to age, sex, pubertal status, duration of diagnosis, and activity. This lets patients adjust their prandial (mealtime) insulin dose according to carbohydrate consumption.

Methods of quantifying carbohydrate include:

- Gram increments of carbohydrate
- 10 – 12 g carbohydrate portions
- 15 g carbohydrate exchanges

The “500-rule” is used as a first estimate for ICR at diagnosis, which is then adjusted according to the individual response of the child. Divide 500 by the Total Daily Dose (Total Daily Dose is the sum in units of all insulin injections on a normal day). Fine-tuning of insulin dosage is guided by blood glucose monitoring. Regular review is necessary as children grow and new foods are introduced.

Physical activity

Physical activity is very important for maintaining optimal blood glucose levels in children. It is difficult to make recommendations on the specific intensity and duration of physical activity among children. Efforts to reduce periods of physical inactivity in children are important. A minimum of 60 minutes of moderate to vigorous level of physical activity per day is recommended (and strength training on at least three days/week).⁴ Insulin dosages should also be adjusted during periods of moderate to vigorous physical activity due to increased insulin sensitivity during exercise, which could lead to hypoglycaemia.

Children and adolescents who engage in competitive sports require an essential support and education management therapy to prevent dehydration and hypoglycaemia during and after exercise maintaining a pre-exercise blood glucose level of 5 – 13 mmol/L (90 – 250 mg/dL) and having access to carbohydrate before exercise.⁵

Blood glucose should be checked frequently before, during and after moderate to vigorous exercise to detect hypoglycaemia or hyperglycaemia.

16.2.2. Insulin Treatment

The treatment for type 1 diabetes in children is insulin. Other forms of diabetes may also require the use of insulin.

The aim of using insulin is to attempt to achieve the natural physiological insulin levels after meals and during fasting periods. Having low levels of insulin can lead to high blood sugar levels which heighten the occurrence of complications and affects normal growth and development of the child.

The two most commonly used insulin regimens are:

- Twice-daily insulin using both short-acting and intermediate-acting insulin. (If these forms of insulin are not always available, pre-mixed insulin can be used as an alternative regimen).
- Basal-bolus regimen (the preferred option) - with short-acting insulin given with main meals (usually three times per day) and intermediate-acting insulin given once or twice daily (evening, or morning and evening)⁶ or basal analogues like Determir or Lantus once a day evening or morning.

Pre-mixed insulins limit the opportunities to adjust insulin dosage with varying amount of food and physical activity.

Insulin should be administered using appropriate needles/syringes or pens when available and should be injected subcutaneously on the various available injection sites on the body in a rotation routine.

Education on the pharmacokinetics (onset, peak and duration) of the types of insulin available and used in the country even if not on the essential drug list is important.

16.2.3. Use of Glucose-Lowering Drugs

Apart from insulin, other glucose-lowering drugs are usually used in adolescents and young people with T2DM.

Metformin is the first-line drug for treating T2DM in adolescents and young people^{7,8} (See Box 15, Chapter 7).

Basal insulin is used as first-line if blood glucose level is as high as 13.9 mmol/L on diagnosis and there are marked symptoms such as frequent urination (bedwetting), weight loss, frequent thirst and dehydration. Basal insulin can also be used when metformin fails to achieve the targeted blood glucose levels. Glucagon-like Peptide 1 receptor agonist though used by the pediatric age group is not yet recommended in children.

16.2.4. Sick Day Rules

Parents and caregivers of children with diabetes who are ill are advised as follows:

- Consult the doctor about the management of diabetes and the cause of the illness.
- Insulin should not stop but dosages may have to be adjusted during periods of illness.
- Avoid sugar-laden medications.
- Measure blood glucose more frequently.
- Give fluids more frequently.
- Ensure children have their vaccinations as scheduled to prevent periods of avoidable ill-health.

16.3. Management of Diabetic Emergencies in Children

16.3.1. Treating Diabetic Keto-Acidosis (DKA) in Children and Young People

Some children may not have typical signs and symptoms of diabetic keto-acidosis (DKA), and vigilance needs to be applied to recognize DKA in children; it can present as other common diseases like severe malaria, pneumonia, gastroenteritis with electrolyte imbalance.

Some children with T1DM may not have been previously diagnosed and may present for the first time in a health facility with DKA. Check the blood glucose of any very ill child or adolescent.

Recognition of DKA in children and young people

Children with no previous diagnosis of DM

Capillary blood glucose should be measured if a child or young person without a previous diagnosis of DM presents with the following symptoms:

- Increased thirst
- Increased urination
- Recent unexplained weight loss
- Excessive tiredness
- Nausea or vomiting
- Abdominal pain
- Hyperventilation
- Dehydration
- Reduced level of consciousness

If blood glucose levels of more than 11 mmol/L are recorded in a child or young person without known diabetes, and the symptoms and signs mentioned above are present, suspect DKA and refer the child or young person to a health facility with expertise and facilities for emergency care.⁸ Start correction of dehydration with oral rehydration therapy (ORT) if the child can tolerate orally and continue with the emergency transfer.

Children and young people with a previous diagnosis of DM

Children and young people with a prior diagnosis of DM who are taking insulin for diabetes may still develop DKA with normal blood glucose levels.

Suspect DKA even if the blood glucose is normal and the child or young person with a known history of diabetes shows any of the following symptoms:

- Nausea or vomiting
- Abdominal pain
- Hyperventilation
- Dehydration
- Reduced level of consciousness

BEST PRACTICE STATEMENT ON RECOGNITION OF DKA IN CHILDREN AND YOUNG PEOPLE

Measure the blood ketones in a child or young person with known DM that shows any of these symptoms:

- Nausea or vomiting
- Abdominal pain
- Hyperventilation
- Dehydration, or
- Reduced level of consciousness

If the levels are elevated, refer to a health facility with expertise and capacity to manage DKA in a child or young person.

Diagnosis of DKA in children and young people

When DKA is suspected in a child or young person, measure:

- Capillary blood glucose
- Urine ketones
- Blood pH

If capillary blood glucose is high, there are ketones in the urine and blood pH is lower than 7.0, a definitive diagnosis of DKA is made.

Educate caregivers and family members about the condition and appropriate care the child or young person will need.

Specialist Care for DKA in children and young people

After making a diagnosis of DKA, check for:

- Level of consciousness
- Vital signs (heart rate, blood pressure, temperature, respiratory rate [look for Kussmaul breathing])
- Signs of dehydration
- Measure blood electrolytes, urea and creatinine
- Check the temperature and blood pressure to rule out septic shock
- Provide adequate nursing and close monitoring.

If unconscious, review with an anaesthetist if available and consider inserting a nasogastric tube to reduce risk of aspiration.

Table 9: Recommendations for Managing DKA in Children and Young People ^{9,10}

Child or young person is alert and not vomiting or nauseated and not dehydrated.	Child or young person is not alert or is vomiting or nauseated or dehydrated.
Treat DKA with oral fluids first and only after initial bolus correction, commence subcutaneous insulin given at a frequency of 1 – 2 hours. Ensure that the child or young person is recovering by monitoring for resolution of ketonaemia and acidosis.	Treat DKA with initial intravenous fluids replacement for 1 hour. Commence intravenous insulin given as a continuous infusion only after commencing intravenous fluid replacement for dehydration.
Do not give an intravenous fluid bolus to children and young people with mild or moderate DKA (indicated by a blood glucose >250 mg/dL, blood pH of 7.1 or above and bicarbonate 15 – 18 mmol/L). Give oral fluid replacement. Commence intravenous fluid bolus or pass in a nasogastric tube to a child or young person with severe DKA that is in stupors or unconscious (indicated by a blood pH below 7.1). Do not give more than one intravenous fluid bolus of 10 ml/kg 0.9% sodium chloride for 1-2 hours to a child or young person with severe DKA (indicated by blood glucose >250 mg/dL, blood pH below 7.1 and bicarbonate <10 mmol/L) without discussion with a specialist.	
When and how to give insulin	
Start an intravenous insulin infusion only after 1 – 2 hours of beginning intravenous fluid therapy in children and young people with DKA.	
When treating DKA with intravenous insulin in children and young people, use a soluble insulin infusion at a dosage between 0.05 and 0.1 units/kg/hour. Do not give bolus doses of intravenous insulin. When expertise to give and monitor insulin infusion is not available, give subcutaneous soluble insulin every hour at a dosage between 0.05 and 0.1 units/kg/hour and refer or discuss with a specialist.	

- Calculate their total fluid requirement for the first 48 hours by adding the estimated fluid deficit to the fluid maintenance requirement.
- When calculating the fluid requirement for children and young people with DKA, assume:
 - A 5% fluid deficit in mild to moderate DKA (indicated by blood bicarbonate of 15 – 18 mmol/L or blood pH of 7.1 or above).
 - A 10% fluid deficit in severe DKA (indicated by blood bicarbonate of less than 10 mmol/L, or blood pH below 7.1).
- Calculate the maintenance fluid requirement for children and young people with DKA using the following 'reduced volume' rules:
 - If they weigh less than 10 kg, give 2 ml/kg/hour.
 - If they weigh between 10 and 40 kg, give 1 ml/kg/hour.
 - If they weigh more than 40 kg, give a fixed volume of 40 ml/hour.
- Aim to replace the fluid deficit evenly over the first 48 hours in children and young people with DKA, because faster rehydration is associated with an increased risk of cerebral oedema.
- Use 0.9% sodium chloride without added glucose for both rehydration and maintenance fluid in children and young people with DKA until the plasma glucose concentration is below 14 mmol/L.
- Ensure that all fluids (except any initial bolus) administered to children and young people with DKA contain 40 mmol/L potassium chloride unless they have renal failure.
- If more than 20 ml/kg of fluid has been given by intravenous bolus to a child or young person with DKA, subtract any additional bolus volumes from the total fluid calculation for the 48 hours.
- Do not give intravenous sodium bicarbonate to children and young people with DKA.
- Change fluids to 0.9% sodium chloride with 5% glucose and 40 mmol/L potassium chloride once the plasma glucose concentration falls below 14 mmol/L in children and young people with DKA.
- If during treatment for DKA a child or young person's plasma glucose falls below 6 mmol/L, increase the glucose concentration of the intravenous fluid infusion, and if there is persisting ketosis, continue to give insulin at a dosage of least 0.05 units/kg/hour.
- If the blood ketone level is not falling within 6 to 8 hours in a child or young person with DKA, think about increasing the insulin dosage to 0.1 units/kg/hour or greater.

- Think about stopping intravenous fluid therapy for DKA in a child or young person if ketosis is resolving, they are alert, and they can take oral fluids without nausea or vomiting.
- Do not change from intravenous insulin to subcutaneous insulin in a child or young person with DKA until ketosis is resolving, they are alert, and they can take oral fluids without nausea or vomiting.
- Start subcutaneous insulin in a child or young person with DKA at least 30 minutes before stopping intravenous insulin.

Monitoring

Monitor and record the following at least hourly in children and young people with DKA:

- Capillary blood glucose.
- Vital signs (heart rate, blood pressure, temperature, respiratory rate [look for Kussmaul breathing]).
- Fluid balance, with fluid input and output charts.
- Level of consciousness (using the modified Glasgow coma scale).
- Heart rate (to detect bradycardia) every 30 minutes.

At 2 hours after starting treatment, and then at least every 4 hours, carry out and record the results of the following blood tests in children and young people with DKA:

- Glucose (laboratory measurement)
- Blood pH and pCO₂
- Plasma sodium, potassium, bicarbonate and urea
- Blood or urine ketones

A doctor involved in the care of the child or young person with DKA should review them face-to-face at diagnosis and then at least every two hours, and more frequently if:

- They are under two years old
- They have severe DKA (indicated by a bicarbonate less than 10 mmol/L or blood pH below 7.1)
- There are other reasons for special concern

At each face-to-face review of children and young people with DKA, assess the following:

- Clinical status, including vital signs and neurological status
- Results of blood investigations
- Cumulative fluid balance record

Provide an update on progress to the caregivers and family members of the child or young person.

Watch out for complications like cerebral oedema and very low potassium.

Cerebral oedema

Immediately assess children and young people with DKA for suspected cerebral oedema if they have any of these early manifestations:

- Headache
- Agitation or irritability
- Unexpected fall in heart rate
- Increased blood pressure

If cerebral oedema is suspected in a child or young person with DKA, treat immediately with the most readily available form of mannitol (20%, 0.5 – 1 g/kg over 10 to 15 minutes) or hypertonic sodium chloride (2.7% or 3%, 2.5 – 5 ml/kg over 10 to 15 minutes).

Immediately treat for cerebral oedema using the most readily available form of mannitol (20%, 0.5 – 1 g/kg over 10 to 15 minutes) or hypertonic sodium chloride (2.7% or 3%, 2.5 – 5 ml/kg over 10 to 15 minutes) if a child or young person with DKA develops any of these signs:

- Deterioration in level of consciousness
- Abnormalities of breathing pattern, for example, respiratory pauses
- Oculomotor palsies
- Pupillary inequality or dilatation

After starting treatment for cerebral oedema with mannitol or hypertonic sodium chloride in a child or young person with DKA, immediately seek specialist advice on further management, including which care setting would be best.

Low potassium levels

If a child or young person with DKA develops hypokalaemia (potassium below 3 mmol/L):

- Think about suspending insulin infusion.
- Discuss hypokalaemia management urgently with a paediatric critical care specialist.
- Refer to a higher center of care.

Avoiding future episodes of DKA in children and young people

Provide education to caregivers and family members of children and young people on how to avoid DKA in the future by adhering to treatment recommendations.

16.3.2. Treatment of Hypoglycaemia

Mild hypoglycaemia occurs when the patient can recognise hypoglycaemia and can self-treat without assistance from others. Blood glucose level is ≤ 3.9 mmol/L (70mg/dL).

Severe hypoglycaemia is when the patient either loses consciousness or has a seizure associated with low blood glucose or is unable to help him/herself.^{11,12,13,14,15}

Managing mild or moderate hypoglycaemia

STEP 1

- Give fast-acting glucose immediately. Examples are:
 - Half cup/glass of a sweet drink
 - 2 cubes of sugar or 3 to 4 teaspoons of sugar or honey
 - 6 large or 12 small jellybeans if available

STEP 2

If hypoglycaemia is caused by a missed meal or snack (but insulin has been taken as usual), follow with a meal or snack including an appropriate amount of carbohydrates. Where blood glucose testing equipment is available, re-test blood glucose 10 to 15 minutes after treatment, to confirm the blood glucose level is within normal limits >5.6 mmol/L (100 mg/dL).

If the blood glucose level remains low or symptoms persist, repeat Step 1.

Managing severe hypoglycaemia with loss of consciousness or convulsions

Give intravenous glucose carefully and slowly over several minutes, using 10% or 25% glucose/dextrose solution (or 50% where these are unavailable).

Total dose over several minutes is 0.2 – 0.5 gm/kg of glucose/dextrose (2 – 5 ml/kg of 10% glucose, 1 – 1.5 ml/kg of 25 – 30% glucose).

BOX 31: RECOMMENDATIONS FOR MANAGING HYPOGLYCAEMIA IN CHILDREN

Mild hypoglycaemia can be managed at home or primary care using fast acting sugar drinks and foods.

Severe hypoglycaemia requires specialist care with glucose drip and close monitoring.

16.4. Transitioning to Adulthood

Most young people are lost to follow-up as they transition from childhood to adolescence and then adulthood. Adequate psychosocial care and support should be put in place to guide the caregivers and family members of children and adolescents with diabetes on this transition period to ensure retention in care and optimal treatment outcomes.

16.5. Considerations about Recommendations for Managing Diabetes in Children and Adolescents

16.5.1. Implementation Considerations

Management of diabetes and especially diabetes complications in children and adolescents should be individualized and done by specialists leading a multidisciplinary team. However, primary care providers should recognise the symptoms and signs (which may be similar to common childhood acute conditions), give appropriate initial care and refer timeously to a centre with paediatric endocrinologists or paediatrician. While the care of children is undertaken by parents, adolescents should be involved in their care early enough for optimal outcomes. The overall focus should be on meeting treatment goals, prevention of acute complications, reduction of diabetes-related organ-specific complications, participation in normal age-appropriate activities and ensuring normal physical and psychological development for age.

16.5.2. Harms/Benefits of Recommendations for Managing Diabetes in Children

The risk of catastrophic hypoglycaemia especially with insulin use is very high in children. The benefits of goal-directed therapy linked to optimal blood glucose control and prevention of diabetes-related complications warrant the use of glucose-lowering agents. These should all be communicated to parents and children.

References

1. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006. 50 p.
2. Gillespie SJ, Kulkarni KD, Daly AE. Using carbohydrate counting in diabetes clinical practice. *J Am Diet Assoc.* 1998 Aug;98(8):897-905.
3. Rabasa-Lhoret R, Garon J, Langelier H, Poisson D, Chiasson JL. Effects of meal carbohydrate content on insulin requirements in type 1 diabetic patients treated intensively with the basal-bolus (ultralente-regular) insulin regimen. *Diabetes Care.* 1999 May;22(5):667-73.
4. World Health Organization. Global recommendations on physical activity for health. Geneva: World Health Organization; 2010. 60p.
5. Colberg S, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. *Diabetes Care.* 2016 Nov; 39(11): 2065-79.
6. International Society for Pediatric and Adolescent Diabetes (ISPAD). Consensus guidelines 2000, ISPAD consensus guidelines for the management of type 1 diabetes mellitus in children and adolescents. Zeist, Netherlands: Medical Forum International; 2000. 128 p.
7. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. *Diabetes Care.* 2002 Jan;25(1):89-94.
8. TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. *N Engl J Med.* 2012 Jun;366(24):2247-56.
9. National Institute for Health and Care Excellence (UK). Diabetes (type 1 and type 2) in children and young people: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2015.
10. Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, et al., editors. *Endotext.* South Dartmouth MA: MDText.com, Inc.; 2000.

11. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. hypoglycaemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care*. 2013 May;36(5):1384-95.
12. Smart CE, Annan F, Higgins LA, Jelleryd E, Lopez M, Acerini CL. ISPAD clinical practice consensus guidelines 2018: nutritional management in children and adolescents with diabetes. *Pediatr Diabetes*. 2018 Oct;19(Suppl 27):136-54.
13. DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, et al. ISPAD clinical practice consensus guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. *Pediatr Diabetes*. 2018 Oct;19(Suppl 27):105-14.
14. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD clinical practice consensus guidelines 2018: assessment and management of hypoglycaemia in children and adolescents with diabetes. *Pediatr Diabetes*. 2018 Oct;19(Suppl 27):178-92.
15. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. *Diabetes Care*. 2018 Sep;41(9):2026-44.

17. Managing Diabetes in Pregnancy

17.1 Preconception Counselling

Diabetes in pregnancy poses a risk to both the mother and the child in the womb if blood glucose levels are high for a long period.^{1,2}

High blood glucose levels within the first 10 weeks of conception are associated with fetal abnormalities.^{3,4}

High blood glucose during pregnancy is also associated with the onset of diabetic retinopathy or rapid progression of existing diabetic retinopathy.⁶

All women of childbearing age with diabetes should be counselled about the importance of tight glycemic control before conception, the risk of fetal abnormalities in unplanned pregnancies and use of effective contraception to avoid unplanned pregnancies.^{5,7}

Women with diabetes who wish to become pregnant should monitor their blood glucose regularly and make adequate lifestyle changes and adjustments in drug regimens to achieve adequate blood glucose targets before pregnancy.⁸

17.2. Blood Glucose Targets in Pregnancy

Blood glucose targets in pregnancy are lower and tighter than targets in non-pregnancy. This is required to balance the effects of increased uptake of glucose by the fetus and insulin resistance caused by placental hormones.^{9,10}

Women with T1DM usually have insulin sensitivity during the first trimester and insulin resistance during the second and third trimesters making it imperative to adjust insulin dosages as pregnancy progresses.^{8,11}

Fasting blood sugar target in pregnancy is 5.3 mmol/L (95 mg/dL)

Pregnancy also increases the risk of DKA in women with DM because pregnancy is a ketogenic state.

Lifestyle changes and strict adherence to recommended drugs are important to maintain blood glucose targets within tight optimal limits.⁸

BOX 32: RECOMMENDATIONS FOR PRE-CONCEPTION COUNSELLING⁵

Pre-conception counselling should be integrated into routine diabetes care for all women of childbearing age.

Family planning should be discussed and offered to women who do not intend to get pregnant.

(Moderate certainty evidence, strong recommendation)

The targeted blood glucose levels for both GDM and pregnant women with pre-existing DM are:

- Fasting blood glucose of 5.3 mmol/L (95 mg/dL)
- 1-hour postprandial blood glucose of 7.8 mmol/L (140 mg/dL)
- 2-hour postprandial blood glucose of 6.7 mmol/L (120 mg/dL)

17.3. Management of Diabetes in Pregnancy

17.3.1. Treatment of Gestational Diabetes Mellitus

Lifestyle management is essential for managing GDM and may be sufficient in reversing blood glucose level to normal thresholds.^{8,12}

Insulin is the preferred drug for gestational diabetes mellitus as it does not cross the placenta.

Metformin and glyburide may be used but they both cross the placenta. Glyburide is associated with neonatal hypoglycaemia and macrosomia while metformin is safer in this regard but has been shown to slightly increase the risk of prematurity.^{13,14,15}

BOX 33: RECOMMENDATIONS FOR MANAGING GESTATIONAL DIABETES MELLITUS¹⁶

Lifestyle management is the first line for pregnant women with fasting glucose levels of 5.3 mmol/L and below.

(High certainty evidence, strong recommendation)

If lifestyle management fails, then insulin or metformin should be commenced.

(High certainty evidence, strong recommendation)

Insulin is first line for fasting glucose levels above 5.3mmol/l.

Specialist care is needed to use insulin

(High certainty evidence, strong recommendation)

17.3.2 Treatment of Pre-existing Diabetes

T1DM

It is important to adjust insulin doses to match the rapidly changing requirements during pregnancy. Frequent blood glucose monitoring is important to recognize when there is a need for insulin changes.⁸

Daily insulin needs might reduce during the first trimester due to insulin sensitivity and increase in episodes of low blood glucose levels.

A biweekly or weekly increase in insulin dose, because of the rapidly increasing insulin resistance, is recommended. The recommended regimen is a smaller proportion of daily doses as basal insulin (<50%) and a greater proportion as bolus insulin (>50%).

The insulin demands at third trimester may reduce and insulin doses will need to be changed accordingly.

T2DM

Oral glucose-lowering drugs are not enough to achieve blood glucose targets because of the marked insulin resistance in pregnancy.⁸

Insulin is required for T2DM during pregnancy.

T2DM is also more likely to be associated with other comorbidities during pregnancy.

BOX 34: RECOMMENDATIONS FOR MANAGEMENT OF PREGNANT WOMEN WITH PRE-EXISTING DIABETES MELLITUS¹⁷

Insulin is the drug of choice for managing both T1DM & T2DM.

Adjust insulin dosages to respond to the changing insulin demands throughout the course of the pregnancy in T1DM.

This adjustments in insulin doses require specialist care.

(Evidence not graded)

Low dose aspirin 60 – 150 mg/day (usual dose 81 mg/day) should be given from the end of the first trimester up to 34 weeks to reduce the risk of pre-eclampsia.

(High certainty evidence, strong recommendation)

Calcium blockers or alpha-methyl dopa should be used to control blood pressure in women with DM who also have chronic hypertension.

(High certainty evidence, strong recommendation)

17.4. Managing or Preventing Comorbidities During Pregnancy

Women with T2DM are more likely to gain weight during pregnancy. Women who are overweight or obese should ensure that they keep weight gain during pregnancy within 6 – 10kg.¹⁸ This can be achieved through lifestyle management and metformin.

Women with DM also have an increased risk of pre-eclampsia.¹⁹ This risk can be minimized by using low dose aspirin (81mg) immediately after the first trimester until 34 weeks.¹⁷ It is discontinued before the baby is born to avoid coagulopathies, clotting disorders, and excessive bleeding.

Women with both DM and pre-existing hypertension should maintain blood pressure within 120/80mmHg and 160/105mmHg to prevent impaired fetal growth and reduce adverse cardiovascular events in the mother.^{20,21} Drugs that are linked to fetal abnormalities such as ACE inhibitors and ARBs should not be used before pregnancy, during pregnancy or breastfeeding. Calcium channel blockers and centrally acting anti-hypertensives (like alpha-methyl dopa) are safe for use during pregnancy and breastfeeding.

17.5. Management of Diabetes after Delivery

Women with diabetes should be encouraged and supported to breastfeed exclusively for six months due to the immediate and long-term nutritional and metabolic benefits breastfeeding confers on both the mother and the baby.^{22,23}

As soon as the baby and placenta are delivered, insulin resistance reverses to insulin sensitivity and then normal insulin regulation returns gradually within 1 to 2 weeks.⁸ This makes it important to establish meal planning and drug regimens that can help to prevent hypoglycaemia during breastfeeding and sleep deprivation.

17.6. Considerations about Recommendations for Managing Diabetes in Pregnancy

17.6.1. Implementation Considerations for Managing Diabetes in Pregnancy

Pre-pregnancy counselling should be undertaken for all women of child-bearing age and especially for women with diabetes. Diabetes in pregnancy should be managed by a multi-professional team that includes an endocrinologist, maternal-foetal medicine specialist, dietitian, and diabetes educator where these are all available. Self-monitoring of blood glucose should be encouraged for glycemic control. Insulin is the preferred glucose-lowering agent and is in the EML and covered by the NHIS.

17.6.2. Harms/Benefits of Recommendations for Managing Diabetes in Pregnancy

The risk of hypoglycaemia in pregnancy is high with insulin use. However, as other agents are not licensed, insulin is the only choice. It has significant benefits leading to optimal maternal and foetal outcomes.

References

1. Holmes VA, Young IS, Patterson CC, Pearson DW, Walker JD, Maresh MJ, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the Diabetes and Pre-eclampsia Intervention Trial. *Diabetes Care*. 2011 Aug;34(8):1683-8.
2. Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. *Diabetes*. 2000 Dec;49(12):2208-11.
3. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with pre-pregnancy diabetes. *Diabetes Care*. 2007 Jul;30(7):1920-5.
4. Jensen DM, Korsholm L, Ovesen P, Beck-Nielsen H, Moelsted-Pedersen L, Westergaard JG, et al. Periconceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. *Diabetes Care*. 2009 Jun;32(6):1046-8.
5. Charron-Prochownik D, Sereika SM, Becker D, White NH, Schmitt P, Powell AB 3rd, et al. Long-term effects of the booster-enhanced READY-Girls preconception counselling program on intentions and behaviours for family planning in teens with diabetes. *Diabetes Care*. 2013 Dec;36(12):3870-4.
6. Chew EY, Mills JL, Metzger BE, Remaley NA, Jovanovic-Peterson L, Knopp RH, et al. Metabolic control and progression of retinopathy: The Diabetes in Early Pregnancy Study. *Diabetes Care*. 1995 May;18(5):631-7.
7. Peterson C, Grosse SD, Li R, Sharma AJ, Razzaghi H, Herman WH, et al. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. *Am J Obstet Gynecol*. 2015 Jan;212(1):74.e1-74.e9.
8. American Diabetes Association. 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes 2018. *Diabetes Care* 2018;41(Suppl. 1):S137–S143.
9. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus. *Diabetologia*. 2000 Jan;43(1):79-82
10. Nielsen LR, Ekbom P, Damm P, Glümer C, Frandsen MM, Jensen DM, et al. HbA1c levels are significantly lower in early and late pregnancy. *Diabetes Care*. 2004 May;27(5):1200-1.
11. Maresh MJ, Holmes VA, Patterson CC, Young IS, Pearson DW, Walker JD, et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. *Diabetes Care*. 2015 Jan;38(1):34-42.

12. Han S, Crowther CA, Middleton P, Heatley E. Different types of dietary advice for women with gestational diabetes mellitus. *Cochrane Database Syst Rev*. 2013 Mar;(3):CD009275.
13. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med*. 2008 Jul;359(1):106.
14. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. *PLoS One*. 2013 May;8(5):e64585.
15. Langer O, Conway DL, Berkus MD, Xenakis EM-J, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N Engl J Med*. 2000 Oct;343(16):1134-8.
16. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002 Feb;346(6):393-403.
17. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2014 May;160(10):695-703.
18. Institute of Medicine and National Research Council. *Weight gain during pregnancy: reexamining the guidelines*. Washington, DC: The National Academies Press; 2009.
19. Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. *BMJ*. 2005 Mar;330(7491):565.
20. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol*. 2013 Nov;122(5):1122-31.
21. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less tight versus tight control of hypertension in pregnancy. *N Engl J Med*. 2015 Jan;372(5):407-17.
22. Stuebe AM, Rich-Edwards JW, Willett WC, Manson JE, Michels KB. Duration of lactation and incidence of type 2 diabetes. *JAMA* 2005 Nov; 294(20):2601-10.
23. Pereira PF, Alfenas Rde C, Araujo RM. Does breastfeeding influence the risk of developing diabetes mellitus in children? A review of current evidence. *J Pediatr (Rio J)*. 2014 Jan-Feb;90(1):7-15.

18. Advocacy

One of the objectives of this guideline is to ensure that diabetes care is rendered to everyone based on recommended standards of care that are evidence-based. Advocacy is essential in many areas in achieving this, including:

- Individuals with diabetes should not suffer any form of discrimination, whether at work, school or within social groups. Communicating the provisions of this guideline with diabetes care-related organizations, schools, policymakers, lawmakers, labour organizations, the prisons, and remand homes is essential.
- Diabetes medications should be available, affordable and accessible. In this regard, the EML's update should include medications not currently listed.
- Engagement of the NHIS to ensure coverage of diabetes care especially concerning diabetes-related organ complications.
- Different cadres of health workers in the health system need to be engaged constructively to ensure buy-in into the task shifting and sharing policy as it affects diabetes care at the different levels.

19. Monitoring and evaluation

The monitoring and evaluation plan for this guideline (see appendix) is linked to key outcome measures expected to be driven by its full implementation. The key indicators have been disaggregated for gender, age, facility type and location and specific responsible agencies named.

20. Planning for update

It is expected that as new evidence emerges, this guideline will be updated. However, it is recommended that the current guideline be updated annually or as often as necessary. In this regard, updates of the EML will warrant an update of recommendations herein.

21. Implications for practice

- Task-shifting of diabetes prevention and community awareness to lay community health workers.
- Task-shifting of diabetes education to nurses and CHEWs/JCHEWs who have been trained on diabetes education.
- Task-shifting necessitates the need to update the curriculum for pre-service and in-service training for nurses, CHEWs and JCHEWs.
- Diagnosis of DM in primary health care facilities using glucometers and risk assessment tools.
- Management of uncomplicated diabetes at primary health care level.
- Management of hypoglycaemia in individuals who are alert at primary care level.
- Active prevention of diabetic keto-acidosis (DKA) and Hyperglycaemic Hyperosmolar State (HHS) at primary care level.

22. Implications for an update of 2016 Essential Medicines List

- Need to include additional glucose-lowering drugs with proven effectiveness in reducing cardiovascular risk factors.
- Need to include ACEIs and ARBs because of their renal protectiveness.
- Need to include statins for reducing cardiovascular risk factors.

23. Implications for future research

- Understanding of the pathway for β -cell destruction in T1DM or dysfunction in T2DM among Nigerians.
- The effectiveness of structured diet and physical activity programs in preventing the onset of T2DM or GDM among individuals with high risk.

- Determining the feasibility and effectiveness of different modes of delivering structured diabetes education in the Nigerian health system.

24. Quality standards

This guideline is essentially an adaptation of the ADA and NICE guidelines for diabetes care. The ADAPTE framework for adapting clinical practise guidelines has been followed and has informed the entire methodology. In this regard, the scope has been carefully defined in line with the task shifting and sharing policy of the country, extensive stakeholder consultation has been done (included patient groups, policymakers, academics, specialists etc.), recommendations have been graded and presented in a clear and readable format, and where necessary, the implications of implementing the recommendations have been highlighted taking into consideration resource constraints etc. The benefits and harms of all considered/recommended interventions have been highlighted.

Appendices

1.0. PIPOH Checklist

1. Patient population (including disease characteristics)					
1.1. Type of diabetes mellitus	Include	Exclude	Did not vote	Details/Rationale	Final decision
Type 1 Diabetes mellitus	6	2	0	<p>Reasons for exclusion</p> <p>Type 1 DM is more of a genetic aetiology and has different management and treatment options.</p> <p>Since resources are limited, it may not be feasible to develop separate guidelines for each type of DM.</p>	Include but have dedicated recommendations for Type 1 DM
Type 2 Diabetes mellitus	8	0	0	Evidence shows that Type 2 DM is the most prevalent form of DM globally and even in Nigeria.	Include
Gestational Diabetes	8	0	0	There is presently no quality standard to screen and identify GDM among pregnant women in Nigeria.	Include
Pre-diabetes/Impaired glucose tolerance	8	0	0	Screening to identify prediabetes/impaired glucose tolerance is important for prevention.	Include
Other types of diabetes mellitus	0	8	0	There is a paucity of data to understand the burden and aetiology of other types of DM in Nigeria.	Exclude other types of DM

1.2. Complication of diabetes mellitus					
Diabetes eye disease	8	0	0	Each of the complications requires specialized care and the specialist in these areas may have different guidelines for their practice in managing each of these complications.	Include but recommendations should be limited to early identification and prevention of complications and referrals.
Diabetic nephropathy	8	0	0		
Diabetic neuropathy	8	0	0		
Diabetic foot disease	8	0	0		
1.3. Management of emergencies in DM					
Diabetic ketoacidosis (DKA)	8	0	0	These are the most common causes of DM related mortality and the recommendations should be lifesaving. The following questions were raised: Is there availability of equipment and other facilities to manage the complications at primary health care? At what point can these emergencies be managed at primary health level before they are referred?	Include but emphasize recommendations for life-saving measures that can be taken at primary care level including home management.
Hyperosmolar Hyperglycaemic state (HHS)	8	0	0		
Normo-osmolar Non-ketotic Hyperglycaemic state (NNHS)	8	0	0		
Lactic acidosis	8	0	0		
Hypoglycaemia	8	0	0		

1.4. Management of other comorbidities in DM patients					
Hypertension	8	0	0	DM is a risk factor for adverse cardiovascular event on its own. It is important to include other cardiovascular risk factors that may further put a person living with diabetes at risk of cardiovascular events (such as myocardial infarction and stroke dyslipidemia) that increase cardiovascular risk factors will be included.	Include but limit recommendations to the identification and management of other cardiovascular risk factors using cardiovascular risk assessment tools. Also, include management of common morbidities like hypertension and dyslipidemia.
Cardiovascular diseases (MI/Strokes)	8	0	0		
Dyslipidemia	8	0	0		
Obesity	1	7	0	It is more of a risk factor and should not be treated as a disease on its own in our settings. It will be included in the preventive section.	Exclude
Other comorbidities like HIV, TB, Sickle cell	4	3	1	There may be possible drug interactions in managing these comorbidities in a diabetic person.	Include only HIV & TB
1.5. Sex					
Male	7	0	1	The guideline will focus on both sexes and if there are any sex differences in the recommendations from existing guidelines, this will be noted when adapting recommendations.	Include both male and female
Female	7	0	1		
1.6. Age					
0-9 years (children)	7	0	1	Type 1 DM treatment and management for children should be considered here. Prevention is a serious global health consideration for childhood obesity. Primary prevention for T2DM is important for this age group in the general population.	Include

10- 24 years (Adolescents and young people)	7	0	1	Prevention & treatment of both type 1 & 2 DM is relevant to these age groups.	Include
25 – 64 years (Adults)	7	0	1		
65 + (Elderly)	0	7	1		Exclude care and treatment for the elderly
Diabetes in Pregnancy	7	0	1	Managing diabetes in pregnancy is challenging and there is a need for recommendations to manage it.	Include
1.7. Cultural and religious context					
Fasting for Christians and Muslims	0	7	1	Cultural and religious considerations are numerous and may be beyond the scope of this guideline.	Exclude
Others					
2. Interventions					
2.1. Prevention					
Individual preventive measures	7	0	1	Frame recommendations for prevention in a way that it emphasizes the distinction between policy recommendations for prevention and individual counselling recommendations	
Community preventive measures	7	0	1		
Environmental preventive measures	7	0	1	Policy recommendations are being considered in the multi-sectoral strategy for NCD prevention.	
Health promotion at policy level	7	0	1		
2.2. Screening					
Risk assessment tool	7	0	1		Include

Random Capillary blood sugar test	7	0	1	Due to resource constraints, questionnaire-based screening tools will be prioritized over the use of capillary blood and glucometer.	Exclude as a screening method but include as a diagnostic method in resource-constrained settings.
2.3. Diagnosis					
HbA1C	7	0	1	All these methods will be considered in the guideline but priority will be given to random blood sugar as a diagnostic test in resource-constrained settings.	Include all but emphasize random blood sugar
Fasting Blood Sugar	7	0	1		
Random Blood Sugar	7	0	1		
OGTT	7	0	1		
2.4. Treatment					
Diabetic education	7	0	1	Diabetes education is now an integral part of diabetes care and treatment and should be considered in this guideline. Diabetes education via nurses has been piloted at the University of Abuja Teaching hospital.	Include
Lifestyle changes (weight loss, physical activity and diet)	7	0	1	Lifestyle change is important for care and treatment.	Include
Pharmacological treatment (drugs/insulin)	7	0	1	Need to ensure that current recommendations for treatment are captured.	Include
Targets for glucose control and monitoring	7	0	1	This needs a dedicated chapter to ensure that the blood sugar control targets for each type of diabetes are adequately considered.	Include

3. Professionals/Patients: Targeted users					
3.1. Health workers					
Doctors (specialists)	0	7	1	Each specialty should have dedicated guidelines	Exclude
Doctors (General)	7	0	1	Make a clear distinction on what each of these cadres will do (roles and responsibility) in terms of diabetes care and treatment. Simple and plain language should be used throughout the document.	Include
Nurses	7	0	1		
Community Health Extension workers	7	0	1		
Lay health workers (Community Resource Persons)	7	0	1		
3.2. Stakeholders					
Federal Ministry of Health	7	0	1		Consider policy implications such as the National Council on Health meeting for stepping down the guideline to the states
State Ministry of Health	7	0	1		
Public health practitioners	7	0	1		
Implementing partners	7	0	1		
3.3. End-users					
Patients	7	0	1	Recommendations are targeted at care and treatment of patients and support for self-care by caregivers.	Include
Caregivers	7	0	1		

4. Outcome- purpose of the guideline For selecting evidence recommendations For measuring implementation					
4.1. Patient outcomes					
Prevent the onset of DM in high-risk individuals	7	0	1	Recommendations for prevention will be aimed at preventing the onset of DM among high-risk individuals. Only evidence-informed interventions that are effective in producing this outcome will be recommended.	Include
Achieving blood glucose target	7	0	1	Interventions that are effective for achieving blood glucose targets will be recommended.	Include
Improving survival	7	0	1	Interventions that are effective in improving survival will also be recommended.	Include
Quality of life	7	0	1	Interventions that also improve quality of life will be recommended.	Include
Treatment adherence	6	1	1	Adherence should be considered in terms of regimens (first line). Adherence should be emphasized in counselling and diabetic education.	Include
4.2. Health system outcomes					
Cost of care	7	0	1	The cost of the interventions will be considered to ensure that recommendations will be affordable, available, feasible and accessible. Equity should also be considered. Refer to the essential medicines list.	Include
Improvement in quality of care (appropriateness, optimized use,	7	0	1	The overall aim of the guideline recommendations is to improve quality of care, optimize efficient use of available resources for care, improve	Include

access, efficiency, safety, continuity, timeliness)				coverage and access at primary care level and avoid loss to follow up as clients go through the cascade of care and treatment.	
Task-shifting/task-sharing	7	0	1	The National task-shifting policy does not include NCDs. This guideline considers the involvement of lay community health workers in diabetes prevention and community support for self-care.	Include
Uniformity in practice	7	0	1	The guideline aims to achieve uniform quality standards for diabetes care and treatment across all levels of care and health facilities in the country. Need to develop quality standards and job aids from the guideline.	Include
4.3. Public health outcomes					
Morbidity	7	0	1	Need to measure the burden of diabetes mellitus using population-based surveys. The global burden of disease that is currently used to determine the burden and risk factors for NCDs is heavily modelled.	Include in M & E section
Mortality	7	0	1		
Incidence	7	0	1		
Prevalence	7	0	1		

5. Healthcare setting					
5.1. Health facility					
Primary health care	8	0	0	Based on the current strategic direction for NCD care and management championed by WHO-PEN, there is a need to prioritize and address quality gaps at the primary care level. Primary health care is aimed at reaching people in their communities and is usually the primary entry into the Nigerian Health System.	Include
Secondary health care	4	4	0	Secondary health facilities are useful for managing complications	
Tertiary health care	0	8	0	Management of complications require specialized care which in turn have their respective specialized guidelines The Nigerian tertiary health care level is highly specialized and each specialty has its respective practice guidelines.	Exclude
5.2. Within the health facility					
In-patient	8	0	0	Interventions that can be provided at in-patient or out-patient or even intensive care will be included and clearly stated. We envisage that emergencies like DKA & HHS will require intensive and in-patient care.	Include all
Out-patient	8	0	0		
Intensive	8	0	0		
5.3. Community					
Home care	8	0		Home care is important for prevention and self-monitoring.	Include
Rehabilitative facility (hospice, aged)	0	8		There is paucity of information on the utilization rate of rehabilitative facilities in Nigeria.	Exclude

5.4. Context					
National context	7	0	1	There may be state-specific contexts that may affect guideline implementation. However, they cannot all be considered at this stage of development.	Include
State- specific context	0	7	1		Exclude
Local context (tribal, religion etc)	0	7	1	During state-level step-down activities, they will be considered.	Exclude

2.0. Guideline Search and Retrieval

Database searched	Filters used	Search yield	Relevant to DM	Included for appraisal
National Guideline Clearinghouse	Date limit: 2015 to 2018	133	17 guidelines	10
NICE	Date limit: last 3 years (2015-2018) Document type: Guidance Guidance category: Clinical guideline, NICE guideline, public health guideline, quality standards	90	6 guidelines 3 quality standards	6
IDF	No filters applied during electronic search But manual screening was done to apply date limit from 2015 to 2018 and to make clear distinction between job-aids and practice guidelines	20	4 guidelines	4

WDF	No filters were applied during electronic search But manual screening was done to apply date limit from 2015 to 2018 and to make clear distinction between job-aids and practice guidelines	36	7 guidelines	0
ADA	No filters applied	1	1 guideline	1

3.0. Guideline Assessment Checklist

AGREE II INSTRUMENT

DOMAIN 1. SCOPE AND PURPOSE

1. The overall objective(s) of the guideline is (are) specifically described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

2. The health question(s) covered by the guideline is (are) specifically described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

DOMAIN 2. STAKEHOLDER INVOLVEMENT

4. The guideline development group includes individuals from all relevant professional groups.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

5. The views and preferences of the target population (patients, public, etc.) have been sought.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

1

6. The target users of the guideline are clearly defined.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

DOMAIN 3. RIGOUR OF DEVELOPMENT

7. Systematic methods were used to search for evidence.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

8. The criteria for selecting the evidence are clearly described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

9. The strength and limitations of the body of evidence are clearly described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

10. The methods for formulating the recommendations are clearly described.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

2

11. The health benefits, side effects, and risks have been considered in formulating the recommendations.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

12. There is an explicit link between the recommendations and the supporting evidence.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

13. The guideline has been externally reviewed by experts prior to its publication.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

14. A procedure for updating the guideline is provided.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

DOMAIN 4. CLARITY OF PRESENTATION

15. The recommendations are specific and unambiguous.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

16. The different options for management of the condition or health issue are clearly presented.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

17. Key recommendations are easily identifiable.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

DOMAIN 5. APPLICABILITY

18. The guideline describes facilitators and barriers to its application.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

19. The guideline provides advice and/or tools on how the recommendations can be put into practice.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

20. The potential resource implications of applying the recommendations have been considered.

1	2	3	4	5	6	7
Strongly Disagree						Strongly Agree

Comments

21. The guideline presents monitoring and/or auditing criteria.

1	<input type="checkbox"/>	2	<input type="checkbox"/>	3	<input type="checkbox"/>	4	<input type="checkbox"/>	5	<input type="checkbox"/>	6	<input type="checkbox"/>	7	<input type="checkbox"/>
Strongly Disagree												Strongly Agree	

Comments

DOMAIN 6. EDITORIAL INDEPENDENCE

22. The views of the funding body have not influenced the content of the guideline.

1	<input type="checkbox"/>	2	<input type="checkbox"/>	3	<input type="checkbox"/>	4	<input type="checkbox"/>	5	<input type="checkbox"/>	6	<input type="checkbox"/>	7	<input type="checkbox"/>
Strongly Disagree												Strongly Agree	

Comments

23. Competing interests of guideline development group members have been recorded and addressed.

1	<input type="checkbox"/>	2	<input type="checkbox"/>	3	<input type="checkbox"/>	4	<input type="checkbox"/>	5	<input type="checkbox"/>	6	<input type="checkbox"/>	7	<input type="checkbox"/>
Strongly Disagree												Strongly Agree	

Comments

OVERALL GUIDELINE ASSESSMENT

For each question, please choose the response which best characterizes the guideline assessed:

1. Rate the overall quality of this guideline.

1	<input type="checkbox"/>	2	<input type="checkbox"/>	3	<input type="checkbox"/>	4	<input type="checkbox"/>	5	<input type="checkbox"/>	6	<input type="checkbox"/>	7	<input type="checkbox"/>
Lowest possible quality												Highest possible quality	

2. I would recommend this guideline for use.

YES	<input type="checkbox"/>
YES, With modifications	<input type="checkbox"/>
NO	<input type="checkbox"/>

NOTES

Large empty text area for notes.

4.0. Guideline Appraisal Inter-rater Spreadsheet and Scoring Sheet

		Guidelines																	
AGREE II Checklist		Combined diet and physical activity promotion programs for prevention of diabetes Community Preventive Services Task Force recommendation		IWGDF guidance on the prevention of foot ulcers in at-risk patients with diabetes		Gestational diabetes mellitus evidence-based nutrition practice guideline		Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes		Final recommendation statement healthful diet and physical activity for cardiovascular disease prevention in adults without known risk factor		Healthy lifestyles		Hypertension evidence-based nutrition practice guideline		IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care Recommendations		IDF-Diabetes_Eye_Health	
Section	Item	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1
Scope and Purpose	1	7	7	7	7	7	7	6	6	7	7	7	7	7	7	7	7	7	7
Scope and Purpose	2	7	6	6	6	2	5	1	5	1	4	7	5	4	5	7	7	7	7
Scope and Purpose	3	7	5	5	5	7	7	5	5	7	7	7	7	7	6	6	7	7	7
Stakeholder Involvement	4	5	6	7	5	6	5	4	7	7	7	7	5	7	6	5	5	1	5
Stakeholder Involvement	5	3	6	6	4	7	3	4	3	7	3	7	3	7	4	4	4	1	5
Stakeholder Involvement	6	7	6	6	6	7	5	6	6	7	6	7	6	7	7	7	7	7	7
Rigour of Development	7	7	7	5	6	7	6	7	7	7	7	7	6	7	7	4	4	1	4
Rigour of Development	8	7	6	5	6	7	6	7	5	7	6	7	6	7	7	4	4	1	4
Rigour of Development	9	7	5	5	4	5	4	6	3	7	4	7	6	7	4	4	3	1	4
Rigour of Development	10	7	4	7	6	6	6	6	7	7	7	7	6	7	6	6	6	1	4
Rigour of Development	11	7	4	7	6	7	6	6	7	7	6	7	5	7	6	6	7	4	7
Rigour of Development	12	7	7	7	6	7	6	7	6	7	6	7	6	7	5	5	4	1	4
Rigour of Development	13	7	6	3	2	7	6	7	7	7	4	7	7	6	7	5	1	4	
Rigour of Development	14	7	4	3	3	7	3	1	3	2	5	3	3	7	4	6	3	1	4
Clarity of Presentation	15	7	6	5	6	7	6	6	6	7	7	7	6	7	6	7	7	5	7
Clarity of Presentation	16	7	4	6	3	7	4	6	5	7	3	7	4	7	3	7	7	5	7
Clarity of Presentation	17	7	7	6	6	7	6	7	6	7	7	7	6	7	7	7	7	4	7
Applicability	18	7	6	5	3	7	3	2	3	5	3	7	3	7	3	6	4	3	5
Applicability	19	7	5	4	3	7	7	6	6	6	6	7	7	7	7	6	7	4	7
Applicability	20	6	6	3	1	4	4	4	6	5	3	7	3	7	7	6	4	2	6
Applicability	21	4	3	5	2	2	3	1	3	3	3	3	4	3	3	4	5	1	4
Editorial Independence	22	7	6	7	6	7	6	2	6	7	6	3	6	7	6	5	4	4	4
Editorial Independence	23	7	7	7	5	7	7	4	7	7	7	7	7	7	6	5	5	3	1
Overall Assessment	OA1	7	6	4	5	6	6	5	5	7	6	6	6	6	6	6	6	3	6
Overall Assessment	OA2	Yes	Yes with modifications	Yes with modifications	Yes with modifications	Yes	Yes with modifications	Yes	Yes	Yes	Yes with modifications	Yes	Yes with modifications	Yes	Yes	Yes	Yes	No	Yes

		Guideline															
AGREE II Checklist		IDF-GDM-model-of-care-2015		IDF-Pocketbook-2nd-edition-low-resource-Mgt of DM in adolescents and children		NICE guidelines		Diabetes type 1 and type 2 evidence-based nutrition practice guideline.		Oral pharmacologic treatment of type 2 diabetes mellitus a clinical		Screening for DM		Standards of care for Diabetes Mellitus		VADoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care	
Section	Item	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1	Appraiser 2	Appraiser 1
Scope and Purpose	1	6	7	5	7	6	6	7	7	7	6	7	6	7	7	6	6
Scope and Purpose	2	1	6	2	7	4	6	5	6	5	6	5	6	6	7	6	5
Scope and Purpose	3	6	6	7	7	7	7	7	6	6	5	7	7	7	6	7	7
Stakeholder Involvement	4	1	5	2	6	5	7	7	6	6	4	7	5	7	6	5	7
Stakeholder Involvement	5	1	5	2	2	5	7	7	5	7	2	7	5	7	3	5	6
Stakeholder Involvement	6	4	4	2	7	7	7	7	4	7	6	6	6	7	7	7	6
Rigour of Development	7	1	2	1	4	7	7	7	7	7	7	7	6	7	7	7	7
Rigour of Development	8	1	2	1	4	7	7	7	7	7	6	7	6	7	6	7	6
Rigour of Development	9	1	1	1	4	7	7	7	5	5	5	7	4	7	6	6	5
Rigour of Development	10	1	3	1	5	7	7	7	6	7	6	7	6	7	7	7	6
Rigour of Development	11	3	4	1	5	6	7	7	6	7	6	6	6	7	6	7	7
Rigour of Development	12	3	3	1	4	7	7	7	7	7	6	7	5	7	7	7	6
Rigour of Development	13	1	2	1	7	7	7	7	7	7	5	7	7	7	5	7	6
Rigour of Development	14	1	2	1	6	7	7	7	3	3	3	7	3	7	7	3	3
Clarity of Presentation	15	6	7	1	7	4	7	7	6	6	3	7	6	7	6	6	6
Clarity of Presentation	16	6	7	6	7	7	7	7	3	7	3	7	4	7	7	6	3
Clarity of Presentation	17	6	7	6	7	5	7	7	7	5	7	7	6	7	7	7	6
Applicability	18	4	5	5	4	5	7	7	4	5	3	6	3	7	4	7	3
Applicability	19	5	6	6	6	7	7	7	6	3	1	7	6	7	5	5	4
Applicability	20	2	4	4	4	6	5	5	1	5	3	4	1	7	6	3	3
Applicability	21	1	5	1	4	6	4	4	1	2	3	2	3	7	6	2	2
Editorial Independence	22	1	2	4	1	7	7	7	7	5	3	6	3	7	6	6	4
Editorial Independence	23	1	1	1	4	3	7	7	7	5	6	7	6	7	7	7	4
Overall Assessment	OA1	4	5	2	6	6	6	6	6	6	5	5	5	7	6	6	5
Overall Assessment	OA2	Yes	Yes with modifications	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes with modifications	Yes	Yes with modifications	Yes	Yes	Yes	Yes with modifications

5.0. Summary of Evidence for the Recommendations

Scope	Health Questions	Recommendation Number	Recommendations	Guideline source of recommendation	Source of evidence for recommendation	Hierarchy/type of evidence	Quality of Evidence
Prevention	1. What individual, community and policy level measures can be taken to prevent T2DM among the general population?	1	Individual behaviour for preventing diabetes focus on healthy eating/diet, increased physical activity, smoking habits and alcohol intake. Individual-level behaviour change interventions are enhanced and sustained through behavioural counselling/therapy. Devices such as pedometers or mobile phone applications should be used to support and monitor behaviour change.	Kottke T, Wilkinson J, Baechler C, Danner C, Erickson K, O'Connor P, Sanford M, Straub R. Healthy lifestyles. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2016 Jan. 58 p. [152 references]	Bertholet N, Daepfen JB, Wietlisbach V, Fleming M, Burnand B. Reduction of alcohol consumption by brief alcohol intervention in primary care: systematic review and meta-analysis. Arch Intern Med. 2005 May 9;165(9):986-95. PubMed Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, Stave CD, Olkin I, Sirard JR. Using pedometers to increase physical activity and improve health: a systematic review. JAMA. 2007 Nov 21;298(19):2296-304. [51 references] PubMed Patnode et al., 2015; U.S. Preventive Services Task Force (USPSTF), 2015; U.S. Department of Health and Human Services, 2008.	Systematic review	Use of pedometers (Moderate certainty evidence); Brief behavioural intervention for individuals who screen positive on a validated tool for risky/hazardous drinking (Moderate); Community program to elderly individuals who have insufficient levels of physical activity (High certainty evidence); Self-monitoring (food journals, mobile applications, tracking websites, advanced meal planning) for obese and overweight patients (High certainty evidence).

		2	Whole of community preventive measures are important for engaging communities to support community members to achieve behaviour changes that will prevent DM.		1)Laine J, Kuvaja-Köllner V, Pietilä E, Koivuneva M, Valtonen H, et al. (2014) Cost-Effectiveness of Population-Level Physical Activity Interventions: A Systematic Review. <i>Am J Health Promot</i> 29: 71–80. doi: 10.4278/ajhp.131210-LIT-622 [PubMed] 2)McGill R, Anwar E, Orton L, Bromley H, Lloyd-Williams F, et al. (2015) Are interventions to promote healthy eating equally effective for all? Systematic review of socioeconomic inequalities in impact. <i>BMC Public Health</i> 15: 1–15. [PMC free article] [PubMed]	Systematic review	Community rail-trails, pedometers and school-health education programmes most cost-effective population-wide interventions (Moderate certainty evidence)
		3	Environmental and policy approaches for promoting healthy eating, physical activity and alcohol/drinking habits include : • Town/city planning to promote active recreation and physical activity. • Fiscal policies to reduce the consumption of calorie-dense foods, alcohol and tobacco to prevent diabetes.	Fiscal policies for diet and the prevention of non-communicable diseases-2016	1)Powel LM, Chriqui JF, Khan T, Wada R, Chaloupka FJ. Assessing the potential effectiveness of food and beverage taxes and subsidies for improving public health: a systematic review of prices, demand and body weight outcomes. <i>Obes Rev.</i> 2013; 14(2):110–28. 2)Andreyeva T, Long MW, Brownell KD. The impact of food prices on consumption: a systematic review of research on the price elasticity of demand for food. <i>Am J Public Health</i> , 2010; 100(2):216–22. doi: 10.2105/AJPH.2008.151415	Systematic review	Low certainty evidence

	2. What recommended intervention can prevent or delay the onset of T2DM among individuals with high risk of developing T2DM?	4	<p>Combined diet and physical activity is more effective than diet or physical activity only.</p> <p>Structured group or individual counselling is essential to achieve dietary, physical activity and weight loss targets. Mobile apps can be used to deliver combined diet and physical activity programs.</p>	<p>NICE guideline: Type 2 diabetes: prevention in people at high risk</p> <p>Combined diet and physical activity promotion programs for prevention of diabetes: Community Preventive Services Task Force recommendation statement.</p>	<p>Balk, E. M., Earley, A., Raman, G., Avendano, E. A., Pittas, A. G., & Remington, P. L. (2015). Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among People at Increased Risk: A Systematic Review for the Community Preventive Services Task Force. <i>Annals of Internal Medicine</i>, 163(6), 437–451. http://doi.org/10.7326/M15-0452</p>	<p>Systematic review</p>	<p>Combined diet and physical activity is more effective than diet or physical activity only (Moderate certainty evidence)</p> <p>Structured group or individual counselling is essential to achieve dietary, physical activity and weight loss targets (Moderate certainty evidence)</p> <p>Mobile apps can be used to deliver combined diet and physical activity programs (Low certainty evidence)</p>
--	--	---	--	--	--	--------------------------	---

	3. What are the recommended measures for preventing progression to T2DM among individuals with pre-diabetes or impaired glucose tolerance?	5	<p>Intensive lifestyle modification should be used to prevent the onset of DM.</p> <p>Metformin should only be used when intensive lifestyle modification is not feasible among pre-diabetic individuals with BMI ≥ 35 kg/m², those aged 60 years, and women with prior GDM</p>	American Diabetes Association standards of medical care-2018		Randomized controlled trials	<p>Intensive lifestyle modification should be used to prevent the onset of DM (High certainty evidence).</p> <p>Metformin should only be used when intensive lifestyle modification is not feasible among pre-diabetic individuals with BMI ≥ 35 kg/m², those aged 60 years, and women with prior GDM (Moderate certainty evidence)</p>
--	--	---	--	--	--	------------------------------	--

Screening	1. What are the recommended tools for risk assessment for T2DM?	6	<p>Recommendations for screening for T2DM. Screening should be provider-initiated whenever a person visits a health facility. Community-based intensified case finding or large-scale community screening programs are not recommended unless there is a clear referral pathway. Screening should be done using a locally validated screening tool such as the FINDRISC score. Individuals identified as high risk should proceed to a diagnostic test. If the result of the diagnostic test is normal, the diagnostic test should be repeated every year.</p>	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care	Noble, D., Mathur, R., Dent, T., Meads, C., & Greenhalgh, T. (2011). Risk models and scores for type 2 diabetes: systematic review. The BMJ, 343, d7163. http://doi.org/10.1136/bmj.d7163	Systematic review	Low certainty evidence
Diagnosis	1. What are the recommendations for the diagnosis of DM at primary care level in resource-constrained settings?	7	Fasting plasma glucose: Plasma glucose after 8 hours of no food/calorie intake of more than 126mg/dl or 7 mmol/L	American Diabetes Association standards of medical care-2018		Expert review	Not graded
		8	75-g oral glucose tolerance test (OGTT): Plasma glucose after two hours following a glucose load of 75g of glucose dissolved				Not graded
		9	HbA1C criteria				
		10	Recommendation for PHC level: Random blood sugar of more than 200mg/dl or 11.1 mmol/L in high-risk individuals with symptoms suggestive of hyperglycaemia or DM (increased thirst, increased frequency of urination and increased appetite)				Not graded

Diabetes education for persons with DM	1. What is the evidence for including diabetes education in routine diabetes care and treatment?	11	A structured Diabetes Education program is recommended as part of comprehensive diabetes care and treatment. Diabetes education should be offered immediately after diagnosis or within 6-12 months of diagnosis or any time it is feasible following diagnosis.	NICE: Type 1 diabetes in adults: diagnosis and management NICE: Type 2 diabetes in adults: diagnosis and management American Diabetes Association standards of medical care-2018	Butcher MK, Vanderwood KK, Hall TO, Gohdes D, Helgerson SD, Harwell TS. Capacity of diabetes education programs to provide both diabetes self-management education and to implement diabetes prevention services. JPublicHealth Manag Pract 2011;17:242–247		Very low to low certainty evidence
	2. What should be the recommended scope for diabetes education?	12	Diabetes education must cover prevention, changes, medication adherence and self-care. Diabetes education must be delivered by a health worker trained on Diabetes Education according to national standards				Not graded
	3. How should diabetes education be delivered in resource-constrained settings?	13	Diabetes education should be delivered in a mode, intensity, frequency and duration that is suitable to the patient needs and health care settings				Not graded

Lifestyle modification	1. What are the recommended targets for lifestyle changes in the treatment of DM?	14	Lifestyle changes are an essential add-on to drug treatment in Diabetes management Lifestyle changes should begin as soon as a diagnosis is made to achieve strict blood glucose control. Lifestyle changes focus on diet, physical activity, alcohol & tobacco intake. Reduce daily caloric intake by 500 to 600 calories in obese and overweight persons with DM. Follow a low-calorie diet (800 to 1200 calories per day) under the supervision of a health worker or diabetes educator Moderate (150 mins/week) or vigorous (90 mins/week) physical activity Smoking cessation	NICE: Type 1 diabetes in adults: diagnosis and management NICE: Type 2 diabetes in adults: diagnosis and management American Diabetes Association standards of medical care-2018			Moderate certainty evidence
-------------------------------	---	----	--	--	--	--	-----------------------------

Drug treatment	1. What drugs are recommended for treating T1DM in children?	15	The treatment for type 1 diabetes in children is insulin. <ul style="list-style-type: none"> • Twice-daily insulin using both short-acting and intermediate-acting insulin. (If these insulins are not always available, pre-mixed insulin can be used as an alternative regimen). • Basal-bolus regimen (the preferred option) - with short-acting insulin given with main meals (usually three times per day) and intermediate-acting insulin given once or twice daily (evening, or morning and evening). 	Pocketbook for management of diabetes in childhood and adolescence in under-resourced countries. American Diabetes Association standards of medical care-2018			High certainty evidence
	2. What drugs are recommended for treating T1DM in adults?	16	<ul style="list-style-type: none"> • A basal-bolus regimen made up of insulin-glargine and rapid-acting soluble human or animal insulin should be used with strict self-blood glucose monitoring to avoid hypoglycaemia • Use a twice-daily human mixed insulin regimen when a multiple daily injection basal-bolus insulin regimen is not possible or a twice-daily mixed insulin regimen is preferred. 		Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose in non-pregnant adults with diabetes mellitus.		Moderate certainty evidence

	3. What drugs are recommended for treating T2DM in children	17	<p>Metformin is the first-line drug for treating T2DM in adolescents and young people.</p> <p>Basal insulin can be used as first-line if blood glucose level is as high as 13.9mmol/L and there is marked symptoms such as frequent urination (bedwetting), weight loss, frequent thirst and dehydration.</p> <p>Basal insulin can also be used when metformin fails to achieve the targeted blood glucose levels.</p>	<p>Pocketbook for management of diabetes in childhood and adolescence in under-resourced countries.</p> <p>American Diabetes Association standards of medical care-2018</p>			High certainty evidence
	4. What drugs are recommended for treating T2DM in adults?	18	<p>Metformin is the preferred choice for initial monotherapy.</p> <p>Dosage should be titrated from 500 to 2000 mg per day with or after meals.</p> <p>Initial combination therapy is recommended when there is marked cardiovascular risk factor or high blood sugar levels between 11 -15 mmol/l</p> <p>A combination of metformin and another glucose-lowering drug except (Glibenclamide and glyburide) is recommended.</p>	<p>IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care.</p> <p>American Diabetes Association standards of medical care-2018</p>			High certainty evidence

	5. What add-on drug (s) is recommended for managing T2DM? and under what circumstances should it be used?	19	Basal insulin can also be added if dual or triple therapy does not yield the blood glucose targets	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. American Diabetes Association standards of medical care-2018. NICE: Type 2 diabetes in adults: diagnosis and management			Moderate certainty evidence
	6. Which hierarchical order should be considered in the choice of first-line, second-line regimens for T2DM?	20	The preferred combination for dual therapy is metformin + another sulfonylurea (except Glibenclamide/glyburide) Consider person's age, body weight, presence of complications and duration of disease. When triple therapy becomes imperative, the recommended and most feasible combination is Metformin + another sulfonylurea + vidagliptin (DPP-4 inhibitor). Basal insulin can also be added if dual or triple therapy does not yield the blood glucose targets	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. American Diabetes Association standards of medical care-2018. NICE: Type 2 diabetes in adults: diagnosis and management	Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus (Cochrane Review)		Metformin + sulfonylurea (low certainty) Metformin + another sulfonylurea + vidagliptin (DPP-4 inhibitor). (Moderate certainty evidence)
	7. Should insulin be considered as a first- or second-line drug in T2DM? If yes, under which circumstances should it be considered as either a first or second-line drug?	21	Insulin only or combination with other glucose-lowering drugs in the essential medicines list can be considered as first-line in the following conditions: • Very high blood glucose level above 16mmol/l • Acute weight loss • Dehydration • Acute illness or • Presence of ketones	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. American Diabetes Association standards of medical care-2018. NICE: Type 2 diabetes in adults: diagnosis and management	Roglic G, Norris SL. Medicines for Treatment Intensification in Type 2 Diabetes and Type of Insulin in Type 1 and Type 2 Diabetes in Low-Resource Settings: Synopsis of the World Health Organization Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Nonpregnant Adults With Diabetes Mellitus. Ann Intern Med. 2018;169:394–397. doi: 10.7326/M18-1149		Very low certainty evidence

	8. Is there a preferred combination for triple therapy for T2DM? If yes, which?	22	When triple therapy becomes imperative, the recommended and most feasible combination is Metformin + another sulfonylurea + vildagliptin (DPP-4 inhibitor).	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care.	Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Mar;15(3):252-7.		Moderate certainty evidence	
DM related emergencies	1. What are the recommended life-saving measures that can be taken at primary health care level to manage DM related emergencies? (disaggregate by each type of emergency)	23	Management of mild and moderate forms of hypoglycaemia is feasible at primary health care setting by giving fast-acting sugars or carbohydrate	American Diabetes Association standards of medical care-2018			Not graded	
		24	Management of DKA and HHS is not very feasible at primary health care setting.				Not graded	
	2. What are the recommended management of DM emergencies at secondary level?	25	Management of severe forms of hypoglycaemia with loss of consciousness	NICE: Type 1 diabetes in adults: diagnosis and management NICE: Type 2 diabetes in adults: diagnosis and management				
		26	Management of DKA and HHS is not feasible at primary health care setting					Not graded

DM complications	1. What are the recommended measures for preventing DM related complications (disaggregate by each type of complication)?	27	Generally, primary health care workers can work with persons with diabetes to prevent all complications by: o Ensuring the person with diabetes achieves and sustains the targets for blood sugar control to reduce or slow disease progression; o Ensuring that blood pressure and blood lipid levels are within normal limits to also reduce or slow the disease progression.	NICE: Type 1 diabetes in adults: diagnosis and management NICE: Type 2 diabetes in adults: diagnosis and management			Not graded
	2. What are the recommendations for early identification of DM related complications?	28	Diabetic retinopathy at primary care Ask questions about difficulties with vision. Conduct visual acuity using a simple visual acuity chart Refer for comprehensive eye examination	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care.			Not graded
		29	Diabetic nephropathy Assess urinary albumin or albumin-to-creatinine ratio at least once a year. Estimate glomerular filtration rate in patients with T1DM with a duration of 5 years and in all patients with T2DM, and in all patients with comorbid hypertension.	IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care.			Not graded

		30	<p>Diabetic Peripheral Neuropathy and foot problems Screen for DPN within 5 years of diagnosis of T1DM and immediately after diagnosis of T2DM Then screen annually after the initial screening, regardless of the results. Conduct full sensory and foot examination annually. Inspect foot at every visit to the health facility.</p>	<p>IDF Clinical Practice Recommendations for Managing Type 2 Diabetes in Primary Care. IWGDF guidance on the prevention of foot ulcers in at-risk patients with diabetes.</p>			Low certainty evidence
Comorbidities	1. What are the recommendations for the management of other CV risk factors?	31	<p>Cardiovascular risk factors can be assessed in resource-constrained settings (with no specialist physician or doctor and no laboratory facility for lipid profile) using the WHO/ISH (World Health Organization/International Society of hypertension) risk prediction chart.</p>	<p>American Diabetes Association standards of medical care-2018</p>			Not graded
		32	<p>Blood Pressure should be measured at every routine visit and at home. All hypertensive patients with diabetes should monitor their blood pressure at home. Lifestyle changes are important to reduce cardiovascular risk factors. Drugs should be used when other cardiovascular risk factors like hypertension and high blood cholesterol levels are identified.</p>	<p>American Diabetes Association standards of medical care-2018</p>			<p>Low certainty evidence</p> <p>Low certainty evidence</p>

		33	Aspirin therapy (75–162 mg/day) may be considered as a primary prevention strategy for persons with diabetes who are ≥ 50 years with at least one additional major risk factor (family history of premature atherosclerotic cardiovascular disease, hypertension, dyslipidemia, smoking, or albuminuria) and are not at increased risk of bleeding.	American Diabetes Association standards of medical care-2018	Baigent C, Blackwell L, Collins R, et al.; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet</i> 2009;373:1849–1860	Systematic review	Low certainty evidence
		34	Use aspirin (75–162mg/day) as a secondary prevention strategy in those with diabetes and a history of atherosclerotic cardiovascular disease.	American Diabetes Association standards of medical care-2018	Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. <i>Lancet</i> 2014;383:1973–1980	Systematic review	High certainty evidence
	2. What are the recommended drug combinations for the treatment of high blood pressure in DM?	35	Depending on the blood pressure at diagnosis or presence of proteins in urine, the first-line antihypertensive drug treatment should be an or a combination that contains Angiotensin Converting Enzyme inhibitor (ACEi) plus either a thiazide-diuretic (long-acting versions have been shown to reduce cardiovascular events) or a generic calcium-channel blocker.	American Diabetes Association standards of medical care-2018	Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. <i>PLoS Med</i> 13(6): e1002064 Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. <i>Lancet</i> 20015 385(9982): 2047-56	Systematic review	High certainty evidence

		36	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman, where it is agreed that there is a possibility of her becoming pregnant – this decision should be made following an informed discussion with the woman – avoid ACE inhibitors or A2RB in women who are planning pregnancy as these drugs cause foetal damage.	American Diabetes Association standards of medical care-2018	BulloM, Tschumi S, Bucher BS, BianchettiMG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012;60:444–450		Very low certainty evidence
		37	Add whichever drug of the calcium-channel blocker or diuretic that was not a part of the initial combination	American Diabetes Association standards of medical care-2018	Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559 Fried LF, Emanuele N, Zhang JH, et al.; VANEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903 Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360		High certainty evidence

		38	<p>Add an alpha-blocker, a beta-blocker or a *potassium-sparing diuretic or a mineralocorticoid receptor antagonist (*where the person is on either an ACE inhibitor or A2RB, potassium-sparing diuretics should be added with caution and serum potassium carefully monitored – additionally, spironolactone should not be administered to a pregnant woman as it causes fetal damage).</p> <p>For patients on any one of an ACE inhibitor, A2RB, thiazide diuretic, or potassium-sparing diuretic, renal function (serum creatinine and estimated glomerular filtration rate) and serum potassium should be checked at least annually.</p>	American Diabetes Association standards of medical care-2018	<p>Bakris GL, Agarwal R, Chan JC, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015;314:884–894</p> <p>Williams B, MacDonald TM, Morant S, et al; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment care for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059–2068</p> <p>Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016;37:2105–2114</p> <p>Bombardieri AS, Klemmer PJ. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012;33:119–124</p>	Randomised controlled trials	Moderate certainty evidence
--	--	----	--	--	--	------------------------------	-----------------------------

	3. What are the recommendations for managing dyslipidemias?	39	<p>Where the individual already has atherosclerotic cardiovascular disease, high-intensity statin treatment is required in addition to lifestyle modification for secondary prevention of further cardiovascular events.</p> <p>High-intensity statin therapy with either Atorvastatin 40mg-80mg daily or Rosuvastatin 20mg to 40mg daily has been shown to reduce LDL cholesterol by ³ 50%.</p>	American Diabetes Association standards of medical care-2018	<p>Mihaylova B, Emberson J, Blackwell L, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–590</p> <p>Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278</p>	Randomised controlled trials	High certainty evidence
--	---	----	---	--	--	------------------------------	-------------------------

		40	In patients with atherosclerotic cardiovascular disease in whom the serum LDL cholesterol remains ³ 70mg/dl despite high-intensity statin therapy (at maximal dosage) and lifestyle modifications, Ezetimibe may be added to the regime following an assessment of the patient's risk, and after careful consideration of the patient's preferences and the side effect profile of the medications.	American Diabetes Association standards of medical care-2018	Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387–2397	Randomized controlled trial	High certainty evidence
	4. What are the recommendations for managing DM in HIV+ individuals?	41	Recommendations for blood glucose targets and lifestyle management for managing DM in PLHIV is the same as in HIV- persons. However, due to drug interaction between glucose-lowering drugs and anti-retroviral drugs, there are special considerations for treating Diabetes in PLHIV.		Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62. doi: 10.1093/cid/ciu779. Epub 2014 Oct 13.		Low certainty
	5. What are the recommendations for managing DM & TB co-morbidity?						

DM & Pregnancy	1. What are the recommended tools for screening for GDM?	42	Screen all pregnant women at their first appointment (booking) to rule-out pre-existing diabetes or overt diabetes before pregnancy that is FPG value ≥ 7.0 mmol/L (126 mg/dl) OR RPG ≥ 11.1 mmol/L (200 mg/dl)	IDF Model of Care for GDM-2015. American Diabetes Association standards of medical care-2018	International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva Ad, Hod M, Kitzmiller JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010 Mar;33(3):676-82.	Consensus panel	Not graded
		43	Perform GDM screening test at 24-28 weeks using Oral Glucose Tolerance Test (OGTT). OGTT should be administered appropriately by a health worker and the lab testing should be done by a lab technician.				Not graded
	2. How can GDM be diagnosed? How can you determine if a woman had overt diabetes before pregnancy?	44	Test women with gestational diabetes mellitus for persistent diabetes at 4–12 weeks postpartum, using the oral glucose tolerance test and clinically appropriate non-pregnancy				Not graded
	3. What are the recommended measures for preventing the onset of GDM in pregnant women with high risk?	45	<p>Combined diet and physical activity is more effective than diet or physical activity only</p> <p>Structured group or individual counselling is essential to achieve dietary, physical activity and weight loss targets</p> <p>Mobile apps can be used to deliver combined diet and physical activity programs</p>	IDF Model of Care for GDM-2015. American Diabetes Association standards of medical care-2018		<p>Combined diet and physical activity is more effective than diet or physical activity only (Moderate certainty evidence)</p> <p>Structured group or individual counselling is essential to achieve dietary, physical activity and weight loss targets (Moderate certainty evidence)</p> <p>Mobile apps can be used to deliver combined diet and physical activity programs (Low certainty evidence)</p>	

	4. What are the recommended measures for managing GDM?	46	Lifestyle management is the first line	IDF Model of Care for GDM-2015. American Diabetes Association standards of medical care-2018	Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403	Randomized controlled trial	High certainty evidence
		47	If lifestyle management fails, then insulin or metformin should be considered.	IDF Model of Care for GDM-2015. American Diabetes Association standards of medical care-2018			High certainty evidence
	5. What are the recommendations for the management of DM in women who were diabetic before pregnancy?	48	Pre-conception counselling should be integrated into routine diabetes care for all women of childbearing age. Family planning should be discussed and offered to women who do not intend to get pregnant.	IDF Model of Care for GDM-2015. American Diabetes Association standards of medical care-2018	Charron-Prochownik D, Sereika SM, Becker D, White NH, Schmitt P, Powell AB 3rd, Diaz AM, Jones J, Herman WH, Fischl AF, McEwen L, DiNardo M, Guo F, Downs J. Long-term effects of the booster-enhanced READY-Girls preconception counselling program on intentions and behaviours for family planning in teens with diabetes. Diabetes Care. 2013 Dec;36(12):3870-4.	Randomized controlled trial	Moderate quality evidence

		49	<p>Insulin is the drug of choice for managing both T1DM & T2DM</p> <p>Adjust insulin dosages to respond to the changing insulin demands throughout the pregnancy in T1DM</p> <p>These adjustments in insulin doses require specialist care.</p> <p>Low dose aspirin 60–150 mg/day (usual dose 81 mg/day) should be given from the end of the 1st trimester up to delivery to reduce the risk of pre-eclampsia.</p> <p>Calcium blockers or alpha-methyl dopa should be used to control blood pressure in women with DM who also have chronic hypertension.</p>	<p>IDF Model of Care for GDM-2015.</p> <p>American Diabetes Association standards of medical care-2018</p>	<p>Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014 May 20;160(10):695-703.</p>	<p>Expert consensus</p>	<p>Insulin is the drug of choice for managing both T1DM & T2DM</p> <p>Adjust insulin dosages to respond to the changing insulin demands throughout the pregnancy in T1DM</p> <p>This adjustment in insulin doses requires specialist care.</p> <p>(Not graded)</p> <p>Low dose aspirin 60–150 mg/day (usual dose 81 mg/day) should be given from the end of the 1st trimester up to delivery to reduce the risk of pre-eclampsia.</p> <p>(High certainty evidence)</p> <p>Calcium blockers or alpha-methyl dopa should be used to control blood pressure in women with DM who also have chronic hypertension</p> <p>(High certainty evidence)</p>
--	--	----	---	--	--	-------------------------	---

	1. What is the recommended role of different cadres of health workers in prevention, care, treatment and management of DM?	50	<p>Doctors: Primary care or general practice doctors are responsible for:</p> <ul style="list-style-type: none"> • Confirmation of diagnosis. • Clinical evaluation • Clinical follow up of persons with diabetes • To identify the circumstances necessary for drug treatment • To prescribe drugs and determine the line of management • Work with other members of the care team to provide structured diabetes education and support for self-care 			Expert consensus	Not graded
		51	<p>Nurses/CHEWs/JCHEWs:</p> <ul style="list-style-type: none"> • To provide culturally – appropriate structured diabetes education. • To convey diabetes self-management information and healthcare provider recommendations accurately to the person with diabetes. • To identify and refer high-risk individuals to physicians. • To identify and overcome cultural barriers to self-care or behaviour change. • Participate in the evaluation of program, unit, or agency using clinical practice guidelines. • To support diabetic persons to prevent complications associated with DM and to identify them early when they do occur. 			Expert consensus	Not graded

Health professionals and settings		52	<p>Lay Community Health Workers: LCHWs should play the following roles</p> <ul style="list-style-type: none"> • Implement diabetes community awareness and prevention program • Provide diabetes prevention messages and information to community members • Support persons with diabetes to gain access to diabetes' support system in their communities • Work with the health provider team to apply basic concepts of behaviour change to support person with diabetes with effective self-management. • Build community coalitions to meet the needs of people affected by diabetes in the community. 	<p>Halimatou Alaofè, Ibitola Asaolu, Jennifer Ehiri, Hayley Moretz, Chisom Asuzu, Mobolanle Balogun, Olayinka Abosede, John Ehiri. Community Health Workers in Diabetes Prevention and Management in Developing Countries. Annals of Global Health, Volume 83, Issues 3–4, 2017, Pages 661-675, ISSN 2214-9996, https://doi.org/10.1016/j.aogh.2017.10.009.</p>			Low certainty evidence
	2. What are the recommended roles of different health care settings of health prevention, care, treatment and management of DM?	53	<p>At community level, the following aspects of diabetes prevention, care and treatment are recommended:</p> <ol style="list-style-type: none"> 1. Community based health promotion. 2. Screening to identify individuals at risk of developing DM, using risk assessment tools. This can be done during outreaches, mobile health services and community engagement. 3. Support to individuals identified to be at high risk for developing DM to prevent or delay the onset of DM. 4. Support to persons with diabetes to achieve self-management and lifestyle changes. 5. Support to persons with diabetes to prevent and identify complications/ emergencies. 			Expert consensus	Not graded

		54	<p>At primary health care level, in addition to community-level activities the following aspects of diabetes prevention, care and treatment are recommended:</p> <ol style="list-style-type: none"> 1. Diagnosis of DM using point-of-care devices, diagnostic algorithms and risk assessment tools. 2. Basic clinical management of non-complicated DM such as: <ol style="list-style-type: none"> a. Patient evaluation. b. Structured diabetes education. c. Drug treatment. d. Support for lifestyle changes. e. Prevention and early recognition of DM complications. f. Early recognition of other comorbidities. 3. Basic life-saving measures in the management of DM related emergencies. 4. Referral of complicated DM cases and emergencies. 			Expert consensus	Not graded
		55	<p>At secondary and tertiary health care level, in addition to the type of care provided at community and primary care level, comprehensive management of DM complications and emergencies.</p>			Expert consensus	Not graded

6.0. Types of Glucose-Lowering Drugs

CLASS	Examples	Essential Medicines List
Insulins	Regular	Yes
	Lispro	No
	Aspart	No
	Glulsine	No
	Glargine	Yes
	Detemir	No
	Pre-mixed	Yes
Biguanides	Metformin	Yes
Sulphonylureas	Glibenclamide	Yes
	Glyburide	No
	Glipizide	No
	Gliclazide	Yes
	Glimepiride	Yes

α-glucosidase inhibitors	Acarbose	No
	Miglitol	No
	Voglibose	No
Meglitinides ('Glinides')	Repaglinide	No
	Nateglinide	No
Thiazolidinediones	Pioglitazone	No
	Rosiglitazone	No
DPP4 inhibitors ('Gliptins')	Sitagliptin	No
	Vildagliptin	Yes
	Saxagliptin	No
	Linagliptin	No
	Alogliptin	No
GLP-1 agonists	Exenatide	No
	Exenatide extended-release	No
	Liraglutide	No

SGLT2 inhibitor	Gliflozins	No
	Canagliflozin	No
	Dapagliflozin	No
	Empagliflozin	NO

